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Prostate cancer is the most commonly diagnosed cancer among men and remains the second leading cause 
of cancer death in men. In 2010, more than 217,000 men in the United States (US) were diagnosed with 
prostate cancer [1]. The American Cancer Society estimated that approximately 32,000 men died from the 
disease in the US in 2010. In Europe, more than 338,00 males were diagnosed with prostate cancer in 
2008 and almost 71000 men died because of prostate cancer [2]. The growth of the population and, more 
importantly, the aging population is a major cause of the high number of prostate cancer cases and will 
contribute to an increase in cancer burden. For that reason, there is a ongoing debate whether screening for 
prostate cancer should be performed.
Screening can help find cancers in an early stage when they are more easily cured. An important trial to 
determine the effect of screening for breast cancer was performed between 1977 and 1984 in Sweden [3]. 
The trial showed that after seven years of follow up a reduction of 31% in breast cancer mortality was 
achieved when screening was applied. This led to the introduction of breast cancer screening in most 
western countries. Recently, several studies have been performed that looked at whether prostate cancer 
screening with the prostate-specific antigen (PSA) blood test saves lives [4, 5, 6, 7]. For example, the 
European Randomized Study of Screening for Prostate Cancer (ERSPC) has shown significant reductions 
in PCa mortality in an intention-to-screen analysis [8, 9]. The reduction in mortality comes, however, at 
the price of over-diagnosis and over-treatment. In the study of Schroder et al. the authors specifically 
warn that, in order to prevent one death from prostate cancer, 1410 men would need to be screened and 48 
additional cases of prostate cancer would need to be treated. Hence, controversy still exists regarding the 
effectiveness of prostate cancer screening. The ongoing debate is essentially a public demand for a more 
reliable, non-invasive method that has a sufficiently high specificity in detecting prostate cancer [10].
Magnetic resonance imaging (MRI) has evolved this decade to a competitive imaging modality for 
the localization of prostate cancer. The non-invasive nature and ability to provide structural, functional 
and metabolic information in a single examination makes the technique suitable to improve specificity 
when screening for prostate cancer. Many studies showed that multiparametric MRI, consisting of high 
resolution 3D T2-weighted sequences, 3D dynamic contrast enhanced MRI, 3D diffusion weighted imaging 
or spectroscopic imaging, leads to a sufficiently high accuracy for prostate cancer detection [11, 12, 13, 14, 
15]. Unfortunately, multiparametric MRI analysis requires a high level of expertise, suffers from observer 
variability and is a labor intensive procedure [16]. For that reason the technique is considered cost inefficient 
and, as a result, has not been implemented in a screening environment [17].
Computer aided diagnosis (CAD) can be of benefit to improve the consistency and accuracy of inter­
preting radiographic images by the radiologist. Additionally, it can speed up the reading time considerably. 
CAD research has been successfully pursued in other diagnostic areas such as mammography [18, 19], CT 
chest [20, 21, 22], CT colonography [23, 24] as well as retinal imaging [25]. However, published literature 
on prostate CAD research is still relatively immature.
The motivation of this thesis was therefore to research state of the art CAD methods that can assist in 
a better diagnosis of prostate cancer, reduce the observer variability and be of benefit to a more efficient 
workflow for the radiologist.
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1.2 Prostate Anatomy
The prostate is a relatively small organ in the pelvis and is part of the male reproductive system. It is located 
between the pelvic bones, in front of the rectum and below the bladder. In healthy males, it is about the size 
of a chestnut and is somewhat conical in shape. Urine that is collected in the bladder goes from the bladder 
neck into the prostate through the urethra. The amount of urine that goes through the urethra is regulated 
by the urethral sphincter. The prostate has a role in the normal sexual functioning. That is, seminal fluid 
is made by and stored in the prostate and is mixed with sperm, which is carried out of the body during 
ejaculation. Development of the prostate is induced by testosterone, a male hormone made in the testicles. 
Fig. 1.1 shows a schematic drawing of the pelvis and its different structures.
(a) Male pelvis (b) Prostate and surrounding structures.
Figure 1.1: A schematic drawing of the male pelvis in which several anatomical structures are indicated 
(source: US government agency National Cancer Institute).
The prostate is divided into an apex, mid and base part, where the apex refers to the lower part and 
the base to the upper part of the prostate. Different functional parts of the prostate are addressed as: the 
peripheral zone, transition zone and (compressed) central gland. The three parts are schematically shown 
in the standardised magnetic resonance imaging (MRI) prostate reporting scheme Fig. 1.2 (source: the 
European Consensus Meeting [26]). The central gland is a cone shaped region that surrounds the ejaculatory 
ducts, extends from bladder base to the verumontanum and comprises 25% of glandular tissue in young 
adults. The transition zone surrounds the urethra and typically, when aging, pushes the central gland away as 
a result of benign prostatic hyperplasia (BPH). The peripheral zone is located posterolateral and comprises 
the majority of prostatic glandular tissue.
1.3 Prostate Cancer Diagnosis in the Clinic
Prostate cancer is generally detected through PSA testing or digital rectal examination (DRE). In a DRE, 
the physician inserts a lubricated, gloved finger into the rectum to feel the surface of the prostate. Healthy 
prostate tissue is soft, whereas malignant tissue is firm, hard, and often asymmetrical or stony. Of all 
prostate tumors, 65% to 74% are located in the peripheral zone [11]. The remaining tumors that are more 
ventrally located cannot be reached by DRE and are therefore missed. Additionally, small tumors are 
difficult to detect by DRE [27]. For that reason, the sensitivity of detecting prostate cancer by DRE is rather 
low. Although it has been suggested that DRE can be replaced by PSA testing only [28], urologists tend to 
be less controversial and state that DRE should only be replaced by a better regimen if it detects a larger 
proportion of cancers with fewer biopsy examinations [29].
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Figure 1.2: Schematic drawing of the prostate with three zones. On the left, three axial slices are shown 
of the prostate. On the right, a sagittal projection of the prostate is shown. The white sections represent the 
peripheral zone and light grey the transition zone and the dark gray sections the fibromuscular stroma. Most 
patients have an enlarged transition zone (BPH) such that the central gland is hardly visible. The central gland 
is therefore not added to the scheme [26].
PSA testing usually detects prostate cancer earlier than it would be detected by a DRE or the devel­
opment of symptoms [28]. In clinical practice though, PSA testing and DRE are performed alongside. A 
PSA test measures the amount of antigen in the blood in nanograms per milliliter (ng/mL) that is specific 
for the prostate. Elevated levels of PSA may indicate presence of cancer in the prostate. The American 
Cancer Society guideline for the early detection of PCa recommends that patients with a PSA level of 4.0 
ng/mL or greater should be referred for further evaluation or biopsy. To increase the sensitivity of the test, 
many other countries lowered their threshold to 3.0 ng/mL taking a significant increase of benign cases into 
account [30]. The poor specificity of PSA testing is caused by the fact that elevated levels are also measured 
at benign conditions such as prostatitis or benign prostatic hyperplasia. Furthermore, some men with PCa 
do not have elevated PSA levels. As a result, PSA testing may produce false-positive or false-negative find­
ings such that men without prostate cancer receive unnecessary additional testing or clinically significant 
cancers are missed.
Definitive diagnoses of PCa is most often established through transrectal ultrasound (TRUS)-guided 
systematic biopsy, as it is the standard procedure for histological sampling. The painful procedure, which 
is somewhat prevented through local anesthesia, involves systematic targeting of core biopsies under ul­
trasound guidance. The European Guideline on Prostate Cancer advises that at least eight cores should be 
sampled, though recommends to increase to higher sampling rates to improve the sensitivity of the tech­
nique. The prostate tissue samples are evaluated by the pathologist to determine whether cancer is present 
and, if so, the Gleason score of the cancer. The Gleason score is based on the degree of abnormality of the 
cells and ranges from 2 to 10. Knowledge of the tumor grade is essential for the choice of therapy, which 
will be discussed below. Although TRUS-guided biopsy is sensitive to PCa located in the peripheral zone, 
it can hardly detect PCa in the central gland and transition zone [31]. More importantly, Noguchi et al. [32] 
demonstrated that grade assessment with needle biopsy underestimated the tumor grade in 46% cases and 
overestimated it in 39 (18%). Therefore, the technique cannot guarantee that the most descriptive part of 
the tumor has been sampled, or whether it has spread beyond the prostate boundaries.
The choice of therapy for men diagnosed with PCa depends on the Gleason score and the stage of the
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tumor, where the stage of the tumor categorizes the risk of cancer having spread beyond the prostate. Mostly, 
the options of treatment are determined using nomograms of which the Partin tables is most commonly 
used [33]. The Partin tables estimate the chance of organ-confined disease, capsular penetration, seminal 
vesicle invasion and lymph node metastasis, based on the result of DRE, biopsy Gleason score and serum 
PSA level [34]. Higher Gleason scores indicate larger differences from normal tissue and more aggressive 
disease. Gleason scores of 2 to 4 resemble well differentiated or low grade tumors. Cancers with Gleason 
scores of 5 to 7 are called moderately differentiated or intermediate grade. Cancers with Gleason scores of
8 to 10 are called poorly differentiated or high grade.
Several options of treatment are available: active surveillance, radical prostatectomy, radiotherapy, and 
focal therapy. Active surveillance is provided to men that have a small, localised, well-differentiated PCa. 
It involves a conservative monitoring of the tumor and not to treat the patient immediately, though the urol­
ogist can intervene when the cancer progresses above pre-defined threshold, such as short PSA doubling 
time or deteriorating histopathological factors on repeat biopsy. With a radical prostatectomy, the prostate 
is removed surgically. This can also include removal of lymph nodes in case of metastases. The neurovas­
cular bundle should be free of tumor tissue to enable a nerve-sparing surgery. In this way, the normal sexual 
function and ability to urinate can be preserved. However, an accurate localization of the tumor is of high 
importance to be able to perform nerve-sparing surgery. Another option would be to perform radiation 
therapy, either with external beam radiation or internal radiation (brachytherapy). In external beam radia­
tion, the patient receives radiation treatment from an external source, usually over an 8- to 9-week period. 
Brachytherapy involves placing small radioactive pellets, sometimes referred to as seeds, into the prostate 
tissue and is recommended for low-risk cancers. Recently, there is a shift towards minimally invasive focal 
therapies such as delivering a boost dose to the dominant intra-prostatic lesion, cryotherapy (ablation of 
prostate tissue by local induction of extremely cold temperatures) or lasertheraphy [35]. It stands to rea­
son that an accurate localization, grading and staging of the PCa is of paramount importance before these 
therapies can be performed.
1.4 Prostate Magnetic Resonance Imaging
With Magnetic Resonance Imaging (MRI), structural, functional and metabolic information can be non- 
invasively obtained from the patient. A typical prostate multiparametric MR examination consists of three- 
directional T2-weighted (T2-w) MR imaging, diffusion weighted imaging (DWI), dynamic contrast en­
hanced (DCE) MR imaging and, in case of staging, spectroscopic imaging. The examination is performed 
within 30 to 60 minutes depending on the amount of sequences used. Fig. 1.3 shows a screen capture of the 
in-house developed system (MRCAD) that is used in the clinic to process and visualize the multiparametric 
MR data for diagnosis of PCa patients. Appendix A provides a detailed explanation of the MRCAD system.
T2-weighted MRI has been used to diagnose PCa for quite some years. T2-weighted MRI is most often 
performed in multiple views, i.e., transversal, coronal and sagittal view, with a high in-plane resolution 
and a relatively thick slice distance. In a T2-weighted image, PCa often appears as an area of low signal 
intensity in a bright normal peripheral zone. However, benign conditions such as biopsy haemorrhage, 
prostatitis, BPH and effect of treatment can mimic the presence of cancer. As a result, the accuracy of 
tumor localization using T2-weighted MRI is rather low, ranging from 67% to 72% [11]. Furthermore, a 
correct interpretation of a T2-weighted image requires a high level of expertise [36].
DCE-MRI is a minimal invasive technique which can be used to study tissue perfusion and vascular 
permeability. Due to the high vascularity, increased capillary permeability as well as interstitial hyperten­
sion in tumors, DCE-MRI shows better distinction between malignant lesions and normal tissue compared 
to T2-weighted MRI alone [37, 38, 3 9 ,4 0 ,41 ,42 ,43 ,44 ]. The principles of DCE-MRI lie in the analysis of 
signal-time or kinetic curves at a specific location in T1-weighted images. A sequential set of T1-weighted 
images is acquired before and during an intravenous bolus injection of paramagnetic gadolinium chelate, 
preferably by using a power injector. The contrast agent will induce an increased signal intensity on a 
T1-weighted image at vessel lumen and interstitial space. The kinetic curves are summarized into a set 
of kinetic parameters. The derived kinetic parameter maps are often displayed as color-coded transparent 
overlays on top of anatomical images. This prevents the need to manually analyze each curve individu­
ally. An example signal-time curve with several descriptive parameters is demonstrated in figure 1.4. The 
kinetic parameters are used to characterize lesions. A typical malignant lesion shows a faster initial rise,
Introduction and Outline 5
Figure 1.3: Screen capture of the in-house developed system (MRCAD) displaying multiparametric MR data 
using a prostate detection hanging protocol. Cross-sectional transversal views of a T1-weighted (top-left) 
volume, T2-weighted (right) volume, ADC map (top-middle) as well as a sagittal (bottom-left) and a coronal 
(bottom-middle) view of T2-weighted volumes. Additionally, a perfusion map is displayed as a color-coded 
overlay on top of the T1-weighted volume. The MRCAD system is explained in detail in Appendix A.
(a) Example kinetic curve showing the different parameters that summa­
rize the curve.
(b) Example kinetic parameter map (LateWash) dis­
played as a color-coded transparent overlay on top of 
an axial T2-weighted image.
Figure 1.4: Example kinetic curve and derived map of DCE-MRI
has a higher peak enhancement and shows a more negative LateWash or Wash-out when compared to a 
benign tissue. As the kinetic parameters do not directly correlate to physiological parameters, they cannot 
be compared among patients. Differences in scan parameter settings, such as repetition time and flip angle, 
unknown native T1 relaxation time of the tissue, presence of coil profile and differences in the patient’s 
systemic blood circulation, make the technique difficult the reproduce among clinical centers [45].
Pharmacokinetic (PK) modeling aims at a more quantitative analysis of DCE-MRI. PK modeling re­
moves the above mentioned dependencies such that the derived PK parameters only reflect local tissue 
properties. The PK parameters have the advantage of being biologically meaningful and help to establish 
objective criteria for classifying lesions [46]. Fig. 1.5 demonstrates the 2-compartment model that is used to
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represent the PK parameters. Multiple studies have shown the benefit of using PK parameters as additional 
information to the traditional T2-w images to diagnose PCa [11, 12, 13, 14, 15]. However, the specificity of 
PK analysis is tempered by post-biopsy hemorrhage, prostatitis and BPH as they mimic PCa enhancement 
patterns. Furthermore, PK analysis requires dedicated software which is not available in every imaging 
center.
Vessel/cappilary lumen Tissue•f ,•••
A  y  A™  a•#y# ••
Blood cells P lasma Interstitia l space T issue cells
—  Plasm a input function
Figure 1.5: Schematic drawing of the 2-compartment model used to represent the pharmacokinetic parameters 
Ktrans and interstitial volume Ve. The red area is the blood volume with blood plasma and blood cells 
(dark blobs). The yellow area represents the tissue volume containing interstitial space and tissue cells (dark 
blobs). The contrast cannot enter the cells but flows through the blood plasma around the cells to pass through 
interendothelial fenestrae and junctions into the interstitial compartment (which relates to permeability of the 
vessels).
Diffusion-weighted MRI (DWI) is a technique that lately attracted much attention. It is a non-invasive 
functional imaging technique that quantifies random Brownian motion properties of water molecules (dif­
fusion) in tissue. The degree of restriction to water diffusion in biologic tissue is inversely correlated to 
tissue cellularity and the integrity of cell membranes [47]. The net displacement of molecules is called the 
apparent diffusion coefficient (ADC). In malignant prostate tissue, the cellular density is increased which 
results in a reduced water diffusion and is represented by a decreased ADC value.
Three-dimensional proton MR spectroscopic imaging enables detection of the metabolites choline, cre­
atine and citrate. The choline plus creatine to citrate (Cho+Cr/Cit) ratio is suggested as marker for prostate 
cancers, since a decrease in citrate and an increase in choline levels is observed in malignant prostate tis­
sue [48].
Multiparametric MRI combines the before mentioned imaging techniques such that anatomical, func­
tional and metabolic information can be obtained within a single examination. It has been demonstrated 
that multiparametric MRI outperforms each independent technique when detecting PCa [11, 12,13, 14,15]. 
This concept was also demonstrated in a study by Futterer e t al. [11], see Fig. 1.6(a). Nevertheless, 
Futterer et al. also demonstrated in a preceding study that the interpretation of multidimensional infor­
mation requires a high level of experience, see Fig. 1.6(b). Furthermore, as there are no strict guidelines, 
the diagnosis is labour intensive and suffers from observer variability [16]. Because of the aforementioned 
limitations, multiparametric MRI is considered cost inefficient and, as a result, has not been implemented 
in a screening environment [17].
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(a) ROC curves for localization performance of prostate cancer by 
the radiologist using information from  1) T2-weighted MRI, spec­
troscopic MRI (MRS), dynamic contrast enhanced MRI (MPKS), 
dynamic contrast enhanced MRI and spectroscopic MRI combined 
(PKMRS) showing that combining multiple MR modalities in­
creases the localization performance considerably. [11].
(b) ROC curves showing that the diagnostic performance of 
the radiologist is experience dependent [36].
Figure 1.6: ROC curves show the results of the interpretation of T2-weighted (unenhanced) and dynamic 
contrast-enhanced MRI by an experienced radiologist and two less experienced radiologists. The results 
indicate an additional value of multiparametric MRI to all radiologist. Additionally, the ROC curves show 
that the diagnostic performance depends on the experience of the radiologist.
1.5 Computer Aided Diagnosis
CAD systems can be of benefit to improve the diagnostic accuracy of the radiologist, reduce reader variabil­
ity, and speed up the reading time. The aim of CAD is to automatically highlight cancer suspicious regions, 
leading to a reduction of search and interpretation errors, as well as a reduction of the variation between 
and within observers [49].
CAD systems generally consist of multiple sequential stages, as illustrated in figure 1.7. In the initial 
stage, lesion candidates are selected within a likelihood map that was generated by voxel classification of 
one or more images. Hereafter, the lesion candidates are segmented into a region of interest from which 
region based features are extracted. Finally, the extracted information is fused by a supervised classifier 
into a malignancy likelihood. The last stage ensures a reduction of the amount of false positives that were 
localized in the initial stage. The radiologist uses the calculated malignancy likelihood and the location as 
additional information in order to diagnose the patient.
Most prostate CAD researchers have focused on the initial voxel classification stage [50, 51, 52, 53, 
54, 55]. They obtained likelihood maps by combining information from multiparametric MR images using 
mathematical descriptors. These studies showed on a voxel basis that the discrimination between benign 
and malignant tissue is feasible with good performances. However, localization of the tumor, the final 
diagnosis and patient management is left to the radiologist. The task of a computer aided detection system 
is, however, to localize suspicious lesions and to estimate a malignancy likelihood for each detected lesion. 
Therefore, the goal of computer aided detection is to reduce search errors, reduce interpretation errors, and 
reduce variation between and within observers [49]. Computer aided diagnosis systems on the contrary 
only have a classification task for differential diagnosis of user provided regions.
The challenge to introduce CAD in the clinical workflow with a prostate cancer screening environment 
is enormous. The lack of standardized sequences and objective quantitative features of PCa are important 
obstacles for prostate MR CAD to become widely available. Furthermore, to become successful in a clinical 
environment, the intended CAD system should be fully automated, robust to the large population variation
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Figure 1.7: Dataflow diagram of a typical CAD system for the automatic detection of cancer. In the initial 
stage, lesion candidates are selected within a likelihood map that was generated by voxel classification of one 
or more images. Hereafter, the lesion candidates are segmented into a region of interest from which region 
based features are extracted. Finally, the extracted information is fused by a classifier into a malignancy 
likelihood that is presented to the radiologist.
and fast enough for a typical screening production of say 30 to 40 cases a day. As of today, there is no 
commercial prostate CAD system available that fulfills the mentioned requirements.
The main topic of this thesis is the research and development of a CAD system for the prostate cancer 
screening environment. Special attention is paid to evaluation of quantitative methods, if they can assist the 
radiologist in localizing prostate cancer and whether they are applicable to the clinic.
1.6 Outline
The outline of the thesis is as follows. In chapter 2, the feasibility is investigated of a CAD system capable of 
objectively discriminating PCa from non-malignant disorders located in the peripheral zone of the prostate. 
DCE-MRI derived features are extracted and summarized by a supervised classifier into a malignancy 
likelihood. In chapter 3 the CAD scheme is extended by extracting additional features from T2-weighted 
images in order to improve the discriminating performance of the CAD method. Chapter 4 continues with 
the research on pharmacokinetic parameters. A fully automatic calibration method is presented for the 
calculation of pharmacokinetic parameters and it is demonstrated that the discriminating performance of 
the CAD method is equal to that of a manual calibration method. Chapter 5 describes an automated prostate 
segmentation method, which is a used to reduce the number of false positive cancer candidates in a fully 
automated prostate cancer detection method, presented in chapter 6 . In the concluding chapter 8 a summary 
is provided as well as a general discussion.
Chapter 2
Computerized analysis of prostate lesions in the 
peripheral zone using dynamic contrast 
enhanced MRI
This chapter is based on the manuscript “Computerized analysis of prostate lesions in the peripheral zone 
using dynamic contrast enhanced MRI.” by Pieter C. V os, Thomas Hambrock , Christina A. Hulsbergen - 
van de Kaa , Jurgen J. Futterer , Jelle Barentsz , Henkjan Huisman Published in Medical Physics, vol. 25, 
no. 4, pp. 621-630, 2008.
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Abstract ______________________________________________________________________________________
A novel automated computerized scheme has been developed for determining a likelihood measure of ma­
lignancy for cancer suspicious regions in the prostate based on dynamic contrast-enhanced MRI (DCE-MRI) 
images.
Our database consisted of 34 consecutive patients with histologically proven adenocarcinoma in the peripheral 
zone of the prostate. Both carcinoma and non-malignant tissue were annotated in consensus on MR images 
by a radiologist and a researcher using whole mount step-section histopathology as standard of reference. The 
annotations were used as regions of interest (ROI). A feature set comprising pharmacokinetic parameters and 
a T1 estimate was extracted from the ROIs to train a support vector machine as classifier. The output of the 
classifier was used as a measure of likelihood of malignancy. Diagnostic performance of the scheme was 
evaluated using the area under the ROC curve.
The diagnostic accuracy obtained for differentiating prostate cancer from non-malignant disorders in the pe­
ripheral zone was 0.83 (0.75-0.92). This suggests that it is feasible to develop a CAD system capable of 
characterizing prostate cancer in the peripheral zone based on DCE-MRI.
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2.1 Introduction
It is estimated that one out of ten male cancer deaths in 2007 will be caused by prostate cancer (PCa). 
Furthermore, with a total of 218,890 cases, PCa is the most common non-cutaneous cancer in the United 
States [56]. PCa incidence rates continues to increase, although at a slower rate than those reported for 
the early 1990s and before. This trend may be attributable to increased screening through prostate-specific 
antigen (PSA) testing as well as the aging of the population. The definitive diagnosis of PCa is most often 
established through transrectal ultrasound (TRUS)-guided sextant biopsy.
For men diagnosed with prostate cancer, a number of treatment options exist, with differing side ef­
fects. The therapeutic options are mostly determined using nomograms of which the Partin tables is most 
commonly used [33]. The Partin tables estimate the chance of organ-confined disease, capsular penetra­
tion, seminal vesicle invasion and lymph node metastasis, based on the result of digital rectal examination, 
biopsy Gleason score and PSA value [34]. However, these clinical assessments are not accurate in deter­
mining the local stage. Elevated PSA levels can be observed in non-malignant disorders such as prostatitis 
or benign prostatic hyperplasia (BPH). The limitations of sextant biopsy are increasingly recognized, which 
has provoked interest in multimodal magnetic resonance imaging (MRI) as an alternative method of tumor 
evaluation [57]. Accurate staging is important for a proper disease management. Curative therapy is only 
effective in cases of organ confined (surgical candidate) PCa, whereas androgen therapy and/or radiother­
apy is more effective in advanced disease. Accurate localization is important for evaluation of the tumor 
location and the distance to the neurovascular bundle and prostate capsule, to determine if a nerve sparing 
operation is possible, or assist the planning of intensity-modulated radiotherapy [58, 59, 60].
MRI localization can reduce the number of repeat biopsies, improve the staging performance and guide 
surgery or radiotherapy. T2-weighted MRI using a pelvic phased-array coil can visualize the prostate in­
cluding the surrounding anatomy and depict tumor suspicious areas of low signal intensity within a high- 
intensity peripheral zone. An endorectal coil improves the spatial resolution, resulting in better anatomi­
cal visualization which may result in an improved diagnostic accuracy of the localization and staging of 
PCa [61, 62, 11, 57]. However, in addition to PCa, the differential diagnosis of a low signal intensity 
area includes post-biopsy hemorrhage, prostatitis, BPH, effect of hormonal or radiation treatment, fibrosis, 
calcifications, smooth muscle hyperplasia and fibromuscular hyperplasia [63].
Dynamic contrast-enhanced MRI (DCE-MRI) can be used as an additional tool to visualize PCa (neo-) 
vascularity and interstitial space. Due to the high vascularity, increased capillary permeability as well 
as interstitial hypertension in tumors, DCE-MRI shows better distinction between malignant lesions and 
normal tissue compared to conventional MRI alone [37, 38, 39, 40, 41, 42, 43, 44]. Futterer et al. [11] 
showed that using T2-w images in combination with DCE-MRI for localizing PCa, equal or greater than 
0.5 cm 3, resulted in an accuracy of 81-91% whereas using T2-w MR images alone resulted in a localizing 
accuracy of 68%.
Post-biopsy hemorrhage, prostatitis and BPH can all mimic PCa enhancement patterns, thus comprising 
the specificity of the technique. Another major obstacle to the application of MRI analysis in the routine 
clinical practice of prostate imaging is the variability of interpretation criteria and absence of interpretation 
guidelines [57]. Our study aims to increase the objectivity and reproducibility of prostate MRI interpretation 
by developing a computer aided diagnosis (CAD) system.
The proposed method enables an objective automated quantification and classification of features to 
discriminate between benign and malignant lesions, and may improve the tumor localization accuracy of the 
radiologist. In addition to objective analysis, computerized analysis can take full advantage of information 
across slices in 3D multi-feature data sets which is difficult to assess visually from individual images. CAD 
has been successfully pursued in other diagnostic areas such as mammography [64, 65], CT chest [66] as 
well as breast MRI [67, 68]. In the field of the prostate, Chan et al. [50] constructed a summary statistical 
map of the peripheral zone based on the utility of multi-channel statistical classifiers by combining textural 
and anatomical features in PCa areas from T2-w images, diffusion weighted images (DWI), proton density 
maps and T2 maps. Madabhushi et al. [69] generated similar statistical maps based on T2-w images using 
histological maps as ground truth and showed the additional value of combining features. However, to our 
knowledge, there has been no reported studies about similar work on PCa using DCE-MRI.
The purpose of this study was to investigate the feasibility of a CAD system capable of objectively 
discriminating PCa from non-malignant disorders located in the peripheral zone of the prostate. Localizing
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PCa in the central gland of the prostate is considered difficult because this area is often affected by BPH, 
which can have areas of low signal intensity on T2-w images and shows enhancement patterns in DCE-MRI 
similar to that of PCa. Nevertheless, 65% to 74% of the prostate tumor nodules are located in the peripheral 
zone and central gland tumors are often less aggressive [11]. The focus of this study is therefore on the 
peripheral zone of the prostate.
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2.2 Methods
The proposed CAD method is based on a typical CAD setup illustrated in figure 2.1 and works as follows: a 
prostate MRI exam is visualized as described in section 2.2.1. While interpreting the images, the radiologist 
can delineate a lesion as a region of interest (ROI) in the images, using a method discussed in section 2.2.2. 
From here the characterization of the ROI is fully automated. The CAD system extracts a relevant feature 
set from the ROI as explained in section 2.2.3. The extracted set of features is presented to a trained 
classifier which calculates the malignancy likelihood for the lesion as described in section 2.2.4. Finally, 
the calculated likelihood is presented to the radiologist to assist in his or her diagnosis. The CAD system 
was implemented in an open source programming environment The Visualization ToolKit (VTK) using the 
Tool Command Language (Tcl) and C++.
Figure 2.1: Dataflow diagram of the implemented CAD system. The user defines a region of interest from 
which features are extracted. The features are used to calculate the likelihood of malignancy in the region of 
interest.
2.2.1 Volume visualization
Figure 2.2: The CAD program using a dedicated prostate hanging protocol, with in the 3 views on top axial 
T2-w images as background and pharmacokinetic paramater maps (latewash and K trans) as foreground. The 
3 views at the bottom show the sagittal and coronal view as well as the pre-contrast T1-w volume.
The CAD program can visualize multimodal MR volumes I k, where k  = 1 . . .  K  and K  is the number 
of image volumes. The set of K  volumes comprises all the volumes acquired in an MR study plus derived
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volumes from the acquired volumes. Examples of acquired volumes are T2-w images and T1-w images. 
Additionally, descriptive parameter maps derived from DCE T1-w images by means of pharmacokinetic 
modeling are computed (see appendix 2.7 for a description on pharmacokinetic modeling) [11]. In each 
view all available volumes can be rendered either as background or as transparent color coded overlays. 
The cursor is positionable in one of the views with the mouse after which the CAD system will instantly 
update the location in all views. Although the MR data is obtained in slices, the CAD system visualizes 
the data as 3D volumes taking all directions into account. Figure 2.2 demonstrates the CAD system with a 
dedicated prostate hanging protocol as it is used in our clinic for localizing PCa.
2.2.2 Lesion segmentation
A 3D drawing tool has been implemented which allows the user to easily delineate a suspicious lesion in 
3D. At the request of the user a 3D sphere shaped ROI is added at the position of the cursor and visualized 
in all views. It is adjustable in size to fully delineate the suspicious area. The intended use is to adjust 
the sphere to be large enough to fully include the lesion’s size, as to reduce inter-observer variability (see 
section 2.2.3).
Let an ROI S r define a set of N cartesian voxel locations x* in the MR coordinate system:
S r = {x i ,  X2, . . . ,  x n }. (2.1)
Let Vr,k represent a set of scalar values in image volume I k , identified by Sr :
Vr,k = {Ik (Xi)\Xi £ S r } (2 .2)
The assumption is that all image volumes I i ,  I 2, . . . ,  I k are registered to each other in the MR coordinate 
system and as a result, a lesion segmentation in I k will segment the same lesion area in I k+ i, regardless of 
the image resolution or orientation.
2.2.3 Feature extraction
A reduced feature set Fr is calculated from the scalars values of the available volumes (Vr k). Each feature in 
the feature vector F r =  { f i , f 2, . . . ,  f L }, with L the number of features, is a first-order statistic of the scalar 
values of volume I k. One of these statistics are the 25% or 75% percentile. These percentiles are especially 
suited for volumes that show an heterogeneous pattern, e.g. the derived volume K trans [70, 71, 72]. This 
heterogeneity is most common for tumor and differs from normal tissue and benign lesions [73, 74]. The 
25% or 75% percentile will differ more from the average value when hotspots are present and will give an 
estimate of the value in that hotspot, as demonstrated in figure 2.3. This heterogeneity is also recognized 
by the pathologist (at macro scale). They base a histological grade on the Gleason system, in which the 
dominant and secondary glandular histological pattern are determined. By segmenting the whole lesion 
and using percentiles to extract the hotspot, variability among users is reduced. Stoutjesdijk et al. [75] 
showed that manual selection of the hotspots is the major source of variation in the interpretation of the 
DCE characteristics of breast MRI lesions. Thus, annotating the whole enhancing region instead of just 
the hotspot and automatically extracting the features sensitive to hotspots within the region, makes the 
technique more reproducible. An additional advantage of using percentiles is that it is less sensitive to 
extreme values.
To do so, Vr,k is summarized into a single scalar value f r,k,p by calculating its percentile p:
Hr,k(fr,k,p) = P, (2.3)
where H r,k is the cumulative density histogram of the scalar values in Vr,k .
2.2.4 Classification
The final step of the CAD program is to combine the computed features and to estimate the likelihood of 
malignancy of the region of interest. The malignancy likelihood lr is calculated using a trained classifier t :
lr = t  (Fr; T ), (2.4)
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Figure 2.3: A prostate cancer case to demonstrate the rationale for using percentiles. Although both regions 
do not differ much in their median, the tumor shows a wide spectrum of heterogeneity in their dynamic en­
hancement patterns and has more high values. Subfigure 2.3(a) shows a transverse T2-w view of the prostate 
with a transparent K trans color-coded overlay. The bi-lateral enhancement in the peripheral zone are both 
suggestive of cancer. In subfigure 2.3(c) a histogram distribution of the malignant lesion is shown, located 
in the right peripheral zone (solid box) and correlated to tumor 1 with Gleason 4+4 in the corresponding 
histopathology slice shown in subfigure 2.3(b). The 75% percentile is 0.36. Note the wide spectrum. Sub­
figure 2.3(d) shows a histogram distribution of a suspicious enhancing normal peripheral zone region (dotted 
box). The 75% percentile is 0.23. Note the narrow spectrum.
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where T  is a training set of feature vectors and truth states. Classification was performed using support 
vector machine (SVM) analysis on the feature set (provided by the statistical package R [76]) [77, 78]. 
SVMs are currently widely used in similar problems as they can act as a general purpose non-linear classi­
fier. SVMs have been shown to perform well on various datasets of limited size. SVMs map input vectors 
to a higher dimensional space where a maximal separating hyperplane is constructed by means of a kernel 
function. For this study the radial basis function kernel K ( u ,  v) = e x p ( - j  * \u — v\2) with parameter 
Y =  1/5 (5 equals the number of features used) was chosen and the cost of constraints violation (or ’C ’- 
constant of the regularization term in the Lagrange formulation) was set to 1 [79, 80]. When the classifier 
has calculated lr , the user is prompted with the estimate of the likelihood of malignancy as shown in the 
example in figure 2.7(c).
2.3 Feature description
The following features were extracted from S r :
50% T1Static: The T1Static parameter is the pre-contrast static value of the T1 estimate of the longitudinal 
relaxation rate in ms. T1-weighted signals are not ideally suitable for use in quantitative assessment 
of contrast media concentration. We therefore use dynamic T1 mapping with snapshot FLASH se­
quences as a direct approach to quantification, as described in Hittmair et al [45]. If a post-biopsy 
hemorrhage is present, it is clearly visible as a high-intensity area on a T1-w image. The biopsy 
hemorrhage is often visible as a large homogeneous area, hence the median is used to capture this.
75% Ve: In the extravascular, extracellular space (EES) of normal tissue, pressure is near atmospheric 
(25m m H g) values, whereas in tumors it may reach 5 0 m m H g  or even more. The interstitial hy­
pertension may be due to increased vascular permeability in combination with a lack of lymphatic 
drainage due to the absence of functional lymphatic vessels within the tumor itself. This results in 
an increase of the EES. The EES is therefore considered a very descriptive parameter defined as per­
centage per unit volume of tissue [81]. Interstitial leakage space at tumor hotspots can be three to five 
times larger than normal tissue, hence the upper quartile is used to capture these hotspots.
75% k ep & K trans: The transfer constant (K trans) and rate constant (kep) both have units 1 /m in ,  where 
K trans relates to permeability surface area. The permeability (or leakiness) surface area refers to 
the ability of tracer molecules to pass through interendothelial fenestrae and junctions into the in­
terstitial compartment. High permeability of the vasculature is a characteristic of pathological blood 
vessels in inflamed tissues and tumors. In case of a tumor, both K trans and k ep often show focal 
enhancement [73]. The upper quartile captures the presence of hotspots.
25% late wash: The late wash parameter quantifies the slope of the curve after the first wash-in phase. 
Although it does not directly correlate to physiological parameters, the presence of washout is highly 
indicative of PCa [39], and therefore used in our clinic as a diagnostic parameter. When capillary 
permeability is very high, the backflow of contrast medium is also rapid, resulting in a negative late 
wash following the shape of the plasma concentrations. Because late wash enhancement is often 
heterogenous, the 25th percentile is used to capture this.
The described pharmacokinetic features were extracted because quantification of kinetic parameters 
has the advantage of being biologically meaningful and help to establish objective criteria for classifying 
lesions [46], see appendix 2.7 for a description of how the kinetic features are derived from the raw T1-w 
images. The feature selection is based on clinical experience, previous work [11] has shown that these 
features are the most descriptive and are therefore preferred in our clinic. Furthermore, preselecting only 
five features prevents the classifier from being distracted by either poor performing or irrelevant features 
(peaking phenomenon) [78].
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2.4 Training and Evaluation
2.4.1 Dataset
The study set consisted of 34 consecutive patients that were selected in a previous study of Fiitterer et 
al. [11]. These patients had biopsy-proven PCa and underwent DCE-MR imaging at 1.5-T, complementary 
to the routine staging MR imaging examination of the prostate. Patients were included (between April 1, 
2002, and June 1,2004) in the study only if they were candidates for radical retropubic prostatectomy within 
6 weeks after MR imaging. The study of Fiitterer et al. was approved by the institutional review board, and 
informed consent was obtained from all patients prior to MR imaging. After imaging, all patients underwent 
radical retropubic prostatectomy. Exclusion criteria were: previous hormonal therapy, lymph nodes positive 
for metastases at frozen section analysis, contra-indications to MR imaging (e.g., cardiac pacemakers, in­
tracranial clips), contraindications to endorectal coil insertion (e.g., anorectal surgery, inflammatory bowel 
disease). The mean prostate specific antigen level was 8 ng/mL (range, 3.2-23.6 ng/mL), mean Gleason 
score was 6.1 (range, 5-8). MRI was performed on average 3 weeks after transrectal ultrasonographically 
guided sextant biopsy of the prostate.
2.4.2 MR Acquisition
Images were acquired with a 1.5T whole body MR scanner (Sonata, Siemens Medical Solutions, Erlangen, 
Germany). A pelvic phased-array coil as well as a balloon-mounted disposable endorectal surface coil 
(MedRad®, Pittsburgh, PA, USA) was inserted and inflated with approximately 80 cm3 of air, were used 
for signal receiving. The machine body coil was used for RF transmitting. An amount of 1 mg of glucagon 
(Glucagon®, Novo Nordisk, Bagsvaerd, Denmark)) was administered directly before the MRI scan to all 
patients, to reduce peristaltic bowel movement during the examination.
The protocol for acquisition consisted first of a localizer and two fast gradient spin-echo measurements 
for patient and coil positioning. Thereafter high-spatial-resolution T2-weighted fast spin-echo imaging in 
the axial, sagittal and coronal planes, covering the prostate and seminal vesicles, was performed. The 
frequency encoding direction was anteroposterior to increase the acquisition speed.
Thirdly, 3D T1-weighted spoiled gradient echo images were acquired before and during an intravenous 
bolus injection of paramagnetic gadolinium chelate (0.1 mmol/kg, gadopentetate, Magnevist®; Schering, 
Berlin, Germany) using a power injector (Spectris, Medrad®, Pittsburgh, PA, US) with an injection rate 
of 2.5 ml/second followed by a 15 ml saline flush. At these settings a 3D volume with ten partitions, 
covering the whole prostate, was acquired every 2 seconds for 120 seconds. Before contrast injection the 
same axial 3D T1-weighted gradient echo sequence was used to obtain proton density images and identical 
positioning to allow calculation of gadolinium chelate concentration curves [45]. See Table 2.1 for the 
precise specification of the acquisitions. Within 3 weeks of biopsy, there can be postbiopsy artifacts on
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*One of each sequence was performed before contrast agent administration. After contrast agent administration, 74 dynamic Tl-weighted fast 3D
gradient-echo and five dynamic T1-weighted high-resolution 3D gradient-echo MR imaging sequences were performed
MRI. This cannot be avoided as we feel it is unethical to unnecessarily delay a scheduled prostatectomy. 
The optimal timing of post-biopsy MR Imaging of the prostate has been researched by Ikonen et al. [82] 
and White et al [83]. They advise deferring MR imaging for at least 3 weeks after biopsy.
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Histopathological analysis
All patients underwent radical retropubic prostatectomy. The prostatectomy specimens were fixed overnight 
(10% neutral-buffered formaldehyde) and coated with Indian ink. Axial whole mount step-sections were 
made at 4-mm intervals in a plane parallel to the axial T2-w images and routinely embedded in paraffin. Tis­
sue sections of 5 ^m  were prepared and stained with haematoxylin and eosin. An experienced pathologist 
(C.A.H.K) who was blinded to the imaging results, established malignancy from microscopy. Regions of 
malignancy were outlined on digital macroscopic whole-mount images from a CCD camera. Figure 2.7(d) 
shows an example of an histopathological map.
Annotation in the MRI data
The whole-mount step-section histology tumor maps were used as ground truth for training and evaluat­
ing the performance of the CAD system. The morphology of the central gland, peripheral zone, cysts, 
calcifications, and urethra were used as landmarks to find the corresponding MRI slice.
Aligning MR slices to whole-mount step-sections is considered difficult [84], it is subjective and the 
section thickness used in the MR imaging sequences can be different. To overcome these problems a 
method was developed that semi-automatically matches MR slices to the step-sections of histopathology. 
The method has the following setup: one of the views is set to a 3D rendering mode for volumes. In this 
mode the volume is rendered in 3 planes in all directions. The planes can be manipulated to move through 
the volume slices. In this 3D view a default 3D ellipsoid is rendered as a transparent surface. The goal is 
to fit the prostate roughly by interactively resizing and translating the ellipsoid. The cross-sections of the 
ellipsoid are simultaneously displayed in the 2D views for a more accurate result. The final ellipsoid is than 
divided in the same number of slices as the prostatectomy specimen was cut. By doing this, the specimen 
images are aligned to the T2-w images. See figure 2.4 for a demonstration.
2.4.3 ROI annotation
Figure 2.4: Example of a prostate segmentation to obtain an objective and more accurate correspondence with 
histopathology. The left view shows a cross-section at transverse view of the prostate, the ellipse indicates the 
surface bounds in the T2-w image. The middle (sagittal) view represents the number of transverse slices in 
which the prostatectomy specimen was cut (9 slices). The right view shows the 3D deformable surface which 
can be positioned, scaled and stretched manually to fit the prostate roughly.
The anatomy of the prostate is best imaged on T2-w images and were therefore used for correlating the 
histopathological map. The features used for this experiment, however, were extracted from T1-w images. 
Because the patient may have moved and no registration is applied to correct for patient movement, the pre­
contrast T1-w images were semi-transparently overlaid on the T2-w images, to allow for visual inspection 
and comparison for anatomic mismatch due to patient related movements. If a mismatch was evident, it 
was compensated for by correcting the annotation on the pre-contrast T1-w images, thereby avoiding the 
annotation of periprostatic vasculature and urethra.
Table 2.2: The three classification types of Q that were assigned to the annotated regions.
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N  (normal) Region of normal enhancement and histopathological analysis 
showed no evidence for tumor.
M  (malignant)
Histopathology confirmed tumor with a clinical relevant 
diameter of at least 5mm.
Regions with prostatic intraepithelial neoplasia (PIN) were 






Region of non-malignant suspicious irregular heterogenous 
enhancing areas where the underlying histopathological 
analysis showed no evidence for tumor.
Region with histopathological confirmed prostatitis.
Region of post-biopsy hemorrhage without any 
histopathological evidence for tumor.
An ROI was placed to cover the whole lesion volume based on histopathology. After a thorough 
inspection of the segmentation, the ROI was saved to disk along with a classification label N , N S  or M . 
The definition of the labels are given in table 2.2.
For all saved ROIs S r with one of the assigned labels N , N S  or M , information was summarized 
by collecting the features fr,K*r°n,,r5, fr ,Kep,75, fr,Ve,75, fr,Washout,25 and fr,Tistatic,50, as described in 
section 2.3, into the feature vector Fr :
Fr = { f r ,Ktrans ,75, fr,Kep,75, fr,Vc,75 , fr,Washout,25, fr,T IStatic, 5o} (2.5)
2.4.4 ROC analysis
The discriminating performance of the CAD system was estimated by means of the area under the receiver 
operator characteristics (ROC) curve (AUC). Let £ = (li , l 2, . . . ,  lm ) be the vector of calculated malignancy 
likelihoods for m  ROIs with the trained classifier t . The ROIs are split into two groups a  and . Let 
Ya = {jlqj  € Q a } and Yp = { j k j € Q p } be the corresponding vectors of indices, where Q a and Qp 
are disjoint and subsets of Q (see table 2.2 for a definition of the labels). The AUC for the classification 
performance between two subsets of ROIs identified by Ya and Yp is given by [86]:
A U C lalß — 3' £7ß (2 .6)
with kernel function
, lj ' ) —
i f  lj  > lj'  
lj — lj' 
i f  lj  < lj'
(2.7)
and nYa and nYl3 the number of ROIs in Ya and Yp, respectively.
For this experiment two separate classifiers were trained and evaluated for its discriminating perfor­
mance. The first classifier Tioc was trained to discriminate regions of type { N , N S } from { M }. This 
reflects localization, hence the subscript loc. The discriminating performance of Tioc is denoted as A U C ioc 
and is computed using Eq. 2.6 by setting Q a to {N,  N S }  and Qp to { M }. The second classifier Tdif  was
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evaluated in a more clinical perspective, were the radiologist typically is only interested in the differentia­
tion between abnormal enhancing areas { N S }  and PCa { M }. The classification performance is denoted as 
AUCdi f  where Q a to { N S }  and Qp  to { M }.
Prospective performance of the lesion analysis was estimated by means of leave-one-patient-out (LOPO) 
cross validation. LOPO avoids training and testing on the same data, estimating the likelihoods of ROIs in 
that left-out case, and repeating the procedure until each case has been tested individually. Our study was 
a diagnostic assessment with patient-clustered data, and, thus, the bootstrap resampling approach with 10
000 iterations was used for estimating the bootstrap mean AUCs and 95% confidence intervals proposed by 
Rutter [86]. When a patient case is drawn, the entire set of S r for that case enters that bootstrap sample. In 
doing so, bootstrapping mimics the underlying probability mechanism that gave rise to the observed data. 
Statistical analyses were performed with the package R [76].
2.5 Results
Of the 34 patient studies, 4 were excluded because of insufficient dynamic data caused by patient movement 
or coil artifacts. In total 39 M  regions were annoted in the peripheral zone. The number of N S  regions 
annotated in the peripheral zone was 21. The number annotated N  regions was 30.
When looking at the scatterplots of figure 2.5 a noticeable clustering of features is seen. The scatterplots 
demonstrate that the feature values are usable to characterize lesions as M , N S  or N . It can be observed 
that the N  regions are compact and well clustered. Although the regions of type N S  and M  show a larger 
spread, they are still clustered and can thus be differentiated. Furthermore, the N S  regions appear to be 
more clustered than the M  regions.
The localization performance of the discrimination between { N , N S } and { M } is demonstrated in 
the ROC curve shown in figure 2.6(a). The figure shows that the diagnostic accuracy (AUCIoc) was 0.92 
(95% confidence intervals = 0.87-0.97)). In figure 2.6(b) the discriminating performance between { N S }  
{ M } regions is demonstrated. The diagnostic accuracy (A U C dif ) in this case was 0.83 ( 95% confidence 
intervals = 0.75-0.92)). The ROC curves show that the performances are statistically better than chance.
Figure 2.7 presents a true positive case as well as a true-negative case: in both the transverse and 
coronal views of the prostate, a bi-lateral enhancement is seen in the peripheral zone when overlaying 
several parametric maps on the T2-w images. Because of the enhancement, both sides are suspicious for 
cancer. The CAD system however, calculated a likelihood of malignancy of 80% for the annotated region 
that was identified as PCa by histophathology. In the other region, the CAD system calculated a likelihood 
of 20% of being malignant. Additionally, histopathology confirmed that there was no evidence for tumor at 
the specific location.
2.6 Discussion
This study showed that it is feasible to develop a CAD system capable of discriminating PCa from the 
normal peripheral zone and non-malignant disorders with a diagnostic accuracy of 0.92 (0.87-0.97). It 
was also shown that it is possible to develop a more clinically relevant CAD system, where the radiologist 
typically is only interested in abnormal enhancing areas. For the discrimination of solely non-malignant 
suspicious enhancing (N S ) areas from PCa in the peripheral zone, a diagnostic accuracy of 0.83 (0.75­
0.92) was obtained. This CAD system thus has the potential of being a valuable, additional diagnostic 
aid.
The proposed CAD method has some similarity with the study of Fütterer et al. [11]. In their study, it 
was shown that when using T2-w images and DCE-MRI in localizing PCa, radiologists achieved an overall 
accuracy of 0.92, when discriminating PCa pre-assigned regions from normal peripheral zone and non- 
malignant disorder pre-assigned regions. Although the focus of this study was the normal peripheral zone of 
the prostate, similar regions were used for the characterization by the CAD system. Furthermore, the same 
patient database was used. Our CAD method on the contrary, was trained with primarily pharmacokinetic 
features, whereas the radiologist used the T2-w images as an additional feature of region characterization.
The results of this study demonstrate for the first time in an objective manner that including DCE-MRI 
can discriminate PCa from N S  areas in the peripheral zone. This is supported by former studies where
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Figure 2.5: Pairwise scatterplots of 4 kinetic parameters and T1 parameter for the whole database with 
triangles representing N  regions, spheres as M  regions and squares as N S  regions. The ellipses summarize 
the three clusters by fitting a bivariate normal distribution and displaying the outline at 2 times standard 
deviation radius. A noticeable clustering of features is seen.
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Figure 2.6: ROC curves showing the discriminating performance of the CAD system of the two separate 
trained classifiers TIoc and rdif . The dotted curves are part of the bootstrapping approach and represent the 
95% confidence intervals of the solid-line ROC curve. Subfigure 2.6(a) shows the discriminating performance 
between regions of type N  and N S  versus M . Subfigure 2.6(b) shows the discriminating performance be­
tween regions of type N S  versus M .
human observers concluded the same [44, 42 ,43, 40, 41, 37, 39, 38, 87, 88].
The developed CAD system is capable of displaying multimodal MR images including DWI, T2*-w 
images, derived spectral maps from spectroscopic data, etc. Although the CAD program is developed in 
such a manner that it can include features from all available images as relevant information to train the 
classifier, only the pharmacokinetic and T1 estimate data was used. To further include features from the 
additional modalities, registration techniques are essential to compensate for patient movements. It can be 
expected that by extracting the additional features, the discriminating performance of the CAD system will 
further improve. Several studies indicated that combining multimodal MR images increased the localization 
accuracy [11, 57].
Histological correlation with MR images is recognized to be an imperfect gold standard for a number 
of reasons. These include: errors in registering the location of the imaging sections with histological 
slice specimens, inaccuracies resulting from tissue shrinkage secondary to fixation and errors due to partial 
volume averaging effects [38, 84, 89]. In most studies the number of slices is simply counted taking the 
shrinkage into account and using the morphology of the central gland, peripheral zone, cysts, calcifications, 
and urethra as landmarks to find the corresponding MRI slice. In this study great effort was put into the 
histopathology and MRI correspondence for an objective annotation of the ground truth. Therefore a 3D 
deformable surface was created to semi-automatically segment the prostate and divide it in the same number 
of slice-sections of the histopathology tumor maps. The method ensures that the user is only guided by the 
histopathology tumor maps, precontrast T1-w and T2-w images for placement of the ROIs. No DCE- 
MRI parametric maps were used as guidance in ROI placement, since this could introduce bias in CAD 
performance estimates. To further reduce user-variability, the whole lesion was annotated instead of just 
the hotspot as suggested by Stoutjesdijk et. al. [75].
Kiessling et al. [90] evaluated the accuracy of descriptive and physiological parameters calculated from 
signal intensity-time curves using T1-weighted DCE-MRI to differentiate prostate cancers from the periph­
eral gland. Although they did not create a CAD system capable of calculating a malignancy likelihood, 
they did evaluate the discriminating performance of the kinetic parameters. Their best performing parame­
ter, early degree of enhancement, achieved an AUC of 0.81. This result can be compared to our localizing 
classifier A U C ioc of 0.92. The difference in performance can be attributed to the method that was cho­
sen to calculate the pharmacokinetic parameters. Kiessling used the method proposed by Brix et al. [91]
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Figure 2.7: Example of two regions in the peripheral zone of the prostate that are difficult to differentiate. 
A bi-lateral enhancement is seen with pharmacokinetic parameters, suggesting that both sides are suspicious 
of prostate cancer. For both regions the CAD system calculated the likelihoods of malignancy using the 
classifier with a diagnostic accuracy (A U Cloc) of 0.92. Subfigure 2.7(a) shows a transverse T2-w image of 
the prostate with Ve color overlay map. Note the bilateral enhancement of the peripheral zone, which makes 
both sides suspicious for cancer. Subfigure 2.7(b) shows a coronal T2-w image of the prostate with K trans 
color overlay map. This parameters also shows a bi-lateral enhancement, suggesting the presence of tumor 
at both sides. In subfigure 2.7(c) the CAD predicted likelihoods of the annotated regions in the left and 
right peripheral zone are shown. The green area summarizes the distribution of all the calculated likelihoods 
for all N  and N S  regions from the database used for training the classifier. The red area summarizes the 
smoothed distribution of all the calculated likelihoods for all M  regions from the database used for training 
the classifier. The areas are smoothed using a two-dimensional nonlinear variable span smoother based on 
local linear fits, in which local cross-validation is used to estimate the optimal span. The black lines are the 
calculated likelihoods of malignancy for the regions. The dotted line corresponds with region in the left of the 
peripheral zone (with a predicted malignancy likelihood of 80%). The solid line corresponds with the region 
in the right of the peripheral zone (with a predicted malignancy likelihood of 20%). Histopathology confirmed 
the adenocarcinoma in the left peripheral zone (subfigure 2.7(d)). The tumor was staged as T2b and with a 
Gleason score of 3+3.
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where a fixed arterial input function for every patient is assumed (fixed calibration), whereas in this study 
the reference tissue model (per patient calibration) was used (see appendix A). In a previous study [92] we 
showed that a per patient calibration indeed has a positive effect on the discriminating performance of PK 
parameters over a fixed calibration.
Chan et al. [50] describe the only in-vivo CAD system that provides an estimated malignancy likelihood 
by combining information from T2-weighted, T2-mapping, and line scan diffusion images. They achieved 
a diagnostic performance of 0.84. This can be compared to our A U C ioc of 0.92. The lower performance 
is likely attributed to the lack of DCE-MRI features. Moreover, we have also researched and demonstrated 
the ability of our method to discriminate suspicious enhancing benign regions from malignant regions. The 
latter is of even greater importance in actual clinical conditions.
The current study has a number of limitations. The CAD system is not fully automated, since the user 
needs to identify normal peripheral zone for calibration with the reference tissue method (see appendix 2.7). 
As a result, the healthy tissue needs to be annotated in advance, which could result in the annotation of PCa, 
which makes the CAD system not clinical usable. An automated calibration technique makes the CAD 
system fully automated and is being researched. The effect of user-variability in annotating the ground 
truth on the performance has not been researched.
In conclusion, this study demonstrated the possibility to develop a CAD system capable of objectively 
discriminating malignant lesions from N S  areas located in the normal peripheral zone of the prostate with 
an accuracy of 0.83 (95% confidence intervals = 0.75-0.92)).
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2.7 Appendix: DCE-MRI postprocessing and pharmacokinetic mod­
eling
All MRI data was transferred to an independent workstation with in-house build software. Each MR signal 
enhancement-time curve was first fitted to a general exponential signal enhancement model as described 
previously [37]. This reduces a curve to a 5 parameter model: baseline (s0); start of signal enhancement 
(to), which defines the onset of the exponential curve; time-to-peak ( t ), the exponential constant; peak 
enhancement (sp), the signal amplitude at which the exponential curve levels off; and late wash,  defined 
as the slope of the late part of the exponential curve. The reduced signal enhancement-time curve was 
converted to a reduced tracer concentration [mmol/ml] - time curve [45] effectively converting sp to Cgd,p. 
We have implemented the method [45] such that in an intermediate step the T1 estimates are computed. 
The TIStatic parameter is the baseline T1 estimate (s0) prior to contrast enhancement.
Analysis of DCE-MRI data is usually based on the indicator dilution theory and requires knowledge of 
the concentration of the contrast agent in the blood plasma. Without any calibration, inter-patient plasma 
profile variability causes fluctuations in PK estimates, which are not related to the tissue condition. When 
using a power injector the most likely cause of plasma curve differences is the patient itself, e.g. differ­
ences in body weight (total distributional volume), heart rate, vascular condition. Removing the plasma 
shape can be regarded as a form of patient calibration. Among the wide variety of techniques for estimating 
plasma profiles, we have chosen for the reference tissue method and experienced robust results with the 
technique [93]. The reference tissue method assumes that a tissue area within the patient is available with 
a known tissue model based on literature values [94, 93]. By doing a deconvolution the actual tissue im­
pulse response can be determined. Deconvolution of the plasma profile and estimation of pharmacokinetic 
parameters conforms to the theoretical derivations [95] but is implemented in the reduced signal space as 
shown in the following equation:
Ve =  (2 .8)
C 99, Pplasma
kep =  ----------3 ----------- (2.9)
t tissue t plasma
K trans = Ve.kep (2.10)
where Ve is an estimate of the extracellular volume [%], K trans the volume transfer constant [1/min], 
and kep the rate constant [1/min] between extracellular extravascular and plasma space. The subscript 
’tissue’ stands for a measurement in the tissue under investigation and subscript ’plasma’ for the reference 
tissue plasma estimates based on literature values [94]. The reference tissue was determined by selecting 
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Abstract _________________________________________________________________________________________
In this study, computer assisted analysis of prostate lesions was researched by combining information 
from two different magnetic resonance (MR) modalities: T2-weighted (T2-w) and dynamic contrast en­
hanced (DCE) T1-w images. Two issues arise when incorporating T2-w images in a Computer Aided Diag­
nosis (CADx) system: T2-w values are position as well as sequence dependent and images can be misaligned 
due to patient movement during the acquisition. A method was developed that computes T2 estimates from 
a T2-w and proton density value and a known sequence model. A mutual information registration strategy 
was implemented to correct for patient movement. Global motion is modelled by an affine transformation, 
while local motion is described by a volume preserving non-rigid deformation based on B-Splines. The ad­
ditional value to the discriminating performance of a DCE T1-w based CADx system was evaluated using 
Bootstrapped ROC analysis.
T2 estimates were successfully computed in 29 patients. T2 values were extracted and added to the CADx 
system from 39 malignant, 19 benign and 29 normal annotated regions. T2 values alone achieved a diagnostic 
accuracy of 0.85 (0.77-0.92) and showed a significantly improved discriminating performance of 0.89 (0.81­
0.95), when combined with DCE T1-w features.
In conclusion, the study demonstrated a simple T2 estimation method that has a diagnostic performance such 
that it complements a DCE T1-w based CADx system in discriminating malignant lesions from normal and 
benign regions. Additionally, the T2 estimate is beneficial to visual inspection due to the removed coil profile 
and fixed window and level settings.
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3.1 Introduction
Several studies have indicated that multimodal MRI increases the prostate cancer (PCa) localization accu­
racy of the radiologist. The accuracy is, however, dependent on the experience of the radiologist [57,11,50]. 
To help improve the diagnostic accuracy of the unexperienced radiologist, we investigated the value of 
a Computer Aided Diagnosis (CADx) system. In a previous study [96], the feasibility was shown of a 
CADx system that calculates the malignancy likelihood of a given suspicious area in the peripheral zone 
of the prostate using T1-w DCE-MRI. Discrimination of malignant and benign regions was performed 
using a support vector machine (SVM) as classifier that was trained with features extracted from quantita­
tive pharmacokinetic (PK) maps as well as T1 estimates. The study showed that a diagnostic accuracy of
0.83 (0.75-0.92) was obtained by a stand-alone CADx. It is expected that by adding more MR modalities, 
the discriminating performance of the CADx system will further improve.
In this paper, the possibility of using T2-w images as an additional MR modality to discriminate PCa 
from benign regions in the peripheral zone (PZ) of the prostate is studied, as they are also used by the 
radiologist for localizing PCa. Two issues arise when including the T2-w images in a DCE based CADx 
system. Firstly, there can be misalignment of T2-w and DCE images as patient movement between the series 
is inevitable during a prostate study. Secondly, the acquired T2-w signal intensities are not linearly related 
to the underlying tissue T2 relaxation times and depend on the 3D spatial position relative to the receiving 
coil elements. To resolve the nonlinearity, a T2 estimator was used that was published previously [97, 98]. 
The approach requires both T2-w, proton density (PD) images and a known sequence model. Note that 
although the acquisition of quantitative T2 maps is possible using a multi-echo spin echo technique in a 
reasonable time span on contemporary MR systems, spatial resolution will be considerably lower. Patient 
movement can be retrospectively corrected by aligning images using image registration, which is necessary 
for both the T2 estimation as well as inclusion in the CADx system. In this study a method is proposed that 
models global shifts with affine transformation and local deformation using B-Splines. The method also 
estimates the coefficients to maximize the mutual information (M I) between the two images. The method 
is based on the work of Rueckert et al. [99] which was further developed and tested by Mattes et al. [100]. 
M I  based registration is a common choice to register different modalities and is considered suitable for 
registration of images that do not have the same pixel intensity range [101, 102, 103, 104].
To our knowledge, there have been no reported studies about similar work on PCa using DCE-MRI and 
T2-w images. Chan et al. [50] describe the only in-vivo CADx system that provides an estimated malig­
nancy likelihood using multimodal MRI. They constructed a summary statistical map of the peripheral zone 
based on the utility of multi-channel statistical classifiers combining textural and anatomical features in PCa 
areas from T2-w images, diffusion weighted images (DWI), PD maps and T2 maps. The achieved diag­
nostic performance of 0.84 is, however, of limited clinical value because the discrimination did not include 
benign regions such as prostatitis or hemorrhage. Madabhushi et al. [69] generated similar statistical maps 
based on T2-w images using whole mount sections as the “ground truth” and showed the additional value of 
combining numerous features. Unfortunately no discrimination performance was calculated, computation 
time for analysis of one complete MRI scene exceeds an hour and the method is limited to 2D ex vivo MRI. 
Viswanath et al. [105] extended the method of Madabhushi et al. with a non-rigid registration scheme to 
map PCa whole mount histological sections onto corresponding 2D DCE-MRI. Though the method po­
tentially improves the objective annotation of PCa, the corresponding slice still needs to be selected. The 
unsupervised classification by k-means clustering achieved an accuracy of 77%. Their advocated method­
ology is, however, evaluated on a per-pixel basis, whereas the proposed method captures the heterogeneous 
nature of PCa by using percentiles within a given region [73, 74].
The purpose of this study was to investigate the feasibility of including T2-w MR in a multi-modal 
computer aided diagnostic system for prostate MR.
3.2 Materials and Methods
3.2.1 Patient Characteristics
The study set consisted of 34 consecutive patients (mean age, 60 years; range, 50-69 years) that were 
selected in a previous study of Futterer et al. [11]. These patients had biopsy-proven PCa and underwent
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DCE-MR imaging at 1.5-T, complementary to the routine staging MR imaging examination of the prostate. 
Patients were included (between April 1, 2002, and June 1, 2004) in the study only if they were candidates 
for radical retropubic prostatectomy within 6 weeks after MR imaging. The study of Futterer et al. was 
approved by the institutional review board and informed consent was obtained from all patients prior to 
MR imaging. After imaging, all patients underwent radical retropubic prostatectomy. Exclusion criteria 
were: previous hormonal therapy, contra-indications to MR imaging (e.g., cardiac pacemakers, intracranial 
clips), contraindications to endorectal coil insertion (e.g., anorectal surgery, inflammatory bowel disease). 
The mean prostate specific antigen level was 8 ng/mL (range, 3.2-23.6 ng/mL), mean Gleason score was 6.1 
(range, 5-8). MRI was performed on average 3 weeks after transrectal ultrasonographically guided sextant 
biopsy of the prostate.
3.2.2 MR Protocol
Images were acquired with a 1.5T whole body MR scanner (Sonata, Siemens Medical Solutions, Erlan­
gen, Germany). A pelvic phased-array coil as well as a balloon-mounted disposable endorectal surface 
coil (MedRad®, Pittsburgh, PA, USA, inserted and inflated with approximately 80 cm3 of air) were used 
as receiver. The integrated body coil was used for transmit. All patients received one mg of glucagon 
(Glucagon®, Novo Nordisk, Bagsvaerd, Denmark) was administered intramuscularly directly prior to the 
MRI scan, to reduce peristaltic bowel movement during the examination.
Table 3.1 shows the sequence parameters. The protocol for acquisition consisted first of a localizer 
and two fast gradient spin echo measurements for patient and coil positioning verification. Thereafter, 
high-spatial-resolution T2-w turbo spin echo imaging in the axial, sagittal and coronal planes, covering 
the prostate and seminal vesicles, was performed. Next, 3D T1-w spoiled gradient echo images were ac­
quired before and during an intravenous bolus injection of paramagnetic gadolinium chelate (0.1 mmol/kg, 
gadopentetate, Magnevist®; Schering, Berlin, Germany) using a power injector (Spectris, Medrad®, Pitts­
burgh, PA, US) with an injection rate of 2.5 ml/second followed by a 15 ml saline flush. The recorded 
repetition time (TR) of 34 msec represents the time to acquire 12 k-lines (two of 12 slices where used for 
oversampling). A 6/8 partial Fourier reconstruction (FFT) was used to reduce the acquisition time. With 
these settings, complete 3D volumes were acquired every two seconds for a duration of 120 seconds. Before 
contrast injection, the same axial 3D T1-w gradient echo sequence, though with a longer TR time without 
partial Fourier reconstruction, was used to obtain PD-w images at identical positioning to allow calcula­
tion of the T2 estimates and the PK parameters. The gadolinium concentration curves and PK parameters 
were calculated as reported by Huisman et al. [37]. The PK parameter set that was used in this experi­
ment, consisted of the pre-contrast static value of the T1 estimate of the longitudinal relaxation rate in [ms] 
(TIStat ic ) ,  the relative size of the extracellular, extravascular space (Ve), the rate constant (kep) and the 
transfer constant (K trans). They are described in detail in [96].
3.2.3 Image Registration Algorithm
This section describes an image registration method that automatically seeks for an estimate of the trans­
formation T  that aligns the PD image F  and T2-w image M  by optimizing a similarity measure S  over the 
transformation T :
S ( F , M  (T )). (3.1)
The registration procedure consisted of several components, the most important of which were the choice 
of similarity measure, the transformation degrees of freedom and the cost function for similarity of mea­
surement.
Deformation model
An initial alignment of F  and M  was achieved using a 12 element affine transformation matrix Tglobal, 
as reported previously [106]. In general, an affine transformation is composed of linear transformations 
(rotation, scaling or shear) and a translation. It ensures a global registration with low computational costs. 
An additional transformation T local modeled local deformation. In this work, deformations are modelled on 
cubic B-splines, because of their computational efficiency (separability in multiple dimensions, calculation
Table 3.1: Parameters for MR Imaging
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via filtering), smoothness, and local control [99]. A B-Spline transformation deforms a volume by manipu­
lating an underlying mesh of control points (D). Deformation is calculated using the positions of a 4x4x4 
neighborhood of control points and third-order spline polynomials, where the parameters of the B-Spline 
transformation are the coordinates of the control points. In the presented method, the initial Tgiobai was 
used as offset of Tlocal:
T  = Tlocal-Tglobah (3.2)
Similarity measure
In this study M I  was used as a similarity measure because F  and M  do not have the same appearance. 
When F  and M  are optimally aligned, their M I  is maximal:
T  =  a rgm in  (—M I  (0 )), (3.3)
where M I (0)  denotes the M I  similarity measure as a function of the transformation parameters, 0 . Al­
though several implementations for the computation of M I  exists, the presented method is based on the 
work of Mattes et a l  [100]. Their registration method makes efficient use of the B-Spline basis functions 
that models the deformation field and converges quickly when compared to other methods, due to stochastic 
sampling [107].
M I  relates the joint entropy to the entropies of the modalities separately:
M I (0)  =  H ( f  (x)) + H ( m ( 0 ( x ) ) )  — H ( f  (x), m ( 0 (x ) ) ) ,  (3.4)
where H  ( f  (x)) and H  (m (0 (x ) ) )  are the marginal entropies, H  ( f ,  m; 0)  the joint entropy, f  (x) and m(x )  
denote observations of F  and M , respectively and x  denotes the voxel coordinate. The joint entropy 
H (  f ,  m; 0 ) uses a set of fixed bin centres in f  and moving bin centres in m  as initialization.
The entropy of an image is computed from the probability density function (pdf) of the image inten­
sities. Parzen-windowing was used to obtain a differentiable pdf. This reduces the effects of quantization 
from interpolation and discretization from binning the data, see Thevenaz et a l  [108] for a detailed descrip­
tion. The joint entropy is computed using:
H ( f , m ;  0 ) = ^ 2  w f  (If (x f ) — f  )wm (IM(g(xF; 0) ) — m) ,  (3.5)
xGXp
where I F (xF ) and I M (g(xF ; 0) )  are samples of the fixed and interpolated moving images, respectively and 
w f  and wm are the Parzen window kernels [100]. To reduce the computational costs, the set of intensity 
samples ( X F ) was set to a randomly selected 20% of the total number of voxels and the joint histogram 
was calculated based on 100 bins for each image. These settings gave robust results on all experiment data. 
To further speed up the calculation of the M I (0),  samples were only drawn from a subregion of F . This 
will be further discussed in section 3.2.3.
Constraint on the transformation
In addition to the M I  similarity measure, a regularization term P  was incorporated in the registration 
method to constrain the deformation of the coordinate space:
C(F,  M ( T )) =  —S(F,  M ( T )) +  a P ( T ), (3.6)
where a  is a user defined weight factor for P , allowing more control over the influence of the regularization 
term on the overall cost C . Similar to the work of Rohlfing et a l  [109], a volume preserving constraint was 
incorporated and implemented by penalizing deviations of the Jacobian determinant J  of the deformation 
from unity, that is, it assumes local rigidity and penalizes local tissue expansion and compression:
P ( 0 )  = N r  ^  l1og ( J  (x)1, (3.7)
D xeD
where D  represents the set of control points used for the deformation.
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Calculation of the gradient of the constraint is necessary for an efficient and robust optimization (see 
section 3.2.3). The derivatives were calculated using the common finite-difference approximation:
SP ^  P ( 0 i + Sj) — P ( 0 i)
~ ~  ~ , (3.8)
Si Si
where Si equals 1 mm and the subscript i refers to the parameter index.
Optimization of the cost function
The L-BFGS-B [110], a limited-memory, quasi-Newton minimization package, was used to optimize the 
cost function C  until termination criteria were satisfied. The limited-memory method is well suited for op­
timizing the large number of parameters 0  in the B-Spline transformation when a high resolution of control 
points is used. L-BFGS-B provides an additional advantage in that it allows bound constraints (B) on the 
independent variables. In this manner, maximum displacements of the control points can be controlled. 
Note that displacements in the slice direction were considered unlikely and therefore restricted with a fixed 
bound set to 0. The optimization terminates when the change in C  between consecutive iterations falls 
below the tolerance of l e - 4 .
Centered cropped optimization strategy
A high resolution of control points in the B-Spline transform T  comes with high computational costs, due 
to the high number of displacements of the control points D  that needs to be explored. For the intended 
application, the focus is on the non-rigid displacement of the prostate. Hence, it suffices to limit the regis­
tration method to the center area of the pelvis, where the prostate is situated. The set of control points (D) is 
defined over the entire volume (F ) plus a finite support region of three at the borders, thereby extending the 
region of interest. Simply defining a smaller mesh inside the volume results in interpolation artifacts near 
the edges of the grid. Therefore, optimization was limited to a centered subset (D R c  D ) of control points. 
Because the number of parameters in D R is much smaller, the registration method becomes considerably 
faster. The resolution of the grid control points was set to 14x14x8 (including the finite support region). A 
centered subregion (D R) of size 4x4x3 was chosen such that the prostate area was covered in all cases.
3.2.4 Histological Verification
All patients underwent radical retropubic prostatectomy. From the prostatectomy specimens, whole-mount 
step-section histology tumor maps were created by an experienced pathologist who was blinded to the imag­
ing results. The whole-mount step-section histology tumor maps were used as ground truth for training and 
evaluating the performance of the CADx system. The morphology of the central gland, peripheral zone, 
cysts, calcifications and urethra were used as landmarks to find the corresponding MRI slice. The anatomy 
of the prostate is best imaged on T2-w images and were therefore used for correlating the histopathological 
map. A method was implemented to prevent bias when annotating the ground truth, as described else­
where [96]. Using this method, regions of normal PZ, PCa, benign PZ tissue (identified as tumor suspicious 
on T2-w and DCE-MRI but not representing tumor on pathology) and levator ani muscle were outlined 
manually. The regions that contained muscle were used for the reference tissue method, as explained in 
section 3.2.5.
3.2.5 Quantitative T2 estimation from T2-w and PD series
T2 relaxation times can be computed with a fast method that uses a known sequence signal model as prior 
knowledge and only a few echo times (TE) to fit the T2 relaxation curve. Hittmair et al. [45] presented a 
method that estimates the T1 relaxation rate with only two repetition times (TR) and a spin echo sequence 
as signal model. In this study a comparable approach is applied to estimate the T2 using a T2-w turbo spin 
echo sequence and PD-w gradient echo sequence. It is assumed that a T2-w sequence is used, such that 
the TR is much larger then the T1 tissue relaxation times. Then the effect of T1 can be neglected and the 
received signal s at location x  for a T2-w turbo spin echo sequence is:
st2w (x) = Gt2w s in (0t2w )p(x)exp(—T  E / T  2(x)), (3.9)
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where G t2w represents the gain setting and 8t2w the excitation flip angle for the T2-w sequence and p is 
a function comprising proton density fluctuations and coil profile at location x . The spatial dependence 
through p(x)  models the commonly observed spatial inhomogeneity that is caused by the receive and send 
coil sensitivity profiles. In case of a PD-w image, the effect of T1 and T2 should be reduced when TE is 
set short and TR is set long. Assuming that both sequences use the same coil setup (p(x)  is identical), the 
received PD signal can be approximated by:
where Gpd is the gain setting and dpd the excitation flip angle for the PD-w gradient echo sequence. The 
T 2 at position x  is derived by rewriting Eq. 3.9 and Eq. 3.10:
where nt2wpd is the gain ratio of G t2wsin(0t2w) to Gpdsin(Opd). In theory, n can be estimated from the 
MR sequences parameters, but the data was not stored in the DICOM header provided by the MR system. 
Furthermore, any coil profile artifacts, differences in voxel size, TR or receiver bandwidth can still result 
in acquisition-to-acquisition signal intensity variations, in spite of the fact that commercial MR systems 
are nowadays equipped with internal calibration methods. These variations are captured in n and need to 
be estimated from the data. Therefore, an estimator for the gain ratio nt2w,pd was built using a reference 
tissue R ref  with known T2 value from literature. In this study levator ani muscle was used (35.3±3.85 
msec at 1.5T and 37°C [111]). The gain setting can now be found by performing least squares optimization 
using the data from all pixels within the annotated reference tissue:
The least square procedure that was used, uses Brent’s method of parabolic interpolation, protected by 
golden-section subdivisions if the interpolation is not converging.
3.2.6 Training and Validation
The CADx system extracts a PK and T2 feature set from a region of interest (ROI) using percentiles. The 
extracted set of features is presented to a trained SVM which calculates the malignancy likelihood for a 
lesion. The calculated likelihood is presented to a radiologist to assist in his or her diagnosis. The CADx 
system was implemented in an open source programming environment The Visualization ToolKit (VTK) 
using the Tool Command Language (Tcl) and C++.
The discriminating performance of the CADx system was estimated using the area under the receiver 
operator characteristics (ROC) curve (AUC). Classification was performed using SVM analysis on the fea­
ture set (provided by the statistical package R [76])
A prospective-performance estimate of the lesion analysis was made by means of leave-one-patient-out 
(LOPO) cross validation. LOPO avoids training and testing on the same data, estimating the likelihoods 
of ROIs in that left-out case and repeating the procedure until each case has been tested individually. This 
study was a diagnostic assessment with patient-clustered data, therefore a bootstrap resampling approach 
with 10 000 iterations, was used for estimating the mean AUCs and 95% confidence intervals, as proposed 
by Rutter [86].
The intent of this study was not to provide a new T2 estimator. Nevertheless, some validation was 
performed to research the validity of the T2 estimates. Firstly, visual inspection was performed. Secondly, 
the median and variation for T2 relaxation time of the normal peripheral zone were computed. The results 
were compared with those found in literature. Thirdly, the method was compared with a multi-echo spin 
echo sequence, where the T2 relaxation curve was automatically fitted by a Siemens mono-exponential 
decay fitting algorithm. The sequence settings were 7 echo times (15.6-109.2msec), a spatial resolution of 
1.2x1.2x3.0mm, matrix of 192x96, field of view of 230x115, TR of 2080, flipangle of 180 and 16 slices. 
Levator ani muscle was used as reference and the mean relaxation time was calculated for Muscle, Benign
spd(x) = Gpdsin(Qpd)p(x), (3.10)
(3.11)
Vopt =  a rg m in  ^  (T2(x; n) -  35)2.
X G Rref
(3.12)
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PZ, Fat, Normal PZ, Normal transition zone (TZ) and Lesion PZ in a random patient case. Linear regression 
and Pearson correlation statistics were performed.
The effect of registration on the diagnostic performance of the CADx system was studied. In this 
experiment, T2-w values, T2 estimates without registration, T2 estimates after affine registration and T2 es­
timates after the implemented non-rigid registration, were extracted from the annotated regions and tested 
for their discriminative value. In the following experiment, the effect of parameter settings on the diagnostic 
performance was valuated. The method was tested with different constraint settings (B) and various Jaco- 
bian weighting factors (a), to search for the optimal discriminative performance. In the final experiment 
the additional discriminative value of T2 estimates in a multimodal setup was tested and compared with the 
performance of the previous developed CADx system.
3.3 Results
In total, 34 consecutive patients with histologically proven adenocarcinoma of the prostate were recruited. 
Four patient studies were excluded because of bad dynamic data caused by large patient movement, coil 
artifacts and one due to large noise values. In total 39 malignant regions were annotated in the peripheral 
zone. The number of benign regions annotated in the peripheral zone was 19. The number of annotated 
regions in the normal peripheral zone was 29.
Fig. 3.1 shows an example case, where the coil profile is prominently visible in the T2-w image, but 
is removed by the method in the quantitative T2 image. In Fig. 3.2 the value of non-rigid registration
Figure 3.1: The left T2-w image of the prostate demonstrates the coil sensitivity of conventional MR images.
Voxels near the endorectal coil are more intense compared to voxels that are ventrally located. The right image
shows the computed T2 image. Note that the coil profile is strongly reduced.
is demonstrated. Patient movement during the examination as well as internal (bowel) movement were 
corrected by the method.
The median calculated T2 relaxation time was 82±7.5 msec for normal PZ, 68±15.4 msec for benign 
regions and 60± 6.9 msec for malignant regions, at the best possible setting of the registration method and 
using levator ani muscle as reference tissue. In Fig. 3.3, T2 values of several tissues of one patient case are 
shown and compared to a Siemens T2 sequence acquired in that same study. A significant linear correlation 
can be observed.
Fig. 3.4 shows the histograms of the distributions of the T2-w values, T2 estimates without registration, 
T2 estimates after affine registration and T2 estimates after non-rigid registration, that were extracted from 
all normal, benign and malignant regions. It can be observed that the amount of overlap between the 
distributions (especially M and N) is lowest after the non-rigid registration.
Fig. 3.6 shows the effect of varying the parameters a  and B  on the registration method. At low Jacobian 
weighting factors (a  <  1.5), the algorithm tends to be sensitive to the settings of B . Best settings were
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Figure 3.2: Sample images illustrating the necessity for nonrigid registration. The acquired T2-w image 
(background image) and the PK parameter K trans (colour-coded transparent overlay) are misaligned in the 
first image. Typical enhancement patterns are observed peri urethral (arrow) and at the neurovascular bundles, 
but due to patient movement during the examination, the enhancement patterns do not match the underlying 
T2-w image (left). This can also be observed in the figure in the middle which shows the result of an affine 
registration, where after a global correction the neurovascular bundles match the enhancement patterns, but a 
peri urethral mismatch is still present. The right image shows the result of the non-rigid registration method. 
Note the correct location of enhancement at the peri urethral region
60 60 100 120 140 160 180
T2 Map
Figure 3.3: Plot showing the mean T2 relaxation times for several tissues in a patient case, with T2 values 
generated by a traditional multi-echo sequence of the MR system on the x-axis and on the y-axis, the T2 
values generated by the proposed method. The linear regression model and the Pearson correlation statistics 
are shown.
found at B  =  ± 25m m  and a  =  1.5. With these parameter settings the diagnostic value of the T2 esti­
mates was quantified by the discriminating performance of the CADx system. In a tumor localization setup, 
where normal PZ regions were discriminated from benign and malignant regions, a diagnostic performance 
of 0.97 (0.94-1.00) was achieved using non-rigid registration, as shown in Fig. 3.5. Using the non-rigid 
registration method, a significant improvement was shown compared to the affine registration method, as 
well as to not using registration. The T2-w values were of no diagnostic value to the CADx system. In a dif­
ferentiation setup, where normal and benign PZ regions were discriminated from malignant PZ regions, the 
CADx system achieved a diagnostic performance of 0.85 (0.77-0.92) after non-rigid registration (Fig. 3.5). 
This accuracy was significantly better than not using registration (p=0.03), but did not show a significant 
improvement to an affine registration.
The accuracy of the CADx system for discriminating normal PZ and benign regions from malignant 
regions was 0.84 (0.76-0.92) using the PK parameters alone. Adding the estimated T2 relaxation times 
to the PK feature set resulted in an accuracy of 0.89 (0.81-0.95), which was a significant improvement
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Figure 3.4: Histograms of T2-w values, T2 estimates without registration (None), T2 estimates using affine 
registration and T2 estimates using B-Spline registration. Here, ’n’ represents all normal PZ regions, ’b’ 
represents all benign regions an d ’m ’ all malignant regions of the database.
(p=0.03) (Fig. 3.7).
3.4 Discussion
This study showed the feasibility of including T2-w MR in a multi-modal CADx system for prostate MR. 
T2 estimates were shown to be of a significant additional diagnostic value for the in-house developed 
CADx system [96]. Moreover, coil profile sensitivity, that was present in the T2-w images, was noticeably 
diminished, making these images potentially more beneficial for clinical interpretation during diagnostic 
viewing.
Registration had a strong influence on the diagnostic performance of the T2 estimates in discriminating 
normal and benign from malignant regions. This study is unique in comparing registration methods on the 
actual effect upon the diagnostic performance. While most registration literature is limited to visual obser­
vation or simulated deformations, the present study quantified the effect upon the diagnostic performance. 
The effect is demonstrated in Fig. 3.5. The non-rigid registration method showed the highest diagnostic ac-
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Figure 3.5: ROC curves showing the discriminating performance of the CADx system using T2 estimates 
and T2-w values. The T2 estimates were first extracted when no registration was applied, second after affine 
registration and third after non-rigid registration. The left graph shows the result at a differentiation setup, 
where PZ and benign PZ regions are discriminated from malignant PZ regions. It can be noticed that normal 
PZ and benign regions are well differentiable from malignant regions. The right graph demonstrates the 
discriminating performance in a localization setup, where normal PZ is differentiated from both benign regions 
and malignant regions.
Figure 3.6: Parameters grid search for the B-Spline registration, with bound (B) the optimizer constraint on 
the displacement of the control points, a  the Jacobian factor and Az the diagnostic performance of the CADx 
system.
curacy. As an example, Fig. 3.2 illustrates organ movement that could not be compensated for using affine 
registration, but was resolved by free form deformation using cubic B-Splines [99]. A disadvantage of this 
technique is, that it can lead to loss of topology. Therefore, the Jacobian determinant as volume preserving 
constraint on the transformation was included. Fig. 3.6 demonstrates that including such a constraint, the 
diagnostic performance of the CADx system improves and leads to a more robust registration, as it is less
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Figure 3.7: ROC curves showing the diagnostic performance of the CADx system using the T2 estimates 
after non-rigid registration, versus only using PK parameters and the additional value of T2 estimates when 
they are combined with the PK parameters.
dependent on other parameter settings.
The T2 estimator in this study is a novel, simple method in a CADx context. Although a full validation 
is outside the scope of this study, some aspects indicate validity. Firstly, visual inspection showed that 
the coil profile was removed. Secondly, the inter-patient variability of T2 estimates in the normal PZ was 
small (±7.5 msec). Thirdly, a significant linear correlation was shown between the T2 estimates of our 
method and the multi-echo spin echo sequence (r=0.97,p=0.001). Finally, adding the T2 values as feature 
to the CADx system resulted in a significantly improved discriminating performance of 0.89 (0.81-0.95), 
compared to only using the PK features (0.84 (0.76-0.92)). The performance increase agrees well with 
previous literature on combining T2 estimates and PK parameters [57, 11, 50].
The calculated T2 relaxation times for the prostate (82±7.5 msec) were compared with those found in 
literature. In the small study of de Bazelaire et al. [112] (based on data from three healthy men), prostate 
and vertebra relaxation rates of 88±0 msec were calculated. Chan et al. [50] found relaxation rates of 
128.3±42.9 for nonbrachytherapy patients and 88±21 msec for post-brachytherapy patients in the normal 
PZ. More recently [113], using a different T2 map imaging sequence, they found, in 18 men with biopsy- 
proven PCa, 193±49msec in healthy tissue and 100±26msec in suspected cancer. Gibbs and Liney et 
al. [70] found in an early study relaxation rates of 96.2±15.2 msec in patients but in a more recent study 
135.5±40.0 msec in the normal PZ of patients [114]. Two observations can be made from this litera­
ture survey. Firstly, there is no consensus on the absolute T2 value of normal PZ. Consequently, any T2 
discrimination protocol or CADx system has to account for the T2 estimation method that was used. Sec­
ondly, a large inter-patient variability. The presented method has a much lower variability, which partly 
explains the good discriminative properties of the estimated T2 relaxation times. The reduced variability 
may be explained by the use of reference tissue (section 3.2.5). In doing so, the method calibrates on a per 
patient basis which may be better in capturing machine dependencies. The effect of using calibration on 
the diagnostic performance was also demonstrated in a previous study [92], but then in a pharmacokinetic 
context.
The T2 estimator has a number of potential shortcomings. Firstly, muscle T2 variability can result in 
different T2 estimates, as it is used as reference tissue. The variability is an effect of physical activity and 
muscle training. In this study, we used levator ani muscle as reference tissue. In contrast to most skeletal 
muscles, levator ani muscles are non-voluntary, therefore intra-patient T2 variation is small. Secondly, the 
method is sensitive to B1 fluctuations. The volume of interest (prostate region), however, is in the middle 
of the image where B1 fluctuations are less present. Thirdly, the T2-w tse sequence has contributed data
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from different echo times (depending on the echo train length and k-space sampling) and therefore the 
estimated T2 values might not be in exact concordance with a multi-echo spin echo derived estimation. The 
slight inaccuracy, however, will be evident in all patients and all tissues evaluated. The inaccuracy will be 
compensated for by using reference tissue calibration (e.g., muscle). Fourthly, the T2-w and PD-w coil 
setup should be identical.
The current study has a number of limitations. One limitation is the amount of time needed for the 
non-rigid registration, which now ranges from 5 min to 15 min. This, however, will not conflict the in­
tended application, since the radiologist does not evaluate the images directly after the acquisition and the 
registration can thus be performed offline. A second limitation is the manual annotation of levator ani m us­
cle, which is needed for the reference tissue method. One solution is to have more information on actual 
gain coefficients and sequence models used by the MR system. Yet the reference tissue method may have 
a positive effect on the discriminating performance as stated above. Another potential method would be 
an automated segmentation of the levator ani muscle and is part of further research. Nevertheless, manual 
segmentation of the muscle and computing the T2 estimates is performed in seconds. Third limitation is 
that the registration method parameter Jacobian constraint weight (a ) requires tuning (Fig. 3.6). Different 
MR hardware (e.g., at 3 Tesla) and sequence settings may require different parameter settings.
In conclusion, the study demonstrated a simple T2 estimation method that has a diagnostic performance 
such that it complements a DCE T1-w based CADx system in discriminating malignant lesions from normal 
and benign regions with a significant improved accuracy of 0.89 (0.81-0.95) compared to only using DCE 
derived features.
Chapter 4
Automated calibration for computerized 
analysis of prostate lesions using 
pharmacokinetic magnetic resonance images
This chapter is based on the manuscript “Automated calibration for computerized analysis of prostate le­
sions using pharmacokinetic magnetic resonance images.” by Pieter C. Vos , Thomas Hambrock (MD) , 




The feasibility of an automated calibration method for estimating the arterial input function when calculating 
pharmacokinetic parameters from Dynamic Contrast Enhanced MRI is shown. In a previous study [96], 
it was demonstrated that the computer aided diagnoses (CADx) system performs optimal when per patient 
calibration was used, but required manual annotation of reference tissue. In this study we propose a fully 
automated segmentation method that tackles this limitation and tested the method with our CADx system 
when discriminating prostate cancer from benign areas in the peripheral zone.
A method was developed to automatically segment normal peripheral zone (P Z ) tissue. Context based seg­
mentation using the Otsu histogram based threshold selection method and by Hessian based blob detection, 
was developed to automatically select normal P Z  as reference tissue for the per patient calibration.
In 38 consecutive patients carcinoma, benign and normal tissue were annotated on MR images by a radiologist 
and a researcher using whole mount step-section histopathology as standard of reference. A feature set com­
prising pharmacokinetic parameters was computed for each ROI and used to train a support vector machine 
as classifier.
In total 42 malignant, 29 benign and 37 normal regions were annotated. The diagnostic accuracy obtained 
for differentiating malignant from benign lesions using a conventional general patient plasma profile showed 
an accuracy of 0.65 (0.54-0.76). Using the automated segmentation per patient calibration method the diag­
nostic value improved to 0.80 (0.71-0.88), whereas the manual segmentation per patient calibration showed a 
diagnostic performance of 0.80 (0.70-0.90).
These results show that an automated per-patient calibration is feasible, a significant better discriminating per­
formance compared to the conventional fixed calibration was obtained and the diagnostic accuracy is similar 
to using manual per-patient calibration.
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4.1 Introduction
Several studies have indicated that multi-modal MRI increases the prostate cancer (PCa) localization accu­
racy of the radiologist. The accuracy is, however, dependent on the experience of the radiologist [57,11,50]. 
To help improve the diagnostic accuracy of the (unexperienced) radiologist, we are investigating the possi­
ble additional value of CADx. Previously [96], the feasibility was demonstrated of an in-house developed 
CADx system that calculates the malignancy likelihood of a given suspicious area in the peripheral zone of 
the prostate using T1-w DCE-MRI at 1.5T. Discrimination of malignant and benign regions was performed 
using a support vector machine (SVM) as classifier that was trained with features extracted from quanti­
tative pharmacokinetic (PK) maps as well as T1 estimates. The study showed that a diagnostic accuracy 
of 0.83 (0.75-0.92) was obtained by a stand-alone CADx, which is comparable to an expert radiologist 
performance.
Pharmacokinetic (PK) DCE-MRI could further improve PCa differentiation by reducing inter patient 
and inter MR scanner fluctuations compared to conventional DCE-MRI. PK tissue parameters are estimated 
by fitting a tracer physiologic compartment model to the observed DCE-MRI data that is driven by a plasma 
profile. Various techniques for estimating plasma profiles exist. Quite some PK estimators do not include 
per patient calibration, but use a general patient plasma profile (fixed calibration) [115, 116]. Huisman 
et al. [117] demonstrated that the plasma profile varies per patient and thus, fixed calibration can cause 
fluctuation among patient when estimating the PK parameters. In [92], it was shown that the CADx system 
performs significantly better using per patient calibration instead of fixed calibration. The presented method 
was, however, dependent on manual annotation of healthy tissue before a malignancy likelihood could be 
calculated. This study addresses that limitation by presenting a more objective and automated calibration 
method and investigates its effect on the diagnostic accuracy of the CADx system.
The purpose of this study was to investigate the feasibility of a CADx system capable of objectively 
discriminating PCa from non-malignant disorders located in the peripheral zone of the prostate using an 
automated per patient calibration method.
4.2 Method
4.2.1 Pharmacokinetic modeling
Analysis of DCE-MRI data requires knowledge of the concentration of the contrast agent in the blood 
plasma. Without calibration (or fixed calibration), inter-patient plasma profile variability causes fluctuations 
in PK estimates, which are not related to the tissue condition. When using a power injector the most likely 
cause of differences in plasma curves are differences in body weight (total distributional volume), heart rate, 
vascular condition. Removing the plasma shape can be regarded as a form of patient calibration whereas 
fixed calibration uses a fixed plasma function over all patients.
The parametric model for analyzing contrast agent concentration time curves in DCE-MRI is the two 
compartment model of Tofts et al. [95]. The observed concentration-time curve can be expressed as:
Cv (t) = h(t; t 0,V e, K trans, W as hout )  <g> Cp(t), (4.1)
where Cv (.) denotes the observed tracer concentration, h(.) the tissue impulse response, Cp(t) the plasma 
input function and to,Ve, K trans,W a s h o u t  are parameters from the model. The reference tissue method 
estimates the plasma input function by:
Cp(t) = Cref,v (t)/href,v (t) , (4.2)
where Cref,v (.) represents the observed plasma profile for tissue v and href,v (.) a reference plasma profile 
for tissue v based on literature. The reference tissue method is considered to be a robust technique [93].
4.2.2 Automated per patient calibration
In a previous study [92], it was demonstrated that using P Z  as reference tissue gave good results for 
estimating PK parameters. In this study a method was developed to auto segment P Z . The method is
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(a) DCE of the prostate area. (b) DCE of the bladder area.
Figure 4.1: Rational for modeling an early and large enhancing blob in the pelvic area.
divided into two stages. First, the location of the prostate is detected using a blob detection method. In the 
second stage, this location is further refined to segment a P Z  region.
Autom ated localization of the prostate
The prostate can be modelled as a large enhancing area (or blob) in the pelvis. Figure 4.1(a) demonstrates 
this model where the prostate can easily be detected by a human observer. Large and strong enhancements 
can be observed in the transition zone of the prostate making it suitable for detection. First experimental 
results showed however, that this assumption is not only true for the prostate. Because the acquisition 
time for the DCE-MRI can be rather long (3 min), contrast agent also arrives in the bladder, resulting 
in a comparably large enhancing blob, as demonstrated in figure 4.1(b). The prostate model is therefore 
extended by including the arrival time of the contrast agent (t0 of Cv (t)). Otsu’s automatic threshold 
selection method from gray-level histograms ([118]) is used to segment early enhancing structures in the 
relative enhancement image V(x):
A common approach to detect blobs is to consider the Taylor expansion of VO at multiscale for a given 
neighborhood of pixel x  [119],
where V CT and H a are the gradient vector and Hessian vector of an image at scale a.  Here, VO is convolved 
using derivatives of Gaussians:
Next, from H a eigenvalues are computed, corresponding the the k-th normalized vector iia}k and 
analyzed to determine the likelihood of a pixel x  belonging to a blob. This analysis is based on the following 
likelihood function (for bright blob, dark background):
(4.3)
VO (x +  Sx, a) «  VO (x, a)  +  SxT V CT +  SxT H a Sx, (4.4)
— Vo(x ,  a ) = a V o ( x ) — G ( x ,a ) .  
Sx  Sx
(4.5)
P ( x ,  a ) =  |A i(x)||A 2( x ) p 3 (x)|, (4.6)
Automated calibration for computerized analysis o f prostate lesions using PK-MRI 45
that is, all three eigen values should be large to represent a blob. A multiscale approach is adopted after 
which the maximum response is selected:
P  (x) =  m ax P  (x ,a ) .  (4.7)
amin max
The center location of the prostate x pc containing the highest probability is then selected by x pc = arg m axx P  ( x ) . 
In figure 4.2(a) a probability map is shown that is used for the prostate detection.
Automated segmentation of normal peripheral zone tissue
In the second stage of the method, a context based segmentation is performed to extract normal peripheral 
zone tissue. The method is based on the model that the P Z  is mainly dorsal located of x pc. Thus, we define 
a box-mask below x pc with height, width and depth set to a  to mask VO. Here, a  corresponds with the size 
of the prostate and is the scale at which P ( x pc) was found by the blob detector:
S ( x pc) = arg m ax (P  (xpc,a )  (4.8)
a
Figure 4.2(b) demonstrates this model.
(c) Strong gradient removal (d) Extrema thresholding
Figure 4.2: Example case of context based segmentation of normal peripheral zone tissue
Simple thresholding of extrema and removal of sharp edges using a gradient magnitude filter can now be 
applied to the box-mask which results in the segmentation of normal peripheral zone tissue, as demonstrated 
in figures 4.2(c) and 4.2(d).
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4.2.3 CADx performance evaluation
The features K trans, Ve and W a s h o u t  were computed and used to train a SVM as classifier [95]. The 
features were combined into a single malignancy likelihood estimate using the SVM. The output of the 
classifier was used as a measure of likelihood of malignancy. The discriminating performance of the CADx 
system was estimated by means of the area under the receiver operator characteristics (ROC) curve (AUC). 
The prospective performance of the lesion analysis with per patient and fixed calibration were estimated by 
means of leave-one-patient-out (LOPO) cross validation. LOPO avoids training and testing on the same data 
and to emphasize the prospective value, one whole patient case was drawn from the set. The LOPO involves 
training on all but one case, estimating the likelihood of that left-out case, and repeating the procedure until 
each case has been tested individually. The bootstrap technique was used to compute 95% confidence 
intervals for the AUC and significance level for the paired difference [86].
4.2.4 Experiment
The study set consisted of 38 consecutive patients that were selected between January 2007 and October 
2008. These patients had biopsy-proven PCa and underwent dynamic contrast-enhanced MR imaging at 
3.0T, complementary to the routine staging MR imaging examination of the prostate. Patients were in­
cluded in the study only if they were candidates for radical retropubic prostatectomy within 6 weeks after 
MR imaging. The study was approved by the institutional review board, and informed consent was obtained 
from all patients prior to MR imaging. Exclusion criteria were: previous hormonal therapy, lymph nodes 
positive for metastases at frozen section analysis, contraindications to MR imaging (e.g., cardiac pacemak­
ers, intracranial clips), contraindications to endorectal coil insertion (e.g., anorectal surgery, inflammatory 
bowel disease)
Images were acquired with a 3.0T whole body MR scanner (TrioTim, Siemens Medical Solutions, 
Erlangen, Germany). A pelvic phased-array as well as a balloon-mounted disposable endorectal surface 
coil (MedRad®, Pittsburgh, PA, USA) inserted and inflated with approximately 80 cm3 of Perfluorocarbon 
(FOMBLIN LC08), were used for receiving. The machine body coil was used for RF transmitting. An 
amount of 1 mg of glucagon (Glucagon®, Novo Nordisk, Bagsvaerd, Denmark)) was administered directly 
before the MRI scan, to all patients to reduce peristaltic bowel movement during the examination.
High-spatial-resolution T2-weighted fast spin-echo imaging in the axial, sagittal and coronal planes, 
covering the prostate and seminal vesicles, was performed. 3D T1-weighted spoiled gradient echo im­
ages were acquired before and during an intravenous bolus injection of paramagnetic gadolinium chelate 
(0.1 mmol/kg, gadopentetate, Magnevist®; Schering, Berlin, Germany) using a power injector (Spectris, 
Medrad®, Pittsburgh, PA, US) with an injection rate of 2.5 ml/second followed by a 15 ml saline flush for 
300 sec every 3 seconds. Fitting the DCE-MRI is described elsewhere [45].
Whole-mount step-section histology tumor maps were used as ground truth for annotating PCa (with 
a relevant diameter of at least 5mm), non-malignant suspicious enhancing (NS) and normal (N) regions on 
T2-w images for all patients in consensus by two readers.
4.3 Results
One patient case was excluded because the DCE examination had failed. In total 42 malignant regions were 
annotated in the peripheral zone. The number of NS regions annotated in the peripheral zone was 29. The 
number of normal peripheral zone regions was 38.
The effect of the per patient calibration on the diagnostic performance was first evaluated by pairwise 
scatterplots of PK parameters of the lesions. It is noticeable in figure 4.3(a) that without calibration the 
clusters overlap more than the clusters in figure 4.3(c) where manual calibration is included. Figure 4.3(b) 
shows similar results for automatic patient calibration. Furthermore, the N  and N S  clusters have a smaller 
covariance when patient calibration is used. An effect on the diagnostic performance can therefore be 
expected. The different distributions demonstrate the strong effect of the chosen calibration method.
The performance of discriminating malignant lesions from NS areas with fixed, manual and automatic 
calibration is demonstrated in the ROC curves shown in figure 4.4. Here, the focus is on the characteriza­
tion of NS and malignant regions, because it is more challenging and clinically relevant. The diagnostic
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(a) Fixed (b) Auto (c) Manual
Figure 4.3: Pairwise scatterplots of 2 kinetic parameters, W ashou t versus K trans, for the whole database 
with squares representing NS regions, spheres as malignant regions and triangles as N regions for the different 
calibration methods used. The ellipsoids summarize the three clusters by fitting a bivariate normal distribution 
and displaying the outline at 2 times standard deviation radius. It is noticeable that the clusters overlap one 
another when fixed calibration is used, whereas manual and automated per patient calibration demonstrate a 
noticeable clustering of features.
accuracy was 0.65 (95% confidence intervals = 0.54-0.76)) when fixed calibration was used. The diagnostic 
accuracy improved significantly for both manual per patient calibration, Az=0.80 (0.70-0.90), as for auto­
mated per patient calibration, Az=0.80 (0.71-0.88). The marginal difference between the automated and 
manual calibration means that they perform similar, which was the intended goal.
False positive fraction
Figure 4.4: ROC curves showing the discriminating performance of the CADx system using the different 
calibration methods fixed, automated per patient and manual per patient calibration.
4.4 Conclusion
In this study, we have demonstrated the feasibility of an automated calibration method for estimating the 
arterial input function when calculating pharmacokinetic parameters from DCE-MRI. The results show a 
significant better discriminating performance (Az=0.80 (0.71-0.88)) compared to the conventional fixed 
calibration. The performance is similar to using the manual per patient calibration.
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Automatic Parametric Multivariate 
Multi-object Segmentation of the Prostate in 
MR images Using Prior Knowledge
This chapter is based on the manuscript “Automatic Parametric Multivariate Multi-object Segmentation of 
the Prostate in MR images Using Prior Knowledge.” by Pieter C. Vos (MSc), Jelle Barentsz (PhD, MD), 




Automatic prostate segmentation is a crucial step for Computer-Aided Detection (CAD) systems to reduce 
the number of false positive cancer candidates. Fully automatic prostate segmentation in MR images is chal­
lenging, mainly due to the lack of well-defined edges, similar intensity profiles with surrounding organs and 
its relative small size in the male pelvis. In this paper, a fully automatic parametric multivariate multi-object 
segmentation method is presented. A parametric model describing the prostate and surrounding anatomical 
structures is first fitted to multiple MR images simultaneously. The obtained anatomical information about 
structure shape, position and appearance is then used as prior knowledge in a Bayesian framework to classify 
the voxels of the multivariate MR images and to segment the prostate. The segmentation performance is com­
pared to the results obtained when (1) information from a single MR image is used and (2) pelvic model fitting 
is not performed as a first step. The results show that a multivariate segmentation including fitting significantly 
outperforms the aforementioned approaches with a dice coefficient index of 0.77±0.05. To the best of our 
knowledge, this is the first time that a method which fits a parametric multi-object model to multivariate MR 
images is presented for prostate segmentation.
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5.1 Introduction
Prostatic cancer (PCa) is the most commonly diagnosed cancer among American men and remains the sec­
ond leading cause of cancer related deaths among males [120]. Prostate Specific Antigen (PSA)-based 
screening programs may reduce mortality from prostate cancer with 20% to 30% but they are associ­
ated with overdiagnosis and overtreatment of indolent disease [8, 9]. Prostate Magnetic Resonance Imag­
ing (MRI) can be used in PSA based screening scenarios in order to reduce the rate of overdiagnosis and 
overtreatment. Several studies showed that combining anatomical, functional and metabolic MRI infor­
mation leads to a sufficient high PCa localizing and detection accuracy of up to 92% [11, 12, 13, 14, 15]. 
The reported accuracy of prostate cancer detection on MR images varies widely, and controversy persists 
regarding recommendations for the use of MR imaging in the initial diagnosis of high-risk patients or in 
patients with previous negative biopsy findings but persistently high PSA level (62). Despite the promising 
results, it has been shown that the accuracy is highly dependent on the experience of the radiologist and the 
interpretations suffer from observer variability [16].
Computer aided detection (CAD) systems can help to improve the diagnostic accuracy of the radiolo­
gist. CAD aims to automatically highlight cancer suspicious regions, leading to a reduction of search and 
interpretation errors, as well as the variation between and within observers [49]. However, for CAD to be 
useful in a prostate screening environment, the following requirements are essential as well as challenging: 
it should be fully automated; it needs to be robust to the large population variation; and it should be fast 
enough in a high volume screening setting.
Automatic prostate segmentation is a crucial step within the workflow of a CAD system. That is, 
it reduces a substantial number of false positive cancer candidates that are detected in the initial step. 
Automatic prostate segmentation in MR images has been a subject of considerable research as it is a difficult 
task to accomplish. Challenges include the presence of imaging artifacts due to air in the rectum and 
inhomogeneities of the magnetic field, the large anatomical variability between subjects, the differences in 
rectum and bladder filling, a lack of well-defined edges in the apex and base, similar intensity profiles with 
surrounding organs and its relative small size in the male pelvis. Most prostate segmentation methods in 
literature are single-object methods of which the majority only operate on univariate images, e.g., on a single 
MR image. In a single-object prostate segmentation, only properties of the prostate are modeled and do not 
include information from surrounding anatomy. As a result these methods are typically semi-automatic and 
are inaccurate at base and apex part of the prostate [121, 122, 123, 124].
Recently, multi-object segmentation has been adopted by several authors [125, 126, 127, 128]. The 
key advantage of this multi-object approach is that organs with low-contrast can be accurately segmented 
when nearby well-defined organs are taken into account. In [127], an atlas-based method was proposed 
for prostate segmentation in univariate (T2-weighted) images. Although good results were obtained, the 
method strongly depends on the training set used and can fail on unforeseen cases. Costa et al. [126] 
showed that statistical shape and appearance models (ASM) are a fast and robust approach. In their method, 
a coupled bladder and prostate segmentation in CT images is used to achieve an automatic prostate segmen­
tation. The disadvantage of those models is that they strongly depend on correct landmark correspondence 
by manual segmentation in the training phase as well as the quality of the initialization [129, 128].
Both approaches require large training efforts and training databases in order to capture the high 
anatomical variability of the pelvis. An alternative approach is to model shape and appearance using para­
metric shape models. This technique does not require the existence of anatomical landmarks and requires 
fewer training samples. Although complex shapes can be modeled with many parameters controlling local 
deformations, it is desirable to reduce the number of parameters and the range of each parameter used in a 
model to obtain a compact representation [130]. In [131], the authors demonstrated that with a relatively 
simple shape model good prostate segmentation results were obtained. Prostate segmentation was achieved 
by first fitting a deformable superellipsoid model to the prostate in ultrasound images. Subsequently, the 
obtained shape information was integrated into a Bayesian prostate segmentation algorithm. However, 
initialization of the model was manual, the method was 2D, did not include information of surrounding 
structures and cannot handle multiple MR images simultaneously.
In this paper we present a fully automatic novel parametric multivariate multi-object method to segment 
the prostate. The first aim of the paper is to demonstrate how to construct a multi-object model with few, 
sufficiently independent parameters describing the absolute and relative shape as well as the appearance
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of pelvic structures. The second aim is to investigate if the supervised method can generalize on small 
training datasets. The performance of the complete method is analyzed by comparing to expert manual 
segmentations. To the best of our knowledge, this is the first time that a method which fits a multi-object 
parametric model to multivariate MR images is presented for prostate segmentation.
5.2 Method
The proposed method consists of two steps: (1) model building and fitting; (2) object segmentation with 
prior model constraints. In the first stage, a model is constructed with multiple parametric objects that 
define the shape and multivariate appearance of each anatomical structure. Next, the model is fitted to 
multivariate images simultaneously. Furthermore, a realistic anatomical structure representation is obtained 
by constraining the parameters within a population model. Relationships between the defined objects (e.g. 
position relative to other object) is captured beforehand by a transformation of the model parameters. This 
prevents the need of a large training database to capture correlation between parameters such they can be 
assumed independent, reduces the complexity of the model and maintains the intuitive parameter setup 
of the model. In the second stage, a Bayesian framework is used to obtain the final segmentation. Here, 
the fitted model is used as a prior to the Bayes classifier such that prior information about spatial and 
multivariate appearance relations between anatomical structures is efficiently taken into account.
5.2.1 Model Fitting
In this section, am ethodis described to fit the model $ (Z ) with parameters Z to M  images [ I 1, . . .  , I j , . . . ,  I M } 
from a patient. The model is fitted by finding the parameters that optimize the correspondence between 
model and images:
Z =  a rgm ax  [ F (I$ (x ; Z) , I i ( x ) , . . . ,  I m (x))} , (5.1)
where F (.) represents the objective function to be optimized, I$ (x ; Z) a 3D synthetic image representation 
of $ (Z ) with same dimensions as I j  (x) and x  =  (x, y, z) denotes a voxel location in cartesian space.
Let the model $ (Z ) be composed of N  objects. Examples of objects are pelvic structures such as 
bladder, prostate, rectum or pelvic bone. The appearance of object i in I$  is modeled with a vector v* of 
mean grey values [v i1, . . .  , v j , . . . ,  viM }, where i =  1 , . . .  , N . The grey value vij  depends on the image 
I j  as well as the object it represents. Additionally, the spatial distribution of an object i is considered the 
same in the different images by means of image registration. A mutual information registration strategy 
was applied to correct for patient movement [132]. Assuming that any object i in the model conforms to a 
multivariate Gaussian shape in I$ , then the spatial distribution fa of object i can be defined as a multivariate 
normal distribution:
fa(X ; Ci, S i ) N (x, Ci, S i )
=  (2n )- 2 |S i |- 2 exp
(x -  Ci)T S - (x -  Ci) 
2
(5.2)
where Ci is the center of the object and E* defines its shape. For this study, it is assumed that objects cannot 
be rotated in space. The covariance matrix E* then becomes:
E i =  d i a g ^ ^  ^  a 23) . (5.3)
A full covariance matrix could be used in order to generalize the model for object rotation but at the ex­
pense of increasing the model complexity. An additional background model is defined with uniform spatial 
distribution fa  defined as follows:
^ m T , (5.4)
2^1 1
where m  is the total amount of voxels in I j .
The synthetic representation I$ (x ; Z) is then defined as:
I$ (x ; Z) =  [v i; ifL (x ; Z) =  i} , (5.5)
Automatic PAMMO Segmentation o f the Prostate in MRI Using Prior Knowledge 53
where L(x; Z) is a label image defined as:
L(x; Z) =  a rg m a x fa (x ; ^ , E*). (5.6)
i
In the label image, the voxels take discrete values i, each corresponding to an object in $ (Z ). Although 
individual objects are defined as an ellipsoid in I$ (x ; Z), they become more realistic shaped in L(x; Z) at 
the boundaries where the objects overlap each other. An example of I$ (x ; Z) is shown Fig. 5.1.
(c) T2 map (d) ADC map
Figure 5.1: Cross-sectional sagittal views of an example synthetic image I$(x; Z) simulating ADC and T2 
maps. The scalar values are population averages of several anatomical structures visible in the ADC and 
T2 maps below. Window and level settings were set equally. Considering the synthetic T2 map, bladder, 
prostate and the rectum are displayed from left to right (Anterior to Posterior) with the rectum as the most 
dark anatomical structure. In the ADC map and the synthetic representation, the bladder and urine stand out 
as a bright anatomical strucure.
Fitting the model can now be considered an optimization problem, where the goal is to search for the 
values of the model parameters that best fit the multivariate images. Thus, the optimization problem defined 
in Eq. 5.1 needs to be solved using the parameter vector:
Z =  [c  1 . . .  Ci . . .  Cn , Vi . . .  Vi . . .  v n , E l . . .  E* . . .  E„} , (5.7)
Let F (.) be defined as a function consisting of a similarity term and a penalty term:
F  (I$ (x ; Z), I i ( x ) , . . .  , I m  (x)) =
M M
=  £ U j S (I$ (x; Z), M ( I j ( x ) , k ) )  -  (1 -  £ Uj)C(Z), (5.8)
j= i  j= i
where S (.,.) measures the similarity between I$  and I j ; C(Z ) is a penalty term to constrain Z within the 
population distribution; u  is a weight to control the balance between the two components and M  a median 
filter with kernel k in order to reduce noise and preserve edges.
C  (Z) is a penalty term to constrain the parameter vector Z to be within a population distribution. We 
define the penalty term as a multivariate Gaussian with mean and covariance estimated from a training 
population (explicit prior knowledge). In that way, a realistic fit of the model is obtained as spurious 
parameter values outside the population range are penalized more heavily.
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5.2.2 Transformation of the Parameter Vector
Spatial and appearance relations between the objects in the model are captured beforehand by redefining the 
parameter vector Z to Z'. The transformation should reduce the complexity of the model and aims to reduce 
dependencies between the parameters. The transformation is firstly based on knowledge about topology,
i.e. spatial relation between objects. Secondly, it is based on knowledge on the appearance relation between 
objects. Applied to the pelvis, the coordinate system of the model is placed in the center of the prostate.
Assuming that objects can only move in the sagittal and coronal plane with respect to the prostate, 
two parameters need to be calculated for each object: the distance d* from the object to the prostate center 
and the angle a* in the sagittal plane. Next, the object intensity vector v* is calculated with respect to the 
intensity vector of the prostate as follows: v- =  v pr -  dv*, where v pr is the intensity vector of the prostate 
and dv* is a vector of shift values for the object i.
5.2.3 Anatomical Structure Segmentation
This section will describe the Bayesian framework used to obtain the final anatomical structure segmen­
tation. The fitted model is incorporated into the segmentation framework as prior knowledge about shape 
and appearance of the objects in the model. Under the maximum a posteriori (MAP) criterion, the optimal 
segmentation field is the result which maximizes the posterior probability:
L  =  a rg m ax  [p(lx =  i | I i ( x ) , .. . , I m (x))} , (5.9)
i
where lx is the optimal segmentation result under the MAP criterion, lx is the label of voxel x  and p (lx =  
i | I i ( x ) , . . . ,  I M (x)) is the probability of lx to belong to class i given the intensity values I i ( x ) , . . . ,  I M (x) 
of the voxel x  in the images. Using the Bayes rule, p(lx =  i | I i ( x ) , . . . ,  I M (x)) can be rewritten as:
p(lx  =  i | I i ( x ) , .. . , I m (x)) <x
p ( I i ( x ) , .. . , I m (x)|lx  =  i)p(lx =  i). (5.10)
In the proposed method, the anatomical structure segmentation is achieved by incorporating the esti­
mated model $(C) as a priori knowledge. Assuming that the grey values of the images within the objects 
are independent, p ( I i ( x ) , . . . ,  I M (x) |lx =  i) can be formulated as:
M
p ( I i ( x ) , .. . , I m (x)|lx  =  i) =  n p ( I j (x)|lx  =  i). (5.11)
j =i
Assuming further that the intensity distribution of each object can be modeled as a Gaussian distribu­
tion, then the likelihood function p ( I j (x) |lx =  i) is defined as:
p (Ij  (x ) |lx =  i) =  N ( I j (x); v1 , a l ), (5.12)
where vj  is the estimated intensity value of object i in I j  obtained after fitting the model and aj  is the 
corresponding standard deviation obtained from training.
The prior probability p(lx =  i) in Eq. 5.12 is defined as the estimated spatial distribution of the object 
fa obtained after fitting:
p(lx  =  i) =  fa(x ; Ci, E i), (5.13)
The final segmentation B ( x )  is then achieved as follows:
s 1, if Ix =  insB ( x ) = \ c ’ x , as (5.14)
0, otherwise
where ias is the index corresponding to the anatomical structure that is to be segmented.
Automatic PAMMO Segmentation o f the Prostate in MRI Using Prior Knowledge 55
5.3 Data
The evaluation of the proposed method was performed on a prostate multivariate MR dataset acquired 
from a cohort of 55 clinical patients. These patients had elevated PSA levels and one negative biopsy; and 
were scheduled for a prostate cancer MR detection between January and April 2009 at the RUNMC radi­
ology department. Images were acquired with a 3.0T whole body MR scanner (TrioTim, Siemens Medical 
Solutions, Erlangen, Germany) using a pelvic phased-array surface coil. For our experiments, MR data 
from each patient comprised a T2-weighted (T2-w) axial volume (with dimensions 256x256x15 and voxel 
size 0.75mmx0.75mmx4mm), a proton density-weighted (PD-w) volume (with dimensions 128x128x12 
and voxel size 1.8mmx1.8mmx4mm) and an ADC map (with dimensions 136x160x10 and voxel size 
1.625mmx1.625mmx3.6mm) that was generated by the MR scanner. The T2-w and PD-w volumes were 
used to generate a T2 map, as explained in [132].
The collected patient data was randomly divided into two groups. The first group consisted of prostate 
MR data from 40 patients and was used as a training set for the proposed method. The remaining 15 patients 
were used to evaluate the prospective segmentation performance.
For evaluation, each prostate was manually annotated in the T2-w images by a radiologist and re­
searcher in consensus. The T2-w images were used because they usually have high spatial resolution and 
provide the most accurate prostate contours. The annotation was performed using an in-house developed 
software in which the user employed a brush tool to select prostate pixels in each MR slice. The annotation 
started at the MR slice where the transition of the external sphincter to the prostate apex was visible and 
ended at the upper part of the transition zone. Additionally, the model was manually fitted to the T2-w 
images to obtain prior knowledge of the optimal model parameter setting. The optimal parameter settings 
were used to determine the population mean and covariance.
5.4 Settings and Experiments
5.4.1 Settings
ADC maps and generated T2 maps were used as input for the segmentation method (M  =  2). The T2 
maps were registered and resampled to the image space of the corresponding ADC maps [133]. To make 
the objects in the images homogeneous and suppress noise, the kernel size of M  was empirically set to 
5x5x3 voxels. The mean of squared differences was used as similarity measure S ( .,.) . The weights Uj in 
the objective function F (.) (see Eq. 5.8), were empirically set to u 1 =  u 2 =  0.1.
The L-BFGS-B [110], a limited-memory, quasi-Newton minimization package was used as the opti­
mizer in Eq. 5.1 until termination criteria were satisfied. The limited-memory method is well suited for 
optimizing objective functions with a large number of parameters and provides an additional advantage in 
that it allows bound constraints on each parameter. Minimum and maximum values of the model parameters 
can be controlled individually. For all experiments, each parameter was hard constrained to be within mean 
± 2 a  of the population distribution. Methods that are Newton based require a gradient estimate during the 
optimization. In this study the common finite-difference approximation approach is used.
5.4.2 Evaluation Measures
The segmentation results were evaluated by voxel-based comparing the automatically generated prostate 
segmentations with the manual annotated ground truths. As performance measure, the Dice similarity 
coefficient (DSC) was used [134]:
2 T P
D S C  =  T P  +  F P  + T P  +  F N , (5.15)
where T P , F P  and F N  are, respectively, the number of true positive voxels, false positive voxels and false 
negative voxels. A DSC value of 1 indicates a perfect overlap, whereas a value of 0 means no overlap at all.
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Table 5.1: A-PRIORI knowledge of the model parameters that was obtained from literature about pelvic 
anatomy. The relative parameter values are calculated with respect to the corresponding prostate value.
Symbol Param eter Description Value Comments
dvn Bladder ADC relative intensity value (mm2/sec) 0.7 ± 0.24 • 10-3 Reference [136]
V21 Prostate ADC intensity value (mm2/sec) 1.57 ± 0.09 • 10-3 Reference [136]
dv3i Rectum ADC relative intensity value (mm2/sec) -0.77 ± 0.09 • 10-3 Reference not found. The value was chosen based 
on the radiologist’s experience.
1dv 2 Bladder T2 relative intensity value (ms) 20.0 ± 10 Reference not found. The value was chosen based
v22 Prostate T2 intensity value (ms) 91.0 ± 13.3
on the radiologist’s experience. 
Reference [114]
dv32 Rectum T2 relative intensity value (ms) -40.0 ± 10 Reference not found. The value was chosen based 
on the radiologist’s experience.
di Bladder relative distance (mm) 50 ± 9.8 Reference not found. The value was chosen based
ai Bladder angle (Degrees) 114 ± 9.5
on the radiologist’s experience.
Reference not found. The value was chosen based
C2 Prostate Center (X,Y,Z) (mm) (0 ±10.0, 0±7.5,0±4.5)
on the radiologist’s experience.
Origin. The standard deviation was based on the
d3 Rectum relative distance (mm) 24 ±4.5
radiologist’s experience.
Reference not found. The value was chosen based
a3 Rectum angle (Degrees) -18 ±4.5
on the radiologist’s experience.
Reference not found. The value was chosen based 
on the radiologist’s experience.
Si Bladder volume (cc) 179 (42-582) Reference [137]. The bladder radius is com-
£2 Prostate volume (cc) 55 (21-154)
puted from the ellipsoid volume formula: Volume 
= height x width x length x 0.52.
Reference [137]. The prostate radius is computed 
similar to the bladder radius.
S3 Rectum volume (cc) 108 (28-223) Reference [137]. The rectum radius is computed 
similar to the bladder radius.
5.4.3 Experiments
In this paper, three experiments were carried out to evaluate the proposed method. In the first experiment, 
the effect of fitting the model to MR images and training size were evaluated. The segmentation perfor­
mance was measured twice: firstly after setting the model parameters equal to a population mean that was 
obtained from training; secondly after fitting of the model was performed and the estimated parameters were 
set to the model. For each scheme (with and without fitting), a group of T  patients from the pool of 40 train­
ing cases were randomly selected to train the proposed method, where T  e  {2 ,5 ,10 ,15 ,20 ,25 ,30 ,35} . 
To reduce the influence of the random selection, the experiment was repeated 10 independent times and the 
results were averaged at each training size T . The influence of training size, training selection and fitting 
on the segmentation performance was analyzed by means of linear modeling. Segmentation performances 
were compared using ANOVA [135] with the Statistical Package for the Social Sciences, Version 15 (SPSS, 
Inc; Chicago, Illinois).
In the second experiment, the additional value of the multivariate approach ( M  > 1) was evaluated. 
The prostate segmentation performance was compared to the results achieved using a univariate approach 
(M  =  1), using only the ADC map. Similar to the previous experiment, for both schemes (multivariate 
and univariate), a group of T  patients from the pool of 40 training cases were randomly selected to train the 
method. This experiment was also repeated 10 independent times. The segmentation results were averaged 
at each T  and compared using ANOVA.
In the last experiment, the effect of the selection of prior knowledge on the segmentation performance 
was investigated. For this purpose, we included prior knowledge that ranged from general to more specific. 
The performance was first evaluated when the proposed method was initialized using a-priori knowledge 
that was not obtained from a training population. This a-priori knowledge was acquired from literature, as 
it is summarized in Table 5.1, providing a general information of the population distribution. Parameters of 
the model can be set intuitively. Therefore, parameters that could not be obtained from literature were set 
by a radiologist based on experience. The result was then compared to the performance obtained in the first 
experiment, in which the method was initialized using a-priori knowledge obtained from a training set. In 
this case, the selection of a-priori knowledge is more specific to our clinical environment. The results were 
compared using ANOVA and a Bonferroni correction was applied.
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(a)
(b)
Figure 5.2: Results of the prostate segmentation (a) with and without fitting; and (b) using multivariate and 
univariate schemes. The x-axis shows the training size T  that was used for training. The y-axis shows the 
mean DSC segmentation performance.
5.5 Results
The results of the first experiment are shown in Fig. 5.2(a). The prostate segmentation performance using 
fitting outperforms significantly (p<0.001) the results obtained when fitting was not performed. Linear 
modeling showed that the segmentation performance was not influenced by training selection. A trend 
is visible in both approaches for which using fitting requires less training (no significant improvement at 
training size T  = 1 0 )  compared to without fitting (performance is not significantly different at training size 
T  =  20).
Fig. 5.2(b) shows the results of the second experiment. In this case, the segmentation performance was 
significantly improved when a multivariate approach was adopted.
Table 5.2 summarizes the DSC and the corresponding 95% confidence intervals of the third experiment.
Fig. 5.3 and Fig. 5.4 show examples of the final prostate segmentation. The example of Fig. 5.4 is a 
difficult case because of tumor in the ventral part of the prostate, which changed the intensity value in both 
T2 and ADC maps. The univariate method clearly fails as it depends too much on the single variate grey 
value, whereas the multivariate approach succeeds by combining the two appearances.
Manually fitting the model to the patient data provides insights on the most accurate segmentation 
achievable which resulted in an average DSC of 0.84.
The average computation time for fitting the model to the T2 and ADC maps and segmenting the 
prostate was 3.2 minutes (range: 2 to 4 minutes) on a Intel Core Duo CPU 2.33GHz.
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Table 5.2: Dice similarity coefficients and the corresponding 95% confidence intervals for the proposed seg­
mentation method with and without fitting using prior knowledge from different sources, which ranged from 
general to more specific. * indicates the performance is significantly different compared to the result obtained 
using fitting and training size T  =  20.  ^ indicates the performance using literature as prior information is 
significantly different compared to the result obtained using a training size T  =  2. Bonferroni correction was 
applied.
Prior knowledge source










Figure 5.3: Example of pelvic segmentation. All views have a color coded overlay with red representing 
bladder, blue represents prostate and green the rectum. (a) ADC map of the pelvic in a transversal view. 
The prostate is successfully segmented by not including loose connective and adipose tissue containing the 
periprostatic venous plexus and neurovascular components that separates muscles from the prostatic capsule. 
(b) Corresponding T2-w image of the pelvic in a transversal view. (c) Corresponding T2-w image of the pelvic 
in a sagittal view. The hole in the bladder segmentation is due to very high ADC values of the urine at that 
location.
5.6 Discussion
In this paper, we have presented a novel fully automatic parametric multivariate multi-object segmentation 
method and applied it to a cohort of prostate MRI data acquired during prostate cancer screening. The 
method can be generalized to any modality and application, e.g. combining ultrasound and MR images. 
Additionally, the amount of objects, their shapes and appearances can be easily modified in the parametric 
model. Moreover, the proposed model allows a general and intuitive setup, with clear object definitions, 
which makes it easy to tune and update.
The proposed method achieved good segmentation performances on small training datasets. Fig. 5.2(a) 
demonstrates that an optimal segmentation performance was obtained using 10 training cases only. The 
good results were achieved by fitting the model to the patient under study, which provides a better spatial 
distribution of the pelvic structures for the Bayesian framework. Table 5.2 supports the idea that the nature
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(a) (b)
(c) (d)
Figure 5.4: Example prostate segmentation on a challenging case due to presence of a tumor (dark inhomo- 
geneous region). (a) Original ADC map of the pelvic in a transversal view. (b) Corresponding T2-w image of 
the pelvic in a transversal view. (c) Overlay of the segmentation result in green on the ADC map. (d) Overlay 
of the segmentation result in green on the T2-w image.
of this a-priori information has an important effect on the final results. Using only information obtained 
from a different population distribution, such as the one extracted from literature, deteriorated the results 
when the method was applied to the provided test cases. The segmentation performance increased when 
more specific information was included using training samples from the same clinical environment. By fit­
ting the model and thus making the a-priori knowledge more patient specific, the segmentation performance 
significantly improved. Table 5.2 also shows that including fitting reduces the dependency on a large train­
ing size, because a maximum segmentation performance was obtained with less training samples. This fact 
shows that fitting is of paramount importance for the final results. The use of this patient-specific informa­
tion can overcome the limitation encountered for other authors when the training set was not representative 
enough to deal with the large variability of prostate appearance and shape [127, 131, 128].
Information obtained from multivariate image helps to increase the segmentation performance com­
pared to a univariate approach. Similar to the workflow of a radiologist, we hypothesized that using the 
appearance of objects in multivariate MR images will improve the segmentation performance. The results 
support this assumption as demonstrated in Fig. 5.2(b): using a T2 and ADC map in a multivariate approach 
significantly outperforms the approach where only the ADC map was used. When a univariate approach 
is used, anatomical structures that are adjacent and with similar intensity may be segmented as one object. 
Adding information from another image, where the intensity ranges for those anatomical structures dif­
fer, makes the segmentation accuracy improve. Therefore, combining information from multivariate MRI 
helps to overcome the drawbacks that each image presents separately. Fig. 5.4 illustrates the idea that using 
information from multivariate MRI will improve the segmentation performance.
The obtained results for prostate segmentation were slightly lower than those reported previously [138, 
127, 123]. However, a direct comparison is not possible due to the lack of publicly available multivariate 
MR data. The reported studies have a strong focus on radiotherapy, where bladder and rectum are con­
sidered as the organs-at-risk that should be protected against high dosage of radiation during treatment of 
prostate cancer. Therefore, their aim is to have an accurate segmentation at prostate boundaries at the cost
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of computation time. The focus of this study, however, was on the development of a segmentation method 
that can be used in a prostate screening environment. In such an environment, prostate size, shape and 
appearance are highly variable as it consists of healthy, benign and tumor patients. To capture this with 
atlas-based and ASM methods would require large training efforts. It was demonstrated that the proposed 
method obtained already good segmentation performances with small training efforts. Additionally, the 
model generalized with good segmentation results without being influenced by the chosen training set.
In [128], it is demonstrated that the use of a spatial constraint increases the robustness of the deformable 
model comparatively to a deformable surface that is only driven by an image appearance model. The spatial 
constraint was obtained by registering a pelvic atlas to the target image. The authors discussed that most 
serious errors occur in prostates which are dissimilar to the atlas. They hypothesize that using a multi-atlas 
approach can improve the segmentation performance. This would come, however, at the costs of large 
training efforts. We believe that our proposed method can be used in a similar fashion, as the method can 
be used instead of an atlas based method for generating the spatial constraint. This can potentially reduce 
the training effort needed to capture the wide range of shape sizes.
Despite the encouraging results achieved by the proposed method, we have identified a number of en­
hancements. Firstly, computation time can be reduced in the fitting stage. The optimization method requires 
derivatives for each parameter which were calculated using the common finite-difference approximation. 
The common finite-difference approximation is computational expensive and sensitive to noise. Using an 
analytic gradient would make the algorithm potentially faster and more robust. Secondly, more robustness 
can be obtained by including more structures in the model and by including more images. For example, 
adding the muscles that surround the prostate or including a T1 map could provide an improved segmen­
tation accuracy and robustness. However, extending the model or adding more multivariate images is at 
the expense of more computational effort. Thirdly, anatomical structure segmentation can be performed 
more accurately by extending their object definition. For example, the prostate is modeled as a homoge­
nous region which in fact consists of several zones. Extending the prostate model in different zones with 
their own shape and appearance properties would make the segmentation method potentially more accu­
rate. However, this can result in more parameters of the model which leads to more computational effort. 
Fourthly, similarity between the synthetic image representation of the model and the multivariate images 
is calculated using the mean of squared differences. The appearance of the anatomical structures that are 
modeled in the synthetic image representation are assumed to be homogenous. Typically, MR images that 
are T1-weighted or T2-weighted show a coil profile such that this assumption does not hold. The method 
that was presented in [133] was used to remove the coil profile. However, choosing a different similarity 
measure could provide similar results such that the correction is not needed.
In conclusion, a fully automatic novel automatic parametric multivariate multi-object segmentation 
method was presented and applied to the task of segmenting the prostate. The proposed method generalized 
good on small training datasets and was not influenced by training selection.
Chapter 6 
Automatic Computer Aided Detection of 
Prostate Cancer Based on Multiparametric 
Magnetic Resonance Image Analysis
This chapter is based on the manuscript “Automatic Computer Aided Detection of Prostate Cancer Based 
on Multiparametric Magnetic Resonance Image Analysis” by Pieter C. Vos, Jelle O. Barentsz, Nico Karsse- 
meijer and Henkjan J. Huisman Submitted to Physics in Medicine and Biology, 2011.
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Abstract _________________________________________________________________________________________
In this paper a fully automatic computer aided detection (CAD) method is proposed for the detection of 
prostate cancer. The CAD method consists of multiple sequential steps in order to detect locations that are 
suspicious for prostate cancer. In the initial stage, a voxel classification is performed using a Hessian based 
blob detection algorithm at multiple scales on an Apparent Diffusion Coefficients map. Next, a parametric 
multi-object segmentation method is applied and the resulting segmentation is used as a mask to restrict the 
candidate detection to the prostate. The remaining candidates are characterized by performing histogram 
analysis on multiparametric MR images. The resulting feature set is summarized into a malignancy likelihood 
by a supervised classifier in a two-stage classification approach. The detection performance for prostate cancer 
was tested on a screening population of 200 consecutive patients and evaluated using free response operating 
characteristic (FROC) methodology. The results show that the CAD method obtained sensitivities of 0.41, 
0.65 and 0.74 at false positive levels of 1, 3 and 5 per patient, respectively. In conclusion, this study showed 
that it is feasible to automatically detect prostate cancer at an acceptable false positive rate. The CAD method 
can assist the radiologist to detect all prostate cancer locations and could potentially guide biopsy towards the 
most aggressive part of the tumour.
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6.1 Introduction
Prostatic adenocarcinoma (PCa) is the second leading cause of cancer related deaths among males in the 
United States, with an estimated number of 217,730 new cases in 2010 [1]. Early detection of PCa can 
be life saving [139]. Recently, it was demonstrated in a large randomized European study that Prostate 
Specific Antigen (PSA)-based screening reduces the rate of death from PCa by 31%. However, the benefit 
was associated with a high risk of overdiagnosis and overtreatment [8, 9].
PSA is a nonspecific marker for prostate cancer. As a result, urologists are often faced with the dilemma 
of how to manage a patient with a high PSA levels and an initial set of negative prostate biopsies. Hence, 
the possibility remains that these patients may still have tumour, as prostate cancer is often multifocal and 
heterogeneous in nature. Systematic prostate transrectal ultrasound (TRUS) guided biopsy is the standard 
procedure for prostate histological sampling. The techniques involves systematic sampling of multiple areas 
in the prostate during TRUS-guided biopsy regardless of the presence of hypoechoic lesions. Over recent 
years, many reports have shown that systematic biopsies do not detect all clinically significant cancers 
and efforts have been made to improve the protocol by increasing the number of biopsies and/or changing 
biopsy positions. Nevertheless, the volume of prostatic tissue sampled is relatively small which makes it 
difficult to detect tumour. More importantly, the technique fails to sample the most representative part of 
the tumour [140, 141]. To prevent patient anxiety, more accurate methods need to be found to detect or rule 
out significant disease [142].
Prostate Magnetic Resonance Imaging (MRI) has the potential to improve the specificity of PSA based 
screening scenarios as a non-invasive detection tool. Several studies showed that combining anatomical, 
functional and metabolic MRI information leads to a PCa detection accuracy of up to 92% [11, 12, 13, 14, 
15]. Furthermore, multiparametric MRI can target biopsies towards regions determined to be suspicious 
of cancer [143]. Unfortunately, prostate MRI analysis requires a high level of expertise and suffers from 
observer variability [16]. Furthermore, the interpretation of the multiple MR images and their derived maps 
for a single patient diagnosis is a labour intensive procedure. For that reason the technique is considered 
cost inefficient and, as a result, has not been implemented in a screening environment [17].
Computer aided detection (CAD) systems can be of benefit to improve the diagnostic accuracy of the 
radiologist, reduce reader variability, and speed up the reading time. CAD aims to automatically highlight 
cancer suspicious regions, leading to a reduction of search and interpretation errors, as well as a reduction 
of the variation between and within observers [49]. CAD research has been successfully pursued in other 
diagnostic areas such as mammography [18, 19], CT chest [144, 21, 22], CT colonography [23, 24] as well 
as retinal imaging [25]. CAD systems generally consist of multiple sequential stages. In the initial stage, 
lesion candidates are selected within a likelihood map that was generated by voxel classification of one or 
more images. Hereafter, the lesion candidates are segmented into a region of interest from which region 
based features are extracted. Finally, the extracted information is fused by a classifier into a malignancy 
likelihood. The last stage ensures a reduction of the amount of false positives that were localized in the 
initial stage.
Most prostate CAD researchers have focused on the initial voxel classification stage [50, 51, 52, 53, 
54, 55]. They obtained likelihood maps by combining information from multiparametric MR images using 
mathematical descriptors. These studies showed on a voxel basis that the discrimination between benign 
and malignant tissue is feasible with good performances. Recently, we presented work that focused on the 
regional classification stage [132]. In the proposed CAD method, the radiologist was instructed to localize a 
lesion candidate in the peripheral zone of the prostate and delineate a region of interest. Hereafter, relevant 
features from multiparametric MRI were extracted on demand and summarized by a supervised classifier 
into a malignancy likelihood. Experience with the system, however, showed that the system is subject to 
observer variability due the differences in lesion segmentation or incorrect segmentation. Furthermore, 
tumours located in the transition zone were not included. To the best of our knowledge, a fully automated 
prostate CAD method based on multiparametric MRI analysis has not been described in literature.
The purpose of this study was to investigate the feasibility of a CAD method that fully automatically 
detects cancer suspicious regions in the prostate. The study focused on a screening population that included 
patients with elevated PSA levels. The ultimate goal was to detect all tumors regions at an acceptable false 
positive rate to potentially guide biopsy towards the most aggressive part of the tumor.
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Figure 6.1: Dataflow diagram of the implemented CAD system. A Hessian based filter initially detects 
possible lesion candidates at multiple scales. A prostate segmentation method is applied to the pelvis and the 
resulting prostate segmentation is used as a mask to restrict the candidate detection to the prostate. A region 
of interest is defined surrounding the candidates from which features are extracted using histogram analysis. 




The proposed CAD method is schematically outlined in figure 6.1. It comprises of multiple sequential steps 
in order to detect locations that are suspicious for prostate cancer. In the initial part of the CAD scheme, the 
method detects lesion candidates in Apparent Diffusion Coefficients (ADC) maps that are acquired during 
the MR examination. Firstly, a voxel classification is performed using a Hessian based blob detection 
algorithm at multiple scales. Next, a parametric multi-object segmentation method is applied to the pelvis 
to segment the prostate automatically. The prostate segmentation is used as a mask to restrict the candidate 
detection to the prostate. Hereafter, candidate lesions are determined by detecting local maxima in the 
generated blob likelihood map and are characterized by performing histogram analysis within a region of 
interest on multiple MR images. Finally, the extracted features are summarized by a Linear Discriminant 
Analysis (LDA) classifier into a malignancy likelihood. The individual steps of the scheme will be explained 
in more detail in the remainder of section 6.2.
6.2.2 Initial voxel classification
In the first stage of the CAD system, dark blob-like regions are localized in the ADC map. This approach 
was inspired by the clinical practise of the radiologist at our hospital as they localize lesions by the less 
diffuse property of PCa in a ADC map. A common approach to automatically determine the blob-likelihood 
of a voxel x  is to use the eigenvalues \ a,k of the Hessian matrix H a at scale a  of the ADC map, with 
k  =  1, 2, 3 [119]. The likelihood of a voxel at scale a  to belong to a blob is defined by [145]:
P  (x, a) =  |  x *,k(x) <  0 k e  1  2  3 (6.1)
Note that the three eigenvalues are sorted as |ACT,x(x)| <  |ACT,2(x)| <  |ACT,3(x) |. The approach is applied 
using a recursive implementation of the Gaussian filter at multiple scales, namely three scales are used 
ranging from 8 mm to 12 mm in diameter. The blob detector is normalized for each scale. The likelihood 
L(x) of a voxel x  to belong to a blob is finally given as:
L (x) =  m ax L (x, a ). (6.2)
a
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6.2.3 Prostate Segmentation
The initial voxel classification is performed on the whole ADC map to prevent the need for boundary 
conditions. As a result, the automatic prostate segmentation is crucial to avoid detection of local maxima 
that lie outside the prostate. We used a parametric multi-object method that was developed in previous 
work [146]. The method consists of two steps: model fitting and voxel segmentation with prior model 
constraints. In the first stage, a model is constructed based on multiple parametric objects that define the 
shape and appearance of each organ in multiple MR images, e.g. ADC and T2 maps. The model is fitted 
to the different MR images simultaneously. A realistic organ representation is obtained by constraining the 
parameters within a population model. In the second stage, a Bayesian framework is used to obtain the final 
segmentation. Here, the fitted model is used as a prior to the Bayes classifier such that prior information 
about spatial and multivariate appearance relations between anatomical structures is efficiently taken into 
account.
The final label image is denoted by B (x) where the image voxels are labeled with the corresponding 
organ. An example of the segmentation method is shown in figure 6.2.
(a) ADC map. (b) T2 map.
Figure 6.2: Cross-sectional transversal views of multiple MR images that were used to segment the bladder 
(red), prostate (blue) and rectum (green) simultaneously.
6.2.4 Lesion candidate detection
This section describes how lesion candidates are selected from the obtained likelihood map L (x). Obvi­
ously, a lesion candidate i should lie within the prostate segmentation B (x ) to be selected. Additionally, 
the candidates are selected based using the following peak detection criteria: the peak value L(x*) should 
exceed t ; L (x) should exceed the mean value of its sphere shaped neighborhood Q with diameter d; and 
the difference between L(x*) and the mean neighborhood value should be more than the squelch threshold 
e. Let $  be the group of final selected candidates, then x* g $  when:
B ( x i )  =  1 A L(x*) > t  A (L(x*) — m e a n (Q (x i ) , r)) > e. (6.3)
For this paper, the diameter d was set to 5mm which represents the minimal size of a significant prostate 
tumour, e and t  where empirically set to 0.1 and 1, respectively. An example of the candidate detection 
procedure is shown in Figure 6.3.
Candidates were removed when the corresponding MR values were outside biological meaningful 
thresholds. The following thresholds were obtained from literature: the ADC value was below 200 or above 
normal prostate intensity value of 1600m m /s2 [136]; the T2 intensity value was above normal prostate 
100 msec or below muscle 36 msec [114]; and the interstitial volume Ve was below normal prostate of 
2 0 m m H g  [81].
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(a) ADC map of the pelvis with dark (b) ADC map with the blob Likelihood (c) ADC map with initially detected can- 
blobs visible in and outside the prostate. map displayed as a colour-coded over- didates within prostate only. The arrow
lay. indicates the location of an tumour with
Gleason grade 3+4
Figure 6.3: Cross-sectional transversal views of an example ADC map of a patient with a tumour in the 
transition zone. Multiple dark blob like regions are visible in and outside the prostate. Lesion candidates are 
detected within the prostate segmentation. De red arrow indicates a tumour with Gleason grade 3+4 which 
was detected by the peak detector with the highest likelihood of all detected blobs.
6.2.5 Local feature analysis
Prostate cancers can be discriminated from benign abnormalities by their heterogenous nature. That is, 
hotspots are visible in multiparametric MR images at different locations within the extent of the tumour. 
Because lesion segmentation methods typically work on a monoparametric MR image only, crucial in­
formation available from the multiparametric MR images may be missed. As a result, those approaches 
potentially underestimate the size and, more importantly, the grade of the tumour. Figure 6.4 illustrates the 
idea that hotspots are visible at different locations among multiparametric MR images. For this paper, we 
therefore define a spherical region R  with radius r  that surrounds lesion candidate i at location x* such that 
analysis can be performed on multiple MR images simultaneously.
(a) ADC map and colour-coded overlay of the output of the blob 
detector. The arrows indicate the extent of the whole tumour with 
Gleason score 4+3. The red arrow indicates the detected location 
by the candidate detector, where the ADC values are most low and 
the Gleason 4 component is present.
(b) ADC map and colour-coded overlay of a pharmacokinetic 
parameter. The pharmacokinetic parameter showed multiple en­
hancing hotspots within the tumour. Notice that the location found 
by the candidate detector (red cursor) and the nearby hotspot (blue 
region) do not overlap. The difference in location is approxi­
mately 2.5mm.
Figure 6.4: Cross-sectional transversal views of an example ADC map, candidate detection and pharma­
cokinetic map to illustrate the idea that hotspots are visible at different locations among multiparametric MR 
images.
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Analysis was performed within region R  by combining histograms of intensity values from T2, phar­
macokinetic, T1 and ADC maps with texture based features. Percentiles were used for further analysis as 
they are less sensitive to extreme values often observed in the MR image data. In total nine features were 
collected from the MR data within each R. The selected intensity based features reflect the clinical practise 
at our hospital, where prostate cancer diagnosis is performed on a daily basis [11]. Based on the preferences 
in our clinic, we expect the following intensity features as most descriptive:
f 1 25% percentile T2:
The 25% percentile was extracted from the T2 map as it has been established that prostate cancer 
typically demonstrates lower signal intensity than normal prostate tissue on T2-weighted MR im­
ages [147].
f 2 25% percentile ADC:
The 25% percentile was extracted from ADC map because lower ADC values in prostate cancer are 
related to tightly packed glandular elements found in cancers that locally replace the fluid-containing 
peripheral and transition zone ducts [148, 149, 47].
f 3 75% percentile K trans:
The pharmacokinetic parameter K trans or transfer constant (1 /m in ) relates to permeability surface 
area. The permeability (or leakiness) surface area refers to the ability of tracer molecules to pass 
through interendothelial fenestrae and junctions into the interstitial compartment. High permeability 
of the vasculature is a characteristic of pathological blood vessels in inflamed tissues and tumours. 
An increased capillary permeability is observed in prostate cancer [73]. The upper quartile captures 
the presence of hotspots.
f 4 75% percentile Ve:
In the extravascular, extracellular space (EES) of normal tissue, pressure is near atmospheric (25m m H g) 
values, whereas in tumours it may reach 50m m H g or even more. The interstitial hypertension may 
be due to increased vascular permeability in combination with a lack of lymphatic drainage due to 
the absence of functional lymphatic vessels within the tumour itself. This results in an increase of the 
EES. The EES, defined as percentage per unit volume of tissue, is therefore considered a descriptive 
parameter. An increased interstitial leakage space is observed in tumour, hence the upper quartile is 
used to capture these hotspots [81].
f 5 25% percentile W a s h  — out:
The kinetic parameter W a s h  — out  quantifies the slope of the curve after the first wash-in phase. 
Although it does not directly correlate to physiological parameters, like pharmacokinetic parameters, 
the presence of washout is considered highly indicative of PCa. When capillary permeability is high, 
the backflow of contrast medium is also rapid, resulting in a negative W a s h  — out  following the 
shape of the plasma concentrations. The 25th percentile is used because the presence of W a s h  — out  
is often heterogenous within the extent of the tumor [73].
f 6 50% percentile T1 map
Post-biopsy hemorrhage mimics high tumour vascularity. Fortunately, hemorrhage is clearly visible 
as a high-intensity area on a T1-w image. As biopsy hemorrhage is often visible as a large homoge­
neous area, the 50% percentile is extracted from the T1 map.
The following texture features were extracted:
f 7 Peak value:
The peak value or blob likelihood L(x*) that was obtained after the initial voxel classification stage 
for lesion candidate i at location x*.
f 8 Mean neighborhood value:
The mean neighborhood value of Q(.) at location x*.
f 9 Squelch value:
The squelch value is the difference between the peak value f 7 and the mean neighborhood value f 8.
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The assumption is that all image volumes I 1 , I 2, . . .  , I k are registered to each other in the MR co­
ordinate system and as a result, a lesion segmentation in I k will represent the same lesion area in I k+1, 
regardless of the image resolution or orientation. A mutual information affine registration strategy was 
applied to correct for patient movement such that the assumption will hold [132].
Let 0* =  { f 1, f 2, . . . ,  f L } represent a feature vector for candidate i, with L  the number of features, 
where each feature is a first-order statistic of the scalar values of volume I k .
6.2.6 Classification
In the classification step, candidate regions are classified into malignant or benign using a two-stage classifi­
cation approach. This approach removes spurious candidates from the data in the first stage by estimating a 
coarse decision boundary using a subset of features. After spurious candidate removal, the decision bound­
ary is refined in the second stage taking into account the complete set of features. The proposed two-stage 
classification approach avoids that the final estimation of the classification boundary is driven by spurious 
and/or outlying data.
For the first stage, the two most discriminant features according to the Fishers discriminant (FD) ra­
tio [135] are independently selected and a Linear Discriminant Analysis (LDA) classifier [150] is trained 
to remove spurious candidates from the data. Note that the FD ratio analyzes the individual discrimination 
power of the features without taking into account the rest of the features. This provides a fast determination 
of a coarse classification boundary. Those candidates that lie far away from the obtained decision boundary 
(i.e., their posterior probability is higher than a specific threshold) are removed. The threshold is set such 
that no true positives are lost in the first phase for the training set. Before performing the feature selection, 
the feature values are transformed using the Box-Cox transformation [151] in order to approximate the 
feature distribution to a normal distribution.
In the second stage, a classifier is trained using a selection of features from the complete feature 
set. After pilot experiments with several classifiers, an LDA classifier was chosen in favour of k Nearest 
Neighbour [152] classifier, Quadratic Discriminant Analysis (QDA) classifier [150] and Support Vector M a­
chines [80]. The selection of features is carried out by Sequential Forward Floating Selection (SFFS) [153] 
to establish the most discriminant features. The SFFS procedure uses leave-one-out training and testing 
with the area under the Receiver Operating Characteristic (ROC) curve as the criterion to be optimized. 
Table 6.2 summarizes the selected features in order of selection.
6.3 Data and Experiments
6.3.1 Data
Imaging data was used from a cohort of clinical patients scheduled between January and December 2009 
at the RUNMC radiology department. These patients had elevated PSA levels and one negative biopsy. 
Images were acquired with a 3.0T whole body MR scanner (TrioTim, Siemens Medical Solutions, Erlangen, 
Germany). A pelvic phased-array surface coil was used for receiving. The machine body coil was used for 
RF transmitting. An amount of 1 mg of glucagon (Glucagon®, Novo Nordisk, Bagsvaerd, Denmark)) was 
administered directly before the MRI scan, to all patients to reduce peristaltic bowel movement during the 
examination.
For our experiments, MR data from each patient comprised a T2-weighted (T2-w) axial volume (with 
dimensions 256x256x15 and voxel size 0.75mmx0.75mmx4mm), a proton density-weighted (PD-w) vol­
ume (with dimensions 128x128x12 and voxel size 1.8mmx1.8mmx4mm), contrast enhanced 3D T1-weighted 
(T1-w) spoiled gradient echo images and an ADC map (with dimensions 136x160x10 and voxel size 
1.625mm x1.625mm x3.6mm) that was generated by the MR scanner. Additionally, gadolinium chelate 
concentration curves were calculated and dynamic contrast enhanced derived parameter maps (K trans, Ve, 
W a s h  — out) were generated at a dedicated workstation [96]. All MR data was automatically normalized 
such that quantitative assessment was possible for the pharmacokinetic, T1 and T2 map using a previously 
presented method [133, 132].
The reference standard for lesion localization and pathology was established by combining the findings 
of one experienced radiologist with, when available, histopathology of MR-guided MR-biopsy samples.
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The workflow was as follows: firstly the radiologist screened the MR examination for PCa. When no 
evidence of PCa could be found, the patient was considered healthy. If a repeat study was advised and per­
formed, that result was used to establish the reference standard. Secondly, all locations that were considered 
malignant by the radiologist were recorded in a local database. At those locations a biopsy was performed 
after which histopathology established the true nature of the finding. The pathologist was blinded to the 
imaging results. The annotated tumour regions were labeled as low grade when histopathology confirmed 
a tumour of Gleason grade less then six. Regions were labeled as high grade tumours when histopathol- 
ogy confirmed a tumour of Gleason grade if seven or more. When the Gleason score was six or when no 
histopathology was available and the radiologist indicated presence of tumour, the region was labeled as 
intermediate.
Our principal interest is detection of malignant abnormalities. Benign abnormalities were not anno­
tated, and therefore will induce a number of false positive signals.
6.3.2 Experiments
Free response operating characteristic (FROC) methodology was performed to evaluate the detection accu­
racy of the CAD system. The detection performance of the CAD system was estimated by three-fold cross 
validation. Cross validation folds were obtained by drawing whole patient cases.
A tumour was considered as detected when the initial detection location was inside the reference stan­
dard. If multiple detections were found inside the same reference standard region they were recorded as a 
single hit. Candidates outside the reference standard were counted as false positives. The specificity was 
computed using those patients where no presence of PCa was found based on radiology reports, follow- 
up reports and MR biopsy outcome. In this way a false positive rate is obtained that is representative for 
a screening population, where the majority of the patients will be normal. Another reason only to use 
non-cancerous patients is that prostate cancer is often multifocal and may incorrectly induce false positive 
signals when not all tumour areas are carefully annotated or if they are missed.
Three experiments were performed to evaluate the detection performance of the CAD method. Firstly, 
it was determined which size of the spherical region R  provides the optimal detection performance by vary­
ing the radius parameter r . In the second experiment, the results of the proposed approach were compared 
to the results obtained using only feature f 7 for classification, i.e., the peak value obtained after the initial 
voxel classification stage. In that way, we analyze the improvement obtained by adding additional infor­
mation from multiple MR images. The difference in performance between the initial voxel classification 
stage and the local feature analysis was evaluated by jackknife FROC analysis (JAFROC) [154]. In the third 
experiment, the detection performance for prostate cancer was analyzed taking into account the malignancy 
grade. Therefore, the detection performance was evaluated for all tumours, high grade tumours, intermedi­
ate tumours and low grade tumours. The results were compared to the performance of a method that detect 
malignant regions based on complete random guess (random detection based on average prostate size and 
tumor size). All detection performances were evaluated at false positive levels of 1, 2 and 5 per healthy 
patient.
6.4 Results
6.4.1 PSA Levels and Histopathological findings
The study set consisted of 200 consecutive patients (mean age, 60 years; range, 50-69 years). The mean 
prostate specific antigen level was 13.6 ng/mL (range, 1-58 ng/mL), mean Gleason score was 7.3 (range, 
5-9). MRI was performed on average 3 weeks after transrectal ultrasonographically guided sextant biopsy 
of the prostate. From those patients, 23 had to be excluded due to failed calculation of the ADC map (2), 
missing or incomplete DCE data (11) or because those patients were scanned for staging (3), post-therapy 
evaluation ( 1 ) or recurrence detection (6).
In the resulting 177 patients, the radiologist annotated 48 locations of prostate cancer in 41 patients. In 
the 41 patients, biopsy confirmed five low grade, five intermediate and 15 high grade tumours. Additionally, 
the radiologist identified 23 patients with prostate cancer that did not undergo a biopsy. Those prostate can­
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cers were graded as intermediate. The prostate volume of all patients was measured by the radiologist and 
was on average 67.5cc(±33.8). The average tumour volume used as reference standard was 2.78cc(±3.9).
6.4.2 CAD performance
The candidate detection step generated 6227 candidates of which 44 where true positives (TPs), resulting is 
a sensitivity of 92%. These candidates were used for training.
The results of the first experiment are shown in table 6.1. It can be observed that using a spherical 
region R  with radius 5 results in the optimal discriminating performance of the classifier. Although the 
obtained performances are not statistically different, a radius of 5 was used in the remaining experiments.
Table 6.1: Discriminating performance (Az) of the CAD system for different radius r  of region R.
r  (mm) Az
3 0.786 ± 0.117
5 0.833 ± 0.052
7 0.832 ± 0.065
9 0.799 ± 0.120
The first stage of the two-stage classification approach removed 37.2% of the candidates at the expense 
of eliminating two TPs, after selecting the features f 9 and f 2. The selected features in the second state 
two-stage classification approach in order of selection are summarized in table 6.2 .




f 5 25% percentile W a s h  — out
f 2 25% percentile ADC
f3 75 % K trans
f l 75 % T2
Figure 6.5 shows the detection results for the second experiment. The results demonstrate that using 
information from multiple MR images significantly improves the detection performance (P<0.05).
The detection performances for the different tumour grades were measured at a false positive level of 1, 
3 and 5 per patient. At these levels, the CAD method obtained a sensitivity of 0.48, 0.73, 0.88 respectively 
for the detection of high grade tumours. The sensitivity for detecting all malignant regions was 0.41, 0.65 
and 0.74 respectively. Detecting intermediate grade tumour resulted in sensitivities of 0.41, 0.65, 0.74. 
Low grade tumours were detected with sensitivities of 0.27, 0.40 and 0.68 respectively. Random detection 
of prostate cancer based on prostate volume and tumour volume resulted in sensitivities of 0.041, 0.12 and 
0.21. Figure 6.6 demonstrates the detection results of the different datasets that were obtained by FROC 
analysis.
6.5 Discussion
In this paper, we have presented a novel fully automatic CAD method and applied it to a cohort of prostate 
MRI data acquired during PCa screening. This study showed that it is feasible to the automatically detect 
PCa using information from multiple MR images simultaneously at an acceptable false positive rate.
The proposed method achieved a good performance for the detection of prostate cancer in a challenging 
cohort of patient MR data. The MR data was acquired during screening for prostate cancer for patients with 
elevated PSA levels. As a result, the patient database consisted of both healthy and prostate cancer patients.
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Figure 6.5: FROC curve showing the detection performances of the CAD method for different selected 
features. The horizontal axis shows the number of false positive detections per healthy patient and the vertical 
axis shows the sensitivity that is achieved at this specificity level. The red dotted FROC curve corresponds to 
the detection performance when only the blob likelihood (f7) was used as feature. The blue solid FROC curve 
corresponds to the detection performance using the two-stage classification approach. The cyan big-dashed 
FROC curve corresponds to the detection performance when a random detection is performed taking into 
account the average tumour and prostate size. There is a significant improvement of the detection performance 
when using a the two-stage approach (P<0.05).
In figure 6.6 it can be observed that high grade tumours are detected with a sensitivity of 0.734 at only a false 
positive rate of 2.3 per patient. When detecting tumour of all grades, the sensitivity was 0.60. Although 
intermediate grades tumours are considered to be more difficult to detect, the obtained performance was 
similar to the result of detecting all tumours. However, it is difficult to differentiate high and intermediate 
tumours. The very difficult to detect low grades tumours were detected with a sensitivity of 40 with 2.3 
FPs, which is still considerably better than randomly detecting PCa.
In figure 6.5, it is demonstrated that the usage of information from multiple MR images has a benefit 
to the detection performance of the CAD system. The results demonstrate that the multi-stage approach 
performs significantly better then only using feature f 7 for classification, i.e., the peak value obtained after 
the initial voxel classification stage. An significant improvement was obtained by adding additional infor­
mation from multiple MR images (P<0.05). Furthermore, the two-stage classification approach removed 
37.2% of the number of candidates after the first stage. This showed to be an important stage to mitigate 
the effect on the training of the classifier.
Only four candidates remained undetected in the initial stage. They are, however, questionable in their 
relevance. In the first undetected case histopathology found only a 5% volume of cancer with Gleason 
3+3 in the biopsy sample and the radiologist indicated a normal diffusion. In two patients, there were 
two regions annotated by the radiologist. In both cases, the most dominant tumour was detected while the 
other location was missed due to a high diffusion. In the fourth undetected case, the radiologist identified 
the location of PCa in both the current and follow-up examination. However, the lesion was graded less 
significant due to a high diffusion. Furthermore, no biopsy was performed such that the reference standard 
could not truly be established.
The two-stage classification approach removed 37.2% of the candidates in its initial stage. The ap­
proach avoided that the final estimation of the classification boundary was driven by the spurious and/or 
outlying data. Experience with a single classification approach showed that the classifier is indeed perform­
ing less. However, two TPs were additionally eliminated. One TP was graded intermediate, but this was not 
confirmed by biopsy. Regarding the second TP, biopsy confirmed a prostate cancer with Gleason score 3+4. 
Both locations was discarded because they appeared to have a high diffusion. Additionally, the peripheral 
zone appeared to have an abnormal high diffusion. This may suggest the need of a normalization step and 
is part of further research.
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Figure 6.6: FROC curves showing the detection performances of the CAD method for different tumour 
grades. The horizontal axis shows the number of false positive detections per healthy patient and the vertical 
axis shows the sensitivity that is achieved at this specificity level. The blue solid FROC curve corresponds to 
the detection performance of high grade tumours. The red dashed FROC curve corresponds to the detection 
performance of intermediate grade tumours. The green dotted FROC curve corresponds to the detection 
performance of all tumours. The purple dot-dashed FROC curve corresponds to the detection performance 
of low grade tumours. The cyan big-dashed FROC curve corresponds to the detection performance when a 
random detection is performed taking into account the average tumour and prostate size.
presented in literature evaluated a discriminating performance of malignant and benign voxels using ROC 
analysis [50, 51, 52, 53, 54, 55]. ROC analysis, however, misses information about the number of false 
positive candidates. Therefore, the method may have a high discriminative performance though presents 
many false positive candidates. This can have a negative influence on the detection performance of the 
radiologist. Furthermore, the studies presented in literature generally use only cancer patients and therefore 
do not reflect a screening population. This study, however, was performed on a cohort of patients that 
had elevated PSA and an initial set of negative prostate biopsies. As a result, it reflects more a screening 
population as both benign and malignant patients were present in the database.
Noguchi et al. [32] demonstrated that grade assessment with needle biopsy underestimated the tumour 
grade in 46% cases and overestimated it in 39 (18%) and as a result, no single parameter in the biopsy 
was a predictor of tumour significance. Hence, the gold standard for detecting PCa, systematic biopsy, 
lacks sensitivity as well as grading accuracy. Multiparametric MRI has to potential to guide prostate biopsy 
towards the most aggressive and representative part of the tumour [143]. However, its clinical application 
is limited due to the required high level of experience of the radiologist. Moreover, it is a difficult and time­
consuming procedure to localize the most aggressive part of the tumour. The presented CAD method has 
the potential to assist radiologists in the detection of prostate cancer and to guide prostate biopsy towards 
the most aggressive and representative part of the tumour. Therefore, the CAD method could improve the 
sensitivity of MR guided TRUS biopsy without introducing many additional biopsies and is part of further 
research.
Limitation of this study was that the reference standard for some patients could not be accurately 
established, as follow-up studies were not yet performed and no biopsy was performed. The reference 
standard was for those patients was graded as intermediate which in fact could be different. Also, the 
patient data used to represent a screening population is somewhat biased, as they were scheduled for an 
MRI examination after one negative biopsy session.
To conclude, this study demonstrated that it is feasible to fully automatically detect prostate cancer at 
an acceptable false positive rate. The CAD method can assist the radiologist to detect all prostate cancer 
locations and could potentially guide biopsy towards the most aggressive part of the tumour.
Chapter 7
Computer-aided diagnosis of prostate cancer 
using multiparametric 3T MR imaging: Effect 
on Observer Performance
This chapter is based on the manuscript “Computer-aided diagnosis of prostate cancer using multipara­
metric 3T MR imaging: Effect on Observer Performance” by Thomas Hambrock, Pieter Vos, Christina 
Hulsbergen-van de Kaa, Jelle Barentsz, Henkjan Huisman Submitted to Radiology, 2011.
Abstract _________________________________________________________________________________________
The purpose of the study was to determine the effect of computer-aided diagnosis (CAD) on observer perfor­
mance in differentiating benign and malignant prostate lesions on multiparametric 3T MRI. 34 Consecutive 
patients with biopsy proven prostate cancer who received a multiparametric 3T MRI incl. T2-weighted, dif­
fusion weighted (DWI) and dynamic contrast enhanced (DCE) imaging prior to radical prostatectomy, were 
retrospectively included. Six less-experienced and four experienced prostate radiologists were asked to char­
acterize different cancer suspicious regions on multiparameteric MRI, first without and subsequently with 
the use of in-house developed CAD software. The effect of CAD was statistically analyzed using a multiple 
reader, multi-case, receiver operating characteristic analysis as well as linear mixed-model analysis. In 34 
patients, a total of 206 pre-annotated regions which included 67 malignant and 64 benign regions in the pe­
ripheral zone (PZ) and 19 malignant and 56 benign regions in the transition zone (TZ) were evaluated. Stand 
alone CAD had an overall area-under the receiver operating characteristic curve (AUC) of 0.90, in discrim­
inating PZ lesions an AUC=0.92 and for the TZ an AUC=0.87. Overall, less-experienced observers (LEO) 
had a pre-CAD AUC of 0.81 which significantly increased to 0.91 (p=0.001) after CAD while for experienced 
observers (EO) the pre-CAD AUC was 0.88 which increased to 0.91 (p=0.17) after CAD. In discriminating 
PZ lesions, LEOs increased their AUC from 0.86 to 0.95 (p<0.001) after CAD while EOs showed an increase 
from 0.91 to 0.93 (p=0.13). Similar, for the TZ lesions, LEOs significantly increased their performances from 
0.72 to 0.79 (p=0.01) after CAD and EOs from 0.81 to 0.82 (p=0.42). In conclusion, the addition of CAD 
significantly improved the lesion discriminating performance for LEOs who reached similar performances as 
EOs. The stand alone performance of CAD is similar to experienced observers.
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7.1 Introduction
Multiparametric MR imaging both at 1.5T and 3T, has proven its value in detection, localization and char­
acterization of prostate cancer [12, 15, 13, 14]. Despite high-resolution imaging (e.g., when using an 
endorectal coil for MR imaging at 3 T), the signal intensities on anatomic T2-weighted MR images show 
overlap among prostate cancer, post-biopsy hematoma, benign prostatic hypertrophy, fibrosis and prostati­
tis. Therefore, functional imaging modalities like dynamic contrast enhanced (DCE), diffusion weighted 
imaging (DWI) and spectroscopic imaging have been added. The multiparameteric approach has been 
proven to be the most useful for evaluation.
DCE MRI which utilizes high-temporal resolution scanning, allows both qualitative and quantitative 
estimations of the perfusion, capillary surface space, extravascular extracellular space, features which all 
change under the influence of angiogenic processes akin to neoplastic disease. Different techniques for 
compartment modeling, arterial input determinations and gadolinium concentration estimation have been 
studied to improve the objectivity and reproducibility of quantitative pharmacokinetic parameters [45,155]. 
Reference tissue techniques have shown promising results in providing a more robust and accurate estima­
tions [92, 93]. DWI which utilizes different gradient strengths to measure the restriction capabilities of free 
proton movement has increasingly been used in prostatic imaging not only for detection and localization of 
tumor but also for assessment of cancer aggressiveness [156,157]. The apparent diffusion coefficient values 
calculated from the DWI, allow a more objective quantitative assessment of the tissue micro-environment. 
However, despite the quantitative nature of pharmacokinetic DCE and ADC, prostate cancer analysis on 
multi-parametric MRI (MP-MRI) is still challenging, requires a high level of expertise and suffers from ob­
server variability [158]. A need therefore exist to aid radiologists in improving their assessment of MP-MRI 
and to reduce inter-observer variability.
Computer assisted diagnosis (CAD) for radiological assessment of various malignancies including 
breast cancer[159], lung cancer [144, 21] and colorectal cancer [23] have been developed. Especially 
their value in supporting less-experienced radiologists in improving overall tumor detection capabilities 
have been emphasized [160, 161]. For prostate cancer, studies that incorporate various features on MRI 
have shown the feasibility of CAD to discriminate benign and malignant lesions [50, 52]. However, no 
CAD system has been evaluated yet in a reader study with radiologists to determine the effect on improving 
observer’s performances for characterization of prostate lesions on MRI.
The CAD performances reported previously are sufficiently high, that a positive effect on reader per­
formance can be expected. The purpose of this study therefore was to clinically evaluate the effect of 
CAD on the ability to characterize prostate lesions for both less-experienced and experienced observers 
using information obtained from quantitative pharmacokinetic DCE parameters and ADC values on 3T MR 
imaging.
7.2 Materials and Methods
7.2.1 Study population
Between January 2008 and January 2009, 50 consecutive patients with biopsy proven prostate cancer sched­
uled for radical prostatectomy, were referred from the department of urology at the Radboud University 
Nijmegen Medical Centre (RUNMC). All patients received a clinically routine MRI for tumor localiza­
tion and staging prior to radical prostatectomy. The ethical committee waived the need for informed con­
sent. Inclusion criteria were: a) MR imaging performed at 3 Tesla using an endorectal coil combined with 
pelvic phased array coils; b) MR imaging included three-directional T2-weighted (T2-w) imaging, diffusion 
weighted imaging (DWI) and dynamic contrast enhanced (DCE) MR imaging; c) prostatectomy performed 
in our institution and analyzed by one expert prostate pathologist. Exclusion criteria were: previous hor­
monal or radiotherapy or substantial imaging artifacts related to patient movement.
7.2.2 MR Imaging
MR imaging was performed using a 3T MR scanner (Siemens Trio Tim, Erlangen, Germany) with the use 
of an endorectal coil (Medrad, Pittsburgh) and pelvic phased array coil. The endorectal coil was filled
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with a 40-mL perfluorocarbon preparation (Fomblin; Solvay-Solexis, Milan, Italy). Peristalsis was sup­
pressed with an intramuscular administration of 20-mg Butylscopolaminebromide (Buscopan; Boehringer- 
Ingelheim, Ingelheim,Germany) and 1 mg of glucagon (Glucagen; Nordisk, Gentofte,Denmark). The imag­
ing sequence parameters are shown in Table 7.1. Gadopentetate dimeglumine (Dotarem; Guerbet, Paris, 
France), of which 15 ml was administered with a power injector (Spectris; Medrad) at 2.5 mL/s and fol­
lowed by a 30-mL saline flush, was used as contrast agent.
Table 7.1: MR imaging sequence parameters. T2-w: T2-weighted; T1-w: Tl-weighted; DWI: Diffusion 
weighted imaging; DCE: Dynamic contrast enhanced imaging; TSE: Turbo Spin Echo; SE-EPI: Spin Echo 
- Echo Planar Imaging; TR: Repetition Time; TE: Echo Time; GRAPPA: Parallel imaging factor; GRE: 
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Pharmacokinetic maps were generated off-line by an in-house developed system in three steps. Firstly, ki­
netic DCE imaging parameters were estimated by fitting each MR signal enhancement-time curve to a gen­
eral exponential signal enhancement model as described previously [37]. Secondly, the signal enhancement­
time curves were converted to tracer concentration [mmol/ml] time curves by applying the approach of 
Hittmair et al. [45]. Thirdly, inter-patient plasma profile variability was removed using the reference tissue 
method presented by Kovar et al. [93]. The reference tissue method assumes that a tissue area within the 
patient is available with a known tissue model based on literature values. For this experiment, the reference 
tissue was manually determined in consensus by two radiologists, by placing a region of interest (ROI) of 
5x5 mm in the normal appearing peripheral zone which was visually characterized by a high-signal inten­
sity on T2-w and ADC as well as homogeneous enhancement after contrast. Estimation of pharmacokinetic 
parameters was thereafter performed, conform to the theoretical derivations [95]. An extensive description 
of the method can be found in Vos et al. [96].
7.2.4 Histopathological evaluation of prostatectomies
Following radical prostatectomy, prostate specimens were uniformly processed and entirely submitted for 
histological investigation. Immediately after surgical resection, specimens were fixed in 10% neutral- 
buffered formalin, using fine needle formalin injections and fixation overnight. Subsequently, the entire 
surface was marked with ink using three different colours, after which the entire prostate specimen was cut 
into serial transverse 4 mm thick slices, perpendicular to the dorsal-rectal surface and all slices were macro- 
scopically photographed with a CCD-camera. After histological staining all specimens were evaluated by 
one expert urological pathologist (C.H, 17 years experience). Tumors were outlined on the microscopic 
slides and subsequently mapped on the macroscopic photographs to allow reconstruction of tumor extent 
and multi-focality.
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7.2.5 Standard of Reference
Histology tumor maps were used as ground truth. Annotations of MR images were performed in consensus 
by two radiologists. The morphology of the central gland, peripheral zone, cysts, calcifications, and urethra 
were used as landmarks to find the corresponding MRI slices. Translation techniques as described previ­
ously were furthermore used [47]. The anatomy of the prostate is best imaged on T2-w images which were 
therefore used for correlation to histopathological maps. First, based on histopathology, all tumor region 
were identified and a region of interest (ROI) placed in the peripheral and transition zone corresponding to 
tumor on histopathology. Only tumors > 0.2 cc in volume were annotated. Additional benign, but tumor 
suspicious regions, were annotated when: a) focal low-signal intensity on T2-w images and/or b) focal 
restriction on ADC maps and/or c) suspicious irregular enhancing areas were evident on images and the un­
derlying histopathological analysis showed no evidence for tumor. Therefore all areas vaguely to strongly 
suspicious of malignancy based on current known features on multiparametric imaging were annotated. To 
allow exact spatial matching of the different imaging sets, a manual registration was applied for all patients, 
to correct for patient related movement.
7.2.6 CAD system
An in-house developed CAD system was used to assist the radiologist in the diagnosis of prostate lesions. 
An extensive description of the system can be found in previous publications [96, 132]. Briefly, the CAD 
system can visualize multi-parametric MRI and derived maps simultaneously in multiple linked views either 
as background or as transparent color coded overlays. Figure 7.1 demonstrates the CAD system with 
a dedicated prostate hanging protocol as it was used in the experiment. The CAD system characterizes 
a region of interest by extracting a relevant feature set from the available quantitative derived DCE and 
ADC maps. The extracted set of features is presented to a trained classifier which calculates a malignancy 
likelihood. Hereafter, the calculated likelihood is presented to the radiologist to assist in their diagnosis, 
as shown in Figure 7.2. For this observer study, two linear discriminant analysis classifiers were trained 
separately for the PZ and TZ. For the two classifiers, selection of features was carried out by Sequential 
Forward Floating Selection (SFFS) [153] to establish the most discriminant features. The SFFS procedure 
uses leave-one-patient-out training and testing with the area under the Receiver Operating Characteristic 
(ROC) curve as the criterion to be optimized. For the PZ, the 25th percentile of ADC values, 75th percentiles 
of k trans and Ve and 25th percentile of WashOut were selected. For the TZ, the 25th percentile of ADC 
values and WashOut were selected. The bootstrap resampling approach with 1000 iterations was used for 
estimating the bootstrap mean area-under-the (AUC) receiver operator characteristic curve as well as the 
95% confidence intervals [86].
7.2.7 Observer Study
All anonimized patients and ROIs were shown in identical order to 9 observers. The observers varied in 
their level of experience: 6 less experience observers (LEO) in MR imaging of the prostate (<  50 prostate 
MRIs evaluated) and 4 prostate experienced observers (EO) (> 100 prostate MRIs evaluated). Observers 
were informed that all patients had biopsy proven prostate cancer followed by prostatectomy. The CAD 
system was designed with an experimental environment where predefined ROIs were automatically dis­
played for characterization by the observers. For each ROI to be evaluated, the axial, coronal and sagittal 
T2-w images, the ADC map, the pre-contrast T1-w images and as color coded transparent overlays, the 
DCE parameters: Ktrans, WashOut and Ve were shown. An automated hanging protocol ensured that all 
images and maps of each patient were displayed at identical positions. A lookup table was displayed at each 
viewport to represent the window and level settings which were automatically set and fixed to a predefined 
intensity range, corresponding to absolute ADC values (0.5 - 1.5x10-3 mm/s2) and DCE enhancement val­
ues: K trans (1-3/s); Washout (-1 - -10/s) and Ve (20 - 70%). See Figure 7.1 for an example. For every 
ROI shown, the observer was expected to provide a malignancy likelihood on a scale of 0-100%. An in­
teractive tool was displayed on top of the CAD system to guide the observer through the successive ROIs 
of each patient. The tool recorded a (pre-CAD) malignancy likelihood entered by the observer for a given 
ROI. Hereafter, features were extracted from multiple parametric images simultaneously within the ROI. 
A supervised classifier summarized the features into a CAD determined malignancy likelihood. The CAD
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Figure 7.1: Example patient case of the observer study. The MRCAD observer hanging protocol shows 
on the top row from left to right a) T2-w axial b) T2-w coronal c) T2-w sagittal and d) ADC map. On 
the bottom row T1-w transversal images are displayed with the pharmacokinetic maps as transparent color 
overlays representing e) K trans , f) Ve, g) WashOut and h) native T1-w image prior to contrast. The separate 
window shows the scoring widget were the observer is asked to enter a malignancy likelihood for the provided 
region of interest.
likelihood was displayed to the observer in combination with a distribution of the predicted likelihoods 
that was obtained during training of the classifier in relation to their reference standard, as demonstrated in 
Figure 7.2. Subsequently, the observer entered an additional (post-CAD) malignancy likelihood before the 
next ROI was shown. Observers were provided with the discriminating performances (as AUC) of the CAD 
system for the PZ and TZ respectively. Prior to the study, all observers were trained and familiarized with 
the CAD system, evaluating 4 cancer patients with a total of 25 different ROIs in the PZ and TZ with and 
without CAD.
7.2.8 Statistical Analysis
A multiple-reader multiple case (MRMC) ROC analysis (DBM MRMC 2.2, Kurt Rossmann Laboratories, 
Chicago, U.S.A) was performed. The average AUC for LEOs and EOs for the whole prostate as well as the 
PZ and TZ separately, were established before and after CAD. As MRMC analysis cannot provide statistical 
significance in repeated observational studies, additional linear mixed model analysis (using SPSS version 




A total of 34 patients were included with a mean age of 64 years (range 53-74); mean PSA of 7.5 (range 3.4 
- 21.8) and median Gleason Score of 7 (range 5-9). In these patients, 120 benign and 86 malignant lesions
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Figure 7.2: The scoring widget used for the observer study. The observer is asked to provide a malignancy 
likelihood for the provided region after which the observer presses the Score button. After the observer pro­
vides the pre-CAD malignancy likelihood, the CAD system calculates a malignancy score which is presented 
in a density plot. The green area in the density plot summarizes the smoothed distribution of all the calculated 
likelihoods for all benign regions from the database used for training the classifier. Likewise, the blue and 
red area corresponds with the normal and malignant regions, respectively. Hereafter, the observer can enter a 
post-CAD malignancy likelihood while taking the CAD prediction into account.
were annotated and evaluated. Of the 120 benign lesions, 64 were in the PZ and 56 in the TZ. Of the 86 
malignant lesions, 67 were in the PZ and 19 in the TZ.
7.3.2 CAD Stand-Alone Performance
The overall CAD stand-alone AUC was 0.90 (CI 0.83-0.96) while for the PZ this was 0.92 (CI 0.88-0.96) 
and for the TZ, 0.87 (CI 0.78-0.96).
7.3.3 Observer Performance without CAD
LEOs had an overall pre-CAD performance of AUC=0.81 (CI 0.76-0.85); for the PZ this was AUC=0.86 (CI 
0.83-0.88) and for the TZ, AUC=0.72 (CI 0.66-0.77). Experienced observers had an overall performance 
of AUC=0.88 (CI 0.85-0.93). A pre-CAD AUC=0.91 (CI 0.89-0.93) and AUC=0.81 (CI 0.69-0.94) was 
determined for the PZ and TZ respectively.
7.3.4 Observer Performance with CAD
When the observers were allowed to change their ratings depending on CAD predictions, the overall av­
erage AUC for less-experienced observers improved significantly to 0.91 (CI 0.90-0.93; p=0.001) and for 
experienced observers to 0.91 (CI 0.86-0.97; p=0.17). For less-experienced observers this was more evident 
for the PZ where the average AUC increased to 0.95 (CI 0.94-0.95; p<0.001) compared to the TZ, where 
the average AUC improved to 0.79 (CI 0.76-0.83; p=0.01). Experienced observers revealed no significant 
improvement in overall PZ (post-CAD AUC=0.93 [0.90-0.97]; p=0.13) or TZ lesion characterization (post- 
CAD AUC=0.82 [0.68-1.00]; p=0.42). A summary of the pre- and post-CAD performances are shown in 
Table 7.2 and Table 7.3 as well as Figure 7.3.
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Table 7.2: Summary of mean pre- and post-CAD performances for readers grouped into less-experienced and 








Overall 0.81 (0.76-0.85) 0.91 (0.90-0.93) 0.001 *
PZ 0.86 (0.83-0.88) 0.95 (0.94-0.95) < 0 .0 0 1*
TZ 0.72 (0.66-0.77) 0.79 (0.76-0.83) 0 .01*
Experienced observers
Overall 0.88 (0.85-0.93) 0.91 (0.86-0.97) 0.17
PZ 0.91 (0.89-0.93) 0.93 (0.90-0.97 0.13
TZ 0.81 (0.69-0.94) 0.82 (0 .68-1.00) 0.42







Reader 1 0.83 0.95
Reader 2 0.84 0.95
Reader 3 0.84 0.93
Reader 4 0.87 0.95
Reader 5 0.88 0.95
Reader 6 0.87 0.94
TZ
Reader 1 0.73 0.81
Reader 2 0.72 0.77
Reader 3 0.65 0.80
Reader 4 0.65 0.77
Reader 5 0.80 0.85
Reader 6 0.74 0.76
Experienced observers 
PZ
Reader 7 0.92 0.95
Reader 8 0.89 0.94
Reader 9 0.91 0.96
Reader 10 0.91 0.91
TZ
Reader 7 0.89 0.92
Reader 8 0.87 0.88
Reader 9 0.80 0.88
Reader 10 0.71 0.69
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Figure 7.3: AUC for less-experienced and experienced observers grouped according to overall, PZ and TZ 
performances.
7.4 Discussion and Conclusion
In this study we have demonstrated the clinically value of CAD to characterize prostate lesions by radiol­
ogists using information obtained from quantitative pharmacokinetic DCE parameters and ADC values on 
3T MR imaging. The discriminating performance significantly improved for LEOs when they were assisted 
by CAD. For both the PZ and the TZ, this improvement was noted. Furthermore, when CAD was used, 
LEOs improved their discriminating ability to such an extent that similar performances were achieved as 
those of EOs. CAD however, did not significantly alter the performance of EOs. To our knowledge this 
study is the first to evaluate the effect of a CAD system for MR prostate evaluation by radiologists.
Multiparametric MR imaging (MP-MRI) is still the most accurate imaging technique available to de­
tect, localize and stage prostate cancer. The additional value of information obtained from DWI is also 
gaining importance as a tumor aggressiveness biomarker, especially at 3T. T2-weighted imaging can still 
be regarded as the cornerstone of prostate evaluation as anatomy is exquisitely well depicted. Prostate can­
cer usually reveals a low-signal intensity region but this lacks specificity as numerous benign conditions, 
can have similar appearances. In addition, low-grade tumors might not be depicted and therefore detected 
as easily as high-grade tumors [147]. The overall accuracy of T2-weighted imaging has therefore been 
rather low with AUC ranging between 0.68 and 0.81 [162, 163]. Unfortunately, quantitative T2-w imaging 
is not easily performed and requires excessively long imaging times [52]. DCE-MR imaging suffers from 
a similar lack of specificity as prostatitis, high-grade PIN and normal BPH can also show increased vas­
cularization and perfusion. For DWI, BPH and fibrosis also reveal increased proton movement restriction. 
Therefore, a multi-parametric approach combining all three imaging modalities has been shown to be most 
optimal [14, 164]. These authors showed that information obtained from the combination of the different 
imaging techniques provides a better discriminating performance then each technique individually. Yet, 
MP-MRI evaluation remains challenging, is largely dependent on experience and substantial inter-observer 
variability in interpretation exists.
As most MR imaging modalities lack specificity, the goal of our CAD approach was to improve the 
characterization accuracy of tumor suspicious lesions incorporating information from multiple features on 
DCE and DWI. This was done using linear discriminant analysis to determine the likelihood that a region 
represent malignancy or not. The current standard paradigm for the use of CAD systems is to use CAD 
as a second reader. After the radiologist has evaluated the multiple imaging sets, CAD offers the tumor 
likelihood for a given suspicious region, therefore aiding in differentiation. Our developed CAD system
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has a discriminating performance (AUC TZ: 0.87, PZ: 0.92) similar to that of an experienced radiologist 
(AUC TZ: 0.81, PZ: 0.91). In clinical practice, radiologists tend to evaluate MR images without quanti­
tative analysis. For example, on DCE-MRI, enhancement patterns that indicate the presence of tumor are 
compared to the relative enhancement of the normal surround prostate tissue. In addition, ADC maps are 
only visually evaluated by looking at a focal area of relative restriction which may be indicative of tumor. 
Because of this relative assessment, no clear cut-off values for the presence of tumor are routinely used. 
As a result, the evaluation of multiparametric MRI requires a high level of experience and induces ob­
server variability [16]. This was confirmed by our study which demonstrated that LEOs have substantially 
lower performances compared to EOs and that the inter-observer variability was large (CI 0.76-0.85). CAD 
not only improved the overall performance to the level of experienced observers, but also decreased the 
inter-observer variability (CI 0.90-0.93 ).
Transition zone tumors are known to have different genetic mutations, biological behavior and over­
all prognosis compared to PZ tumors [165, 166]. TZ tumors are furthermore often larger in volume and 
associated with higher PSA values. On the contrary they often are of lower grade and more likely to be 
confined to the prostate. Histologically the PZ consists of more glandular components compared to the TZ, 
which due to common BPH formation, has a larger stromal component including compact muscle fibers. 
On MR imaging this results in a lower T2-w signal and ADC values compared to the normal PZ where 
higher values are seen. In addition, the higher vascular features associated with BPH result in enhancement 
patterns on DCE similar to that of tumor [97]. The differences in MR appearances of TZ tumors compared 
to PZ tumors have been reported before [167, 168]. For this reason we have developed a CAD system 
which consists of two classifiers for characterization of the PZ and TZ lesions separately. The results of 
this study confirm that the TZ is indeed more challenging to evaluate than the PZ, as a lower stand-alone 
CAD performance (AUC 0.87 vs. 0.91 in the PZ) as well as lower overall observer performances (AUC 
0.72-0.81) were achieved compared to the PZ (AUC 0.86-0.91).
Our study has a number of limitations. Firstly, we have used multiple observation per patient which may 
hamper a straight forward interpretation of the results. A linear mixed model analysis which incorporates 
findings from multiple observation in the same patient was performed to determine significance. Secondly, 
the number of TZ tumors was fairly low compared to PZ tumors. This is in accordance with the known 
overall lower prevalence (30%) of these tumors [169] identified on a normal basis. Therefore the overall 
performance of both the CAD system as well as the readers, may rather constitute a PZ dominated effect. 
Thirdly, as an integral part of DCE MRI quantification, the reference tissue calibration method requires 
an annotation of normal PZ. For this study this was done manually prior to the experiment. Ideally such 
annotation should be performed automatically without requiring any user interaction. Previous studies 
have shown that despite the fact that automatic calibration performs better compared to a general estimate, 
manual calibration is still superior at this stage [92]. Finally, all regions scored by the observer were 
annotated and predefined beforehand. This was done to prevent observer variability caused by annotating. 
In a clinically routine setup, either CAD should localize regions suspicious for cancer beforehand or provide 
a tumor likelihood based on radiologists interactive assessment, indicating regions suspicious of malignancy 
to be evaluated by CAD.
In conclusion, we have shown that the addition of CAD on multi-parametric 3T MP-MRI, significantly 
improves the discriminating performance for LEOs for both the PZ and TZ. Furthermore LEOs assisted by 
CAD, reached similar performance compared to EOs. Therefore CAD appears to be a promising method 
for implementation into routine clinical environment for MR imaging assessment of prostate cancer.

Chapter 8
Summary and General Discussion
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Introducing Computer Aided Diagnosis (CAD) in the clinical workflow of a radiology department to 
assist in prostate cancer diagnosis is an enormous challenge. The lack of standardized MR sequences, 
consensus in interpretation of the acquired data and available objective quantitative features to diagnose 
prostate cancer obstructs the implementation of prostate CAD in medical centers. Furthermore, to become 
successful in a clinical environment, the CAD method should be fully automated, robust to the large pop­
ulation variation and fast enough for a typical screening production of say 30 to 40 cases a day. In this 
thesis, several methods are described that allow diagnosis of prostate cancer using objective quantitative 
features. Furthermore, a complete CAD scheme has been developed that assist radiologists in the diagnosis 
of prostate cancer and its additional value to the human observer was evaluated. In this final chapter, the 
results are summarized and the current status and future directions for prostate CAD methods in MRI are 
discussed.
8.1 Summary
Chapter 2 This chapter introduces a novel automated computerized scheme that was developed to deter­
mine a likelihood measure of malignancy for cancer suspicious regions in the prostate based on dy­
namic contrast-enhanced MRI (DCE-MRI) images. To evaluate the method, 34 consecutive patients 
with histologically proven adenocarcinoma in the peripheral zone of the prostate were collected. Both 
carcinoma and non-malignant tissue were annotated in consensus on MR images by a radiologist and 
a researcher using whole mount step-section histopathology as standard of reference. The annotations 
were used as regions of interest (ROI). A feature set comprising pharmacokinetic parameters and a 
T1 estimate was extracted from the ROIs to train a support vector machine as classifier. The output 
of the classifier was used as a measure of likelihood of malignancy. Diagnostic performance of the 
scheme was evaluated using the area under the ROC curve. The diagnostic accuracy obtained for 
differentiating prostate cancer from non-malignant disorders in the peripheral zone was 0.83 (0.75­
0.92). This suggests that it is feasible to develop a CAD system capable of characterizing prostate 
cancer in the peripheral zone based on DCE-MRI.
Chapter 3 In this chapter, the CAD scheme is extended by extracting additional features from T2-weighted 
images in an attempt to improve the discriminating performance of the CAD method. Two issues arise 
when incorporating T2-w images in a CAD system: T2-w values are position as well as sequence de­
pendent and images can be misaligned due to patient movement during the acquisition. A method 
was developed that computes T2 estimates from a T2-w and proton density value and a known se­
quence model. A mutual information registration strategy was implemented to correct for patient 
movement. Global motion is modeled by an affine transformation, while local motion is described 
by a volume preserving non-rigid deformation based on B-Splines. The additional value to the dis­
criminating performance of a DCE T1-w based CAD system was evaluated using Bootstrapped ROC 
analysis. T2 estimates were successfully computed in 29 patients. T2 values were extracted and 
added to the CAD system from 39 malignant, 19 benign and 29 normal annotated regions. T2 val­
ues alone achieved a diagnostic accuracy of 0.85 (0.77-0.92) and showed a significantly improved 
discriminating performance of 0.89 (0.81-0.95), when combined with DCE T1-w features. In con­
clusion, the study demonstrated a simple T2 estimation method that has a diagnostic performance 
such that it complements a DCE T1-w based CAD system in discriminating malignant lesions from 
normal and benign regions. Additionally, the T2 estimate is beneficial to visual inspection due to the 
removed coil profile and fixed window and level settings.
Chapter 4 This chapter continues with the research on pharmacokinetic parameters derived from DCE- 
MRI. The feasibility of an automated calibration method for estimating the arterial input function 
when calculating pharmacokinetic parameters from DCE-MRI is shown. In chapter 2, it was demon­
strated that the CAD system performs optimal when per patient calibration was used, but required 
manual annotation of reference tissue. In this study we propose a fully automated segmentation 
method that tackles this limitation and tested the method with our CAD system when discriminating 
prostate cancer from benign areas in the peripheral zone. A method was developed to automatically 
segment normal peripheral zone (PZ ) tissue. Context based segmentation using the Otsu histogram
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based threshold selection method and by Hessian based blob detection, was developed to automati­
cally select normal P Z  as reference tissue for the per patient calibration. In 38 consecutive patients 
carcinoma, benign and normal tissue were annotated on MR images by a radiologist and a researcher 
using whole mount step-section histopathology as standard of reference. A feature set comprising 
pharmacokinetic parameters was computed for each ROI and used to train a support vector machine 
as classifier. In total 42 malignant, 29 benign and 37 normal regions were annotated. The diagnos­
tic accuracy obtained for differentiating malignant from benign lesions using a conventional general 
patient plasma profile showed an accuracy of 0.65 (0.54-0.76). Using the automated segmentation 
per patient calibration method the diagnostic value improved to 0.80 (0.71-0.88), whereas the manual 
segmentation per patient calibration showed a diagnostic performance of 0.80 (0.70-0.90). These 
results show that an automated per-patient calibration is feasible, a significant better discriminating 
performance compared to the conventional fixed calibration was obtained and the diagnostic accuracy 
is similar to using manual per-patient calibration.
Chapter 5 Automatic prostate segmentation is a crucial step for CAD systems to reduce the number of 
false positive cancer candidates. Robust and fully automatic prostate segmentation in MR images is 
challenging, mainly due to the lack of well-defined edges, similar intensity profiles with surround­
ing organs or its relative small size in the male pelvis. In this chapter, a fully automatic parametric 
multivariate multi-object (PAMMO) segmentation method is presented that is generalizable to any 
modality and application including multiple MR modalities of any kind, i.e. combining ultrasound 
and MR images, as well as the freedom to define the amount of objects and their shapes and appear­
ances. Segmentation is performed in two stages. The first stage is a novel approach where a PAMMO 
model is fitted to multiple MR images. Information from the multivariate MR images is simultane­
ously used during fitting of the model while it’s parameters are constrained within a population model 
leading to realistic solutions. In the second stage, the obtained knowledge about organ shape, posi­
tion and appearance is used as prior knowledge in a Bayesian framework to classify the voxels of the 
multivariate MR images and to segment the prostate. The performance of the method is compared to 
approaches that (1) use information from a single MR image and (2) do not incorporate pelvic model 
fitting in their segmentation process. The results show that a multivariate segmentation including 
fitting significantly outperforms the other approaches with a dice coefficient index of 0.77±0.05.
Chapter 6 This chapter presents a fully automatic computer aided detection (CADe) method for the de­
tection of prostate cancer. The CADe method consists of multiple sequential steps in order to detect 
locations that are suspicious for prostate cancer. In the initial stage, a voxel classification is per­
formed using a Hessian based blob detection algorithm at multiple scales on an Apparent Diffusion 
Coefficients map. Next, a parametric multi-object segmentation method is applied and the result­
ing segmentation is used as a mask to restrict the candidate detection to the prostate. The remain­
ing candidates are characterized by performing histogram analysis on multiparametric MR images. 
The resulting feature set is summarized into a malignancy likelihood by a supervised classifier in a 
two-stage classification approach. The detection performance for prostate cancer is evaluated using 
methodology. The results show that the CADe method obtained sensitivities of 0.41, 0.65 and 0.74 
at false positive levels of 1, 3 and 5 per patient, respectively. The study showed that it is feasible to 
automatically detect prostate cancer using information from multiple MR images simultaneously.
Chapter 7 In this chapter, the effect of computer-aided diagnosis (CAD) was determined on observer per­
formance in differentiating benign and malignant prostate lesions on multiparametric 3T MRI. 34 
Consecutive patients with biopsy proven prostate cancer who received a multiparametric 3T MRI 
incl. T2-weighted, diffusion weighted (DWI) and dynamic contrast enhanced (DCE) imaging prior 
to radical prostatectomy, were retrospectively included. Six less-experienced and four experienced 
prostate radiologists were asked to characterize different cancer suspicious regions on multiparam- 
eteric MRI, first without and subsequently with the use of in-house developed CAD software. The 
effect of CAD was statistically analyzed using a multiple reader, multi-case, receiver operating char­
acteristic analysis as well as linear mixed-model analysis. In 34 patients, a total of 206 pre-annotated 
regions which included 67 malignant and 64 benign regions in the peripheral zone (PZ) and 19 ma­
lignant and 56 benign regions in the transition zone (TZ) were evaluated. Stand alone CAD had an 
overall area-under the receiver operating characteristic curve (AUC) of 0.90, in discriminating PZ
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lesions an AUC=0.92 and for the TZ an AUC=0.87. Overall, less-experienced observers (LEO) had 
a pre-CAD AUC of 0.81 which significantly increased to 0.91 (p=0.001) after CAD while for expe­
rienced observers (EO) the pre-CAD AUC was 0.88 which increased to 0.91 (p=0.17) after CAD. 
In discriminating PZ lesions, LEOs increased their AUC from 0.86 to 0.95 (p<0.001) after CAD 
while EOs showed an increase from 0.91 to 0.93 (p=0.13). Similar, for the TZ lesions, LEOs sig­
nificantly increased their performances from 0.72 to 0.79 (p=0.01) after CAD and EOs from 0.81 
to 0.82 (p=0.42). The study concluded that the addition of CAD significantly improved the lesion 
discriminating performance for LEOs who reached similar performances as EOs. The stand alone 
performance of CAD is similar to experienced observers.
8.2 General discussion
The challenge to introduce CAD in the clinical workflow with a prostate cancer screening environment 
has been and still is enormous. The lack of standardized sequences, interpretation variability and objec­
tive quantitative features of PCa has been an important obstruction to develop adequate CAD methods for 
prostate MR diagnosis. This thesis presented a number of methods that allow diagnosis of prostate cancer 
using objective quantitative features obtained from multiparametric MRI. Furthermore, a complete prostate 
CAD system was developed and showed to be beneficial to the radiologist when diagnosing prostate cancer. 
In the next coming years, research towards automatic detection of prostate cancer will proceed further. Cur­
rently, multi-center studies are evaluating standardized MR imaging protocols for prostate cancer diagnosis 
and international prostate cancer societies emphasize on the importance of a scoring mechanism similar to 
the BIRADS score. The European Society of Urogenital Radiology is currently working on new guidelines 
that will have the purpose to standardize the current imaging techniques and diagnosis for prostate cancer. 
This is a convenient trend for the implementation of prostate CAD methods in the clinic, as they typically 
rely on a contained environment. Furthermore, standardization of prostate MRI and a structured way of 
reporting will benefit prostate cancer research enormously as they will produce large and well described 
datasets. In that way, prostate CAD systems can be trained and tested on larger datasets which is, of course, 
beneficial for the robustness of the CAD system.
The following key aspects can be identified from this thesis for future work:
Additional features: In this thesis, pixel intensity values were most often used for feature analysis. Espe­
cially in a multiparametric MR setup, histogram analysis on the pixel intensity values showed to be 
of benefit to discriminate tumor from benign conditions. In chapter 3 it was demonstrated that com­
bining information from different MR images improves the discriminating performance, compared to 
using information from each image type separately. This concept is further demonstrated in chapter 6, 
where feature analysis was performed on three different MR images, i.e., T2, DCE, and ADC. The 
discriminating performance could potentially increase even more when information obtained from 
spectroscopy is included.
It stands to reason that texture features that are similar to the criteria used in the clinic, will fur­
ther improve the discriminating performance. For example, in T2-weighted images the criterion of 
smoothness in combination with a low T2 signal is used. Another example is the DCE symmetry cri­
teria in the transition zone. Asymmetrical enhancement in the transition zone is a marker for prostate 
cancer whereas symmetrical enhancement is typical for BPH [97]. Additionally, pattern recognition 
techniques can be applied for a final boost of the discriminating performance of the CAD method. Ex­
amples that have been published in literature are Markov random fields and fractals [50, 51, 52, 55]. 
Anatomical features can be added which are extracted from e.g. T2-weighted MR images. In clinical 
practice they still form the basis of prostate cancer diagnosis, where the radiologist searches for shape 
features such as bulging or an irregular shaped prostate capsule.
Another way to improve the CAD system would be to employ contextual information, such as patient 
age, PSA level and history.
Prostate cancer aggressiveness: This thesis primarily focussed on the capability of detecting clinically 
significant prostate cancer and the ability to differentiate prostate cancer from benign abnormalities. 
In a clinical perspective however it is becoming more important to only detect the more aggressive 
tumors or the ability to differentiate high grade from low grade tumors. Therefore, several authors
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have attempted to establish a correlation between the Gleason score and image modality [47, 170, 
157, 171]. However, a substantial overlap between the different Gleason scores and the information 
obtained from the image modality was present. In chapter 6, primarily results were presented of 
the developed CAD system with the ability to detect tumor with different grades. As the results are 
promising, future work could focus on the evaluation of the correlation between Gleason score and 
information obtained from multiparametric MRI.
MR CAD image guidance: The precise localization and grading of prostate cancer is becoming a very 
important aspect when diagnosing prostate cancer. For example in case of focal therapy, the exact 
location and most aggressive part of the tumor is of paramount importance. Another example is 
biopsy, where it is essential to target the most aggressive and thus representative part of the tumor. 
Future research would be whether MR CAD image guidance can assist in localizing the dominant 
tumor and objectively guide, e.g. biopsy, towards the most aggressive part of the tumor. Chapter 6 
presented a method that detects prostate cancer by localizing the most dark region of the tumor in 
the ADC map. This is similar performed at an MR guided biopsy, where the operator determines the 
most aggressive part of the tumor by visual inspections of the ADC map. The developed CAD system 
is able to provide exact coordinates of the most aggressive part of the tumor, which can be transferred 
towards the biopsy targeting system. Another application would be to incorporate the prostate CAD 
results into in TRUS guided biopsy system by means of e.g. image registration.
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Appendix A 
MRCAD: a In-house Developed Toolkit for 
Prostate MR Computer Aided Diagnosis
This chapter is based on the paper “MRCAD for daily clinical analysis of prostate MR” by Henkjan Huis­
man, Pieter C. Vos, Published at The Kitware Source, April 2010.
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The Diagnostic Image Analysis Group (DIAG) from the Department of Radiology at Radboud Univer­
sity Nijmegen Medical Centre in The Netherlands researches computer aided diagnosis of breast, lung 
and prostate cancer. The research in prostate cancer is a collaborative effort with the clinical prostate 
group in the department and is focused on high resolution anatomical, functional (diffusion and dynamic 
contrast enhanced) and metabolic (spectroscopy) MR. During various prostate and breast MR projects an 
image analysis workstation, MRCAD, has been gradually developed based on VTK, ITK and IncrTCL. 
This workstation provides dedicated image analysis tools and display facilities for various state-of-the-art 
MR sequences and hardware as well as a platform for testing new computerized image analysis techniques. 
Currently, MRCAD is in daily clinical use at our clinic and at a few other sites. MRCAD is being used to 
reporting prostate MR and in various research projects and publications. This article will address some of 




To get an impression of MRCAD, first two example patient cases. Fig A.1 shows an MR detection study of
Figure A.1: MR detection study of a patient with elevated PSA, where prior ultrasound biopsy could not 
confirm the presence of cancer.
a patient with elevated PSA, where prior ultrasound biopsy could not confirm the presence of cancer. The 
detection protocol includes: t2-w, ADC, and DCE-MRI sequences. The radiologist marks a finding, which 
is suspicious for cancer, with a transparent red sphere (vtkUnstructuredGrid) and is presented with CADx 
output to assist in differentiating between benign and malignant. A malignancy score of .33 (green and red 
are scores of benign and malignant training findings) indicates that the region is unlikely to contain cancer. 
This patient is currently in an active surveillance program.
Fig. A.2 shows a 59-year-old patient with a PSA of 12 ng/ml and a confirmed biopsy Gleason 8 tumor 
in the right peripheral zone. The MRCAD hanging protocol shows T2-w transversal (right view) and in 
color overlays: Pharmacokinetic DCE-MRI; and ADC-map (left upper row); and choline metabolite con­
centration; coronal T2-w image (left bottom row); The separate window shows a time-concentration curve 
and an MR Spectroscopy spectrum at the cursor location. The reporting radiologist rated all 4 modalities 
5 on a 5 point scale: where 1 is no tumor, and 5 is definitely tumor. These MR findings were confirmed 
retrospectively with a stage T3a determined after prostatectomy.
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Figure A.2: MR staging study used by the radiologist to diagnose the PCa in terms of extracapsular extension, 
tumor stage, etc.
A.3 Overview of the software
The workstation is running an OpenSuse Linux OS. A DCMTK server daemon is receiving DICOM imag­
ing that are automatically forwarded by the PACS system. A polling mechanism triggers automatic pre­
processing of MR studies (e.g. fitting DCE-MRI curves). The studies are then ready for viewing and fur­
ther analysis. MRCAD features are: compressed, multiframe DICOM Reading/Writing; multi-modal color 
overlay; DCEMR pharmacokinetic modeling and registration; manual and semi-automatic segmentation; 
region of interest statistics; CADx, CADe; MRS (using LCModel), and Structured Reporting.
The MRCAD software has a layered structure as shown in Fig. A.3. The main programming language is 
Tcl/Tk with the object oriented extension IncrTcl. Processing and display are performed in VTK pipelines 
that are setup using the Tcl wrapped interface. Local VTK classes provide additional high computational 






Figure A.3: The layered structures of the MRCAD software.
A.4 Annotation and Structured Reporting
Clinical findings and ground truth for CAD are annotated and stored in XML. Example tags are: tumor 
location, tumor grade, scorings, access time, etc. For structured reporting findings can be collected and
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added to the XML database. A pdf file can be generated from the XML file (using LaTeX) and, after 
inspection, send to an Electronic Patient Database using SOAP requests. The XML data is additionally 
used for training CAD systems, and performing clinical observer studies. An XML example of an observer 
scoring is:
< m a r k d a t a s e t l i s t s  P a t i e n t s N a m e = ” Anonym ous” P a t i e n t I D  =” 12345”
St udy  Dat e  =” 2 0100217” I n s t i t u t  i on  N a m e  =” UMC_St_Radboud”
S t u d y  D e s c r i p  t io n =”ABDOMEN-ONDERBUIK”>
< m a r k l i s t  u s e r n a m e = ” p i e t e r ” mode=” d e t e c t ”
r e p e a t  =” 1” s t u d y  s e t n a m e = ” D e f a u l t ”>
<m ark  i d = ”mar k1”>
<Tim e >2 0 1 0 . 0 2 . 2 4  -  11:51:05 < /Time>
< P o s i t i o n  > - 2 5 . 7 9 0 4  9 . 30513  — 53.7623 < / P o s i t i o n  >
< Al i g n e d Mo d a l i t y BG >T2Tra1 < / A l i g n e d Mo d a l i t y BG >
<Type>Tum or < / Type>
<T 2>5</T2X D C E>4</D C EX D IFF >4</D IFF 
< L i n k  i d = ” L i n k 1 ”>
< S t u d y Da t e  >20091220< / S t u d y D a t e >
< / L i n k >
< /m ark>
< m a r k p a t i e n t  i d = ” p a t i e n t l e v e l ”>
< St age >T2c < / St age  >
<!—  p r o s t a t e  s i z e  — >
< A P > 46< /A P xR L > 57< /R L xC C >  46 </CC>
< / m a r k p a t i e n t >
< / m a r k l i s t >
< / m a r k d a t a s e t l i s t s / >
The node markdatasetlists is the root node for all annotations of the MR study. In this example (user 
’pieter’ in the marklist node) a tumor is detected and is rated 5-4-4 on 3 MR modalities. Furthermore, the 
finding is linked to another finding in a prior MR study (Link1). The patient diagnosis is in the markpatient 
node: a T2c tumor. After reporting the patient case, MRCAD can use the findings stored in the XML 
database to collect screenshots and format the information into a PDF file using dedicated stylesheets. This 
PDF structured report is then send to the Electronic Patient Database using SOAP: set token
[: : h t t p  :: g e t u r l  $ p o s t u r l  — t ype  ” t e x t / x m l ;  b o u nda r y  = ’ ’” — h e a d e r s  
[ l i s t  Cook i e  $ s e s s i o n i d ]  —que r y  [ $ s o a p r e q u e s t  asXML]] 
s e t  body [ h t t p : : d a t a  $ t o k e n ]  
h t t p  : : c l e a n u p  $ t oke n
A.5 Coordinate system
MRCAD uses three coordinate systems to handle the variety of image volume and voxel dimensions and 
orientations in an MR scan: ijk voxel location in an MR series, xyz patient position, uvw viewport co­
ordinate. A vtkDCMTKImageReader directly reads DICOM images in single slice, multiframe, and/or 
compressed format and produces a vtkImageData and a vtkTransform (ijk2xyz). The latter transform maps 
voxel location ijk to an xyz patient position. The viewer uses an additional uvw2xyz transform to han­
dle: zooming, panning and slice selection. This allows for accurate (sub-voxel) overlay of any image (e.g 
transversal 0.5x0.5x3mm) onto any other orientated image (oblique (15deg) sagittal (1x1x4mm)). Arbitrar­
ily shaped 3D volume annotations are created and stored in xyz coordinates using the vtkUnstructuredGrid 
format. These annotations can be added and overlayed to any view and are also used to compute region of 
interest statistics in the various multi-model images.
A.6 Data and widget factory
The core of the MRCAD application is designed as a factory method pattern. The approach ensures fast 
initializing of the application, by constructing data objects on demand. As a result, VTK pipelines are only 
created when needed. An IncrTcl coded part of the factory:
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c l a s s  M RCADDataFactory { 
p u b l i c  {
# s t a t i c  met hod t h a t  r e t u r n s  t he  s i n g l e t o n  
pr oc  I n s t a n c e  {}
# che ck  wh e t h e r  t he  d a t a  o b j e c t  ’ ’mapname’ ’ is r e g i s t e r e d  
met hod I s A v a i l a b l e  {m apnam e}
# R e g i s t e r  t he  d a t a  o b j e c t  named ’ ’mapname’ ’ to t he  f a c t o r y  
met hod  AddD ata {mapname d a t a  }
# R e t u r n s  t he  d a t a  o b j e c t  f rom t he  f a c t o r y  
met hod Ge t Da t a  {m apnam e}
}. . .
}
# I m p l e m e n t a t i o n
body M RCADDataFactory :: Ge t Da t a  {m apnam e} { 
s e t  d a t a  $ _ r g C o n t a i n e r  ($mapname)  
s e t  o b j e c t  [ f i n d  o b j e c t  * $ d a t a ]  
i f  { $ o b j e c t  == ”” } {
# c r e a t e  t he  o b j e c t  on l y  once
s e t  o b j e c t  [ [ l i n d e x  $ d a t a  0] \ # a u t o  [ l r a n g e  $ d a t a  1 e nd ] ]  
s e t  _ r g C o n t a i n e r  ($mapname)  $ o b j e c t
}
r e t u r n  [ na me s pa c e  which $ o b j e c t ]
}
The factory is implemented as a singleton and can be queried using the static member function Instance. 
The factory is filled with possible data during MRCAD initialization, for example a diffusion-w series might 
be present, then:
# R e g i s t e r  a D i s k I ma g e Da t a  o b j e c t
[ MRCADDat aFac t or y :: I n s t a n c e  ] AddData  ” D i f f 1 ” [ l i s t  D i s k I ma g e Da t a  $ f i l e s ]
adds an imagedata object with mapname ”Diff1”, which is constructed by a specialized class DiskIm- 
ageData (an IncrTcl wrapper of the vtkDCMTKImageReader).
To view the diffusion-w image in the application:
i f  { [ [MRCADDataFactory :: I n s t a n c e  ] I s A v a i l a b l e  ” D i f f 1 ” } {
# Get  t he  d a t a  o b j e c t  and
# c r e a t e t h e VTK p i p e l i n e n e c e s s a r y t o p r o d u c e t h e d a t a 
s e t  obj  [[ M RCADDataFactory :: I n s t a n c e  ] Ge t Da t a  ” D i f f 1 ” ]
# D i s p l a y  t he  image in t he  v i e we r  
v l S e t I m a g e  BG [ $ob j  GetVolume]  
v l S e t T r a n s f o r m  BG [ $ob j  G e t T r a n s f o r m ]
}
Data objects can be accompanied by data widgets to allow user interaction with the data object. In 
the image shown below the spectroscopic metabolite image data object output is displayed as a transparent 
color-coded overlay on top of a T2-w image. Multiple metabolites map are available and the accompanying 
data widget (shown to the right) allows selection of the metabolite and provides other interactions with the 
data object. In Fig. A.4 is an example where the 3th available metabolite, choline (Cho), is selected:
A.7 MRCAD used for research
MRCAD is being used in a number of research projects. MRCAD was used to detect and annotate the Dom­
inant Intraprostatic Lesion for radiotherapy IMRT planning [172]. A successful Computer Aided Diagnosis 
system has been researched and implemented to discriminate benign from malignant suspicious regions 
using region of interest statistical features derived from DICOM images directly or processed parametric 
maps [96]. Pattern recognition as well as ROC analysis was performed using the statistical package R.
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(a) t2-w image with a color coded map of (b) Widget to control the metabolite to be
the metabolite that is selected in the wid- displayed.
get.
Figure A.4: Metabolite map which is controlled by the widget.
Pharmacokinetic features computed from Dynamic Contrast Enhanced MRI provided the highest diagnos­
tic accuracy. Subsequently in [132], more modalities/features were added to improve the discriminating 
performance. An ITK based registration method was extended with a local incompressibility term to add 
MR series features that were misaligned by possible patient movement during acquisition. Currently, an 
initial system for fully automatic detection of prostate cancer is being developed using a locally developed 
vtkClass based on the itkHessianRecursiveGaussianImageFilter to detect lesions [133, 173]. MRCAD is 
also used in several observer studies that are performed by radiologists to determine the diagnostic value of 
a certain MR modality or protocol. In [11] MRCAD was used for scoring DCE-MRI derived parameters 
and establish the value for localizing prostate cancer. Recent use includes detecting MR suspicious lesions 
for MR or ultrasound guided biopsy and detecting recurrence after radiotherapy [143, 174].
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Het introduceren van een computer werkstation dat ondersteuning geeft bij de diagnose van prostaatkanker 
in MR beeldvorming blijkt, in de klinische praktijk van een radiologieafdeling, een enorme uitdaging. Prob­
lemen als het ontbreken van gestandaardiseerde MR sequenties, geen consensus tussen radiologen bij de 
interpretatie van de verkregen beeld gegevens en het missen van objectieve kwantitatieve kenmerken voor 
de diagnose van prostaatkanker in de beelden belemmert de uitvoering van computer ondersteunende diag­
nose (CAD) van prostaatkanker in medische centra. Om een prostaat CAD werkstation verder succesvol te 
laten opereren in een klinische omgeving, dient het volledig geautomatiseerd te zijn, robuust berekeningen 
te kunnen uitvoeren om de grote populatie variatie te kunnen ondervangen en snel genoeg te zijn om een 
grote productie van zeg 30 tot 40 prostaatkanker patienten per dag te kunnen diagnosticeren.
Dit proefschrift beschrijft verschillende methoden die diagnose van prostaatkanker in MR beelden mo­
gelijk maakt voor radiologen met behulp van objectieve kwantitatieve computer analyses. Een volledig 
prostaat CAD systeem is beschreven in deze proefschrift en de aanvullende waarde voor de radioloog is 
gevalueerd.
Dit laatste hoofdstuk presenteert een samenvatting van de resultaten.
B.1 Sammenvatting
Hoofdstuk 2 Dit eerste hoofdstuk presenteert een nieuw computer systeem dat werd ontwikkeld om een 
kans op maligniteit automatisch vast te stellen voor regio’s in de prostaat die kanker verdacht zijn. 
Het systeem werkt op basis van automatische interpretatie van dynamisch contrast-versterkende MRI 
(DCE-MRI) beelden. Het evalueren van het systeem werd gedaan op een dataset bestaande uit een co­
hort van 34 patienten met histologisch bewezen adenocarcinoom in de perifere zone van de prostaat. 
Zowel carcinoom als niet-kwaadaardig weefsel werd gemarkeerd op MR beelden door een radioloog 
en een onderzoeker in consensus met histologisch geheel ingebed prostaat weefsel als gouden stan­
daard. De markeringen werden gebruikt ter referentie (ROI) voor verdere evaluatie. Een feature set, 
bestaande uit perfusie en diffusie parameters en een T1 schatting, werd geextraheerd uit iedere ROI. 
De feature set werd gebruikt om een support vector machine te trainen als classifier. De output van 
de classifier werd gebruikt als een maat voor kans op maligniteit. De diagnostische waarde van het 
systeem werd geevalueerd met behulp van de opvlakte onder de statistische receiver operating char­
acteristic (ROC) curve. De diagnostische nauwkeurigheid voor de differentiatie van prostaatkanker 
en niet-kwaadaardige aandoeningen in de perifere zone resulteerde in 0,83 (0,75 - 0,92). Hieruit 
kan worden geconcludeerd dat het CAD systeem in staat was prostaatkanker van niet-kwaadaardig 
weefsel in de perifere zone te onderscheiden gebruikt makend van DCE-MRI beelden.
Hoofdstuk 3 In dit hoofdstuk wordt uitgelegd hoe het CAD systeem werd uitgebreid met de analyse van 
T2-gewogen (T2-w) beelden in een poging om het discriminerend vermogen te verbeteren. De in­
tegratie van mbox T2-w beelden in het CAD systeem heeft twee kwesties die opgelost dienden te 
worden: 1) de T2-w waarden worden benvloed door de keuze van MR sequentie als mede het spoel 
profiel; 2) doordat beweging van de patient tijdens de MR beeldvorming lastig voorkomen kan wor­
den, zijn er positionele verschillen aanwezig tussen de MR beelden. In het hoofdstuk wordt een 
methode beschreven dat kwantitatieve T2 berekend uit een mbox T2-w en protonendichtheid MR 
beeld tezamen met een sequentie model. Een Mutual Information registratie strategie was geïmple­
menteerd om bewegingen van de patient te corrigeren. In deze strategie werden globale bewegin­
gen gemodelleerd door middel van een affine- transformatie algoritme en lokale bewegingen wer­
den gemodelleerd door van een niet-rigide transformatie algoritme met behoud van volume. De 
additionele waarde van de kwantitatieve T2 informatie op het CAD systeem werd geevalueerd met 
behulp van een Bootstrapped ROC analyse. T2 schattingen werden succesvol berekend voor alle 
29 patienten. 39 kwaardaardige, 19 goedaardige en 29 normale gebieden werden gemarkeerd door 
een radioloog waaruit T2 schattingen en DCE parameters werden geextraheerd. De geextraheerde 
informatie werd gebruikt om het CAD systeem voor zijn discriminerende voormogen te evalueren. 
Uit de experimenten bleek dat met T2 schattingen afzonderlijk, het CAD systeem een diagnostische 
nauwkeurigheid behaald van 0,85 (0.77-0.92). Een sterke verbetering was zichtbaar wanneer DCE 
parameters werden toegevoegd: 0,89 (0,81-0,95). Het hoofdstuk concludeert dat de informatie van de 
T2 schattingen een aanvulling is voor het CAD systeem omdat het diagnostisch vermogen drastisch
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verbetert. Daarnaast zijn de kwantitatieve T2 schattingen gunstig voor visuele inspectie aangezien 
het spoel profiel wordt verwijderd en een objectief vaste contrast instelling gebruikt kan worden.
Hoofdstuk 4 In hoofdstuk 2, werd aangetoond dat het CAD systeem optimaal presteert wanneer een per­
patient kalibratie werd gebruikt. Echter, de methode vereiste een handmatige markering van refer­
entie weefsel. In dit hoofdstuk wordt de haalbaarheid van een automatische kalibratie methode on­
derzocht en getest met behulp van CAD systeem. De methode betreft een volledig geautomatiseerde 
segmentatie van gezonde perifere zone weefsel dat gebruikt wordt ter referentie. De methode om­
vat een context gebaseerde segmentatie bestaande uit een Otsu histogram drempel selectiemethode 
en een Hessian gebaseerde bol detectie. De database voor de evaluatie bestond uit een cohort van 
38 patienten met carcinoom. Een radioloog en onderzoeker markeerde in consensus kwaadaardig, 
goedaardig en normaal weefsel op MR beelden. Hierbij werd histologisch geheel ingebed prostaat 
weefsel als gouden standaard gebruikt. Voor iedere ROI werd een feature set berekend bestaande 
uit PK parameters. De feature set werd gebruikt om een support vector machine te trainen voor 
de classificatie van de verschillende gebieden. In totaal, 42 kwaadaardige, 29 goedaardige en 37 
normale regio’s werden gemarkeerd. De diagnostische nauwkeurigheid voor de differentiatie van 
kwaadaardige en goedaardige laesies werd bepaald voor drie verschillende kalibratie technieken: 1) 
een conventioneel algemene patient plasma profiel; 2) handmatige segmentatie per patient kalibratie; 
en 3) automatische segmentatie per patient kalibratie. De experimenten lieten zien dat met behulp 
van een conventioneel algemeen patient plasma profiel een nauwkeurigheid van 0.65 (0.54-0.76) kan 
worden gehaald. De geautomatiseerde segmentatie per patient kalibratie methode liet een duidelijke 
verbetering zien van het discriminerend vermogen: 0.80 (071- 0.88). De handmatige segmentatie per 
patient kalibratie methode toonde een gelijkwaardige diagnostische prestatie van 0.80 (0.70-0.90). 
Deze resultaten tonen aan dat een automatisch per patient kalibratie haalbaar is, de automatische 
methode een significant betere discriminerende prestatie laat zien ten opzichte van de conventionele 
algemene patient plasma profiel en vergelijkbaar presteert met een handmatig per patient kalibratie 
methode.
Hoofdstuk 5 Automatische segmentatie van de prostaat is een cruciale stap voor het CAD systeem om de 
het aantal detecteerde false-positive kandidaten te beperken. Een volledig geautomatiseerde prostaat 
segmentatie methode in MR beelden is een enorme uitdaging, veroorzaakt door het gebrek aan 
goed gedefinieerde randen, overlappende intensiteit waarden met omliggende organen en de relatief 
kleine omvang in het mannelijke bekken. Het hoofdstuk beschrijft een volledig geautomatiseerde 
parametrische multivariate multi-object (PAMMO) segmentatie methode dat generaliseerbaar is naar 
elke modaliteit en toepassing, bijvoorbeeld het combineren van echografie en MR beelden. De meth­
ode is toepasbaar op een willekeurig aantal objecten en laat de definitie van hun vormen en opmaak 
volledig vrij. De segmentatie wordt in twee fasen uitgevoerd. De eerste fase betreft een nieuwe 
benadering, waarbij een PAMMO model wordt gefit op meerdere MR beelden tegelijk. Informatie 
van de MR beelden wordt door het PAMMO model gebruikt bij het generen van vergelijkbare syn­
thetische MR beelden. Alleen realistische oplossingen worden gegenereerd doordat de PAMMO 
parameters binnen de grenzen van een populatie model worden gehouden. In de tweede fase wordt 
de verkregen kennis over orgaan vorm, positie en opmaak gebruikt als voorkennis in een Bayesiaans 
strategie om de voxels van de MR beelden classificeren en de prostaat te segmenteren. In het hoofd­
stuk worden experimenten besproken waarbij de prestatie van de PAMMO methode wordt vergeleken 
met (1) de prestatie van een segmentatie methode dat alleen informatie uit een enkele MR beeld haalt 
en (2) en een segmentatie methode dat het fitten achtwege laat. De behaalde resultaten tonen aan 
dat het PAMMO segmentatie methode inclusief fitting aanzienlijk beter presteert dan de andere be­
naderingen met een Dice coefficient index van 0.77 ±  0.05
Hoofdstuk 6 Dit hoofdstuk presenteert een volautomatische computergestuurde detectie (CADE) algo­
ritme voor de detectie van prostaatkanker. De procedure om locaties op te sporen die verdacht zijn 
voor prostaatkanker bestaat uit meerdere opeenvolgende fases. In de eerste fase wordt een voxel 
classificatie uitgevoerd met behulp van een Hessians gebaseerde bol detectie algoritme, welke op 
meerdere schalen wordt uitgevoerd op een Apparent Diffusion Coefficients map. Vervolgens wordt 
het PAMMO segmentatie (zie hoofdstuk ?? methode toegepast. De daaruit resulterende segmentatie
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wordt gebruikt om de kandidaat-detectie tot de prostaat te beperken. De overige kandidaten wor­
den geclassificeerd door middel van histogram analyse op de multiparametrische MR beelden. De 
geextraheerde kenmerken worden vervolgens samengevat tot een kans op kwaadaardigheid gebruik 
makend van een supervised classifier in een two-stage classificatie methode. De prestaties voor het 
detecteren van prostaatkanker werd geevalueerd met behulp van free response operating characteris­
tic (FROC) methodologie. De resultaten tonen aan dat het CAD algoritme gevoeligheden van 0,41, 
0,65 en 0,74 haalt bij vals positieve ratios van 1, 3 en 5 per patient respectievelijk. De studie toonde 
aan dat het mogelijk is om volledig automatisch prostaatkanker te detecteren met behulp van infor­
matie uit verschillende typen MR beelden.
Hoofdstuk 7 In dit hoofdstuk werd het effect van computer-aided diagnose (CAD) bepaald op radiologen 
bij het differentieren van goedaardige en kwaadaardige prostaat afwijkingen op multiparametrische 
3T MRI. Het hoofdstuk beschrijft een experiment met 34 opeenvolgende patienten die door biop­
sie bewezen prostaatkanker hebben. Bij deze patient was, voorafgaand aan radicale prostatectomie, 
een multiparametrische 3T MRI inclusief T2-gewogen, diffusie gewogen (DWI) en DCE beeldvorm­
ing uitgevoerd. Zes minder ervaren en vier ervaren prostaat radiologen werden gevraagd om met 
kanker verdachte regios te karakteriseren met behulp van de multiparameteric MRI, eerst zonder en 
vervolgens met het gebruik van het ontwikkelde CAD systeem. Het effect van CAD was statistisch 
geanalyseerd met behulp van multiple reader, multi-case ROC analyse en een lineaire mixed-model 
analyse. Bij de 34 patienten werden in totaal 206 regios gemarkeerd bestaande uit 67 kwaadaardige 
en 64 goedaardige regios in de perifere zone (PZ) en 19 kwaadaardige en 56 goedaardige regios in de 
transitie zone (TZ). Het discriminerend vermogen in van het CAD systeem op deze dataset had een 
totale oppervlakte onder ROC curve (AUC) van 0.90, bij het onderscheiden van PZ laesies een AUC 
van 0.92 en voor de TZ een AUC van 0.87. Over het geheel genomen hadden minder ervaren radi­
ologen (LEO) een pre-CAD AUC van 0,81 die aanzienlijk werd verbeterd tot 0,91 (p = 0.001) na het 
gebruik van CAD, terwijl voor ervaren radiologen (EO) de pre-CAD AUC 0.88 was, die verhoogde 
naar 0.91 (p = 0.17) na het gebruik van CAD. In de PZ, LEOs stegen in hun AUC van 0,86 naar 0,95 
(p< 0,001) na het gebruik van CAD, terwijl EO een stijging lieten zien van 0.91 naar 0.93 (p = 0.13). 
In de TZ, LEOs stegen aanzienlijk in hun prestaties van 0.72 naar 0.79 (p = 0.01) na CAD en EO 
een stijging lieten zien van 0,81 naar 0.82 (p = 0,42). Het hoofdstuk concludeert dat de toevoeging 
van CAD significant het discriminerend vermogen van minder ervaren radiologen verhoogd naar een 
vergelijkbare prestatie van ervaren radiologen. Bovendien presteert het CAD systeem zelfstandig op 
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